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“Digo: o real não está na saída nem na chegada: ele se dispõe para a gente é no 
meio da travessia.” 




I decided to write a bit about the history behind this thesis. I have always been 
a great enthusiastic about science since my childhood. Indeed, during my graduation 
in Medicine, biochemistry and physiology were my favorite subjects. Unfortunately, 
as time went by, I have realized the emergence of an invisible barrier between the 
basic research and the clinical practice in Brazil. For some reason I could not fully 
understand, as the medical course progresses, all the subjects considered “basic” 
are set apart from the clinical practice. This partition is not totally evident, but the 
system that governs most of the medical courses in our country tends to commend 
the pragmatic point of view in detriment of the “basic” research. In other words, the 
medical doctor profile here is either someone able to work directly with patients, 
participating in their evaluation, propaedeutic and treatment, or the person involved in 
basic research, whose activity is delimited within the laboratory. 
The truth is that the aforementioned partition between the basic research and 
clinical practice has always been present along the past years. However, this trend 
has been modified since the end of last century. The birth of the Translational 
Medicine enhances the importance of approximating the laboratory (lab) work with 
the practical medicine. Great efforts have been made to enable the future 
generations of medical doctors to work in both fields, in order to build up a faster 
result to the society. Nevertheless, this process in many universities of Brazil is still 
crawling. Truly, after my graduation, I completed my medical training in the Internal 
Medicine and Nephrology Residency Program in Brasilia. I have been taught to 
manage all sorts of situations in patients, however I had tiny knowledge in the basic 
research involved in Nephrology. Actually, neither me nor my colleagues and even 
preceptors were able to read, interpret and fully comprehend the papers published in 
the Nephrology basic research. None of us had received the proper training to do 
that, despite the ability to conduct in clinical practice any kidney disease.  
As a person whose passion for kidney physiology was the main determinant to 
become a nephrologist, I was very disappointed with that situation. Therefore, I 
decided to apply for a Master degree in the University of Brasília, at the laboratory of 
Molecular Pharmacology, under the supervision of Prof. Dr. Francisco de Assis 
Rocha Neves. It was my first contact with the lab work and my first experience in 
performing molecular biology techniques by myself. At the end of 2012, I defended
my thesis entitled: “GQ-16, a partial PPARγ agonist, represses human mesangial 
cells proliferation”. 
In 2013, I started my doctorate aiming to evaluate the regulation of renin 
transcription by the PPARγ agonist. In 2015, as part of sandwich PhD program, I 
moved to the Laboratory of Vascular Medicine and Pharmacology in the university of 
ErasmusMC, in Rotterdam, the Netherlands, under the supervision of Prof Dr. AHJ 
Danser. The study on the role of PPARγ full and partial agonist on renin synthesis 
could not be continued because our As4.1 cell model did not reproduce previous 
results showing that PPARγ interfere within renin production. Therefore, most of my 
studies were concentrated in the molecular mechanisms involved in the phenotypic 
plasticity of human juxtaglomerular cells (JGC).  
Thus, this thesis represents the work I developed in the Netherlands, and 
which I also have used at my PhD defense in ErasmusMC, Rotterdam. In the first 
part, we will review the classical, new aspects and paradigms of the renin-
angiotensin system (RAS). Then, we provide a broad review about the current 
knowledge on the renin-synthesizing cells (RPC). It summarizes not only classical 
concepts like the so-called “recruitment” phenomenon, growth and developmental 
processes, but also novel contexts such as inflammation, cell repair mechanisms and 
tissue regeneration.  
The following section describes a new approach to understand RPC biology. It 
is the first report of a gene expression catalogue of human renin-producing tumors, 
or reninomas, that culminated in the discovery of 36 genes that are new to the RPC 
gene signature. Noteworthy, the cell models available to study RPC are mouse-
derived, and therefore, proper knowledge of human RPCs is limited, relying on 
speculation on the basis of murine models. This fact makes our approach unique, 
and furthermore, among the genes identified, the platelet-derived growth factor 
(PDGF) β - PDGF β receptor signaling pathway was revealed as a promising RPC 
regulator. 
Thereupon, we investigated the existence of the brain RAS, whose activity 
relies on the assumption that local renin synthesis by RPC would be a sine qua non 
condition, since the presence of the blood-brain barrier would preclude renin uptake 
from blood by central nervous system cells. We were unable to find evidence to 
support the aforementioned concept. Instead, our data suggest that renin in the brain 
represents trapped plasma renin and/or locally activated trapped plasma prorenin.
These findings uphold the conception that RPC in the kidney are the only renin 
source in the body. 
The plausibility of ‘open’ prorenin (prorenin in an open conformation, capable 
of displaying angiotensin-generating activity) release by renin and/or prorenin-
synthesizing cells was then investigated. After many decades, prorenin physiological 
role remains a riddle: is it just renin’s inactive precursor or more than that? JGCs, i.e. 
RPC located at the juxtaglomerular apparatus, are the main source of prorenin and 
the only source of renin in circulation under unstressed conditions. In addition, other 
tissues are also able to synthesize and release prorenin. Under physiological 
conditions (pH 7.4, 37°C), prorenin is present in a ‘closed’ conformation, which 
cannot result in angiotensin generation. We hypothesized that prorenin might exert 
local angiotensin-generating effects, at the site of its release, provided that is 
released in an open conformation from prorenin-synthesizing cells, before returning 
to the closed conformation in the extracellular milieu. Our in-vitro study did not reveal 
any evidence to support this conjecture, and, thus, at least under cell culture 
conditions, RPC and other prorenin-synthesizing cells do not release open (active) 
prorenin. 
Ultimately, we investigated renin and prorenin reabsorption by human 
conditionally immortalized proximal epithelial tubule cells (ciPTEC). The reabsorption 
of RAS components like angiotensinogen, renin and prorenin occurs in the kidney 
proximal tubule, in a megalin-dependent manner, and may underlie renal angiotensin 
production. Patients with Dent’s disease or Lowe syndrome (resulting in impaired 
megalin function) exhibit an increase in urinary renin and angiotensinogen levels, 
suggestive for diminished reabsorption. Strikingly, the defective reabsorption also 
allowed the detection of urinary prorenin, which is normally undetectable. We 
demonstrated that ciPTEC bind and internalize renin and prorenin in a temperature-
dependent manner, resulting in prorenin activation at 37°C. This process involved 
megalin and/or mannose-6-phosphate (M6P) receptors, and surprisingly, the M6P 
receptor antagonist, M6P, interfered with megalin endocytosis. 
Here, I should also mention I had unfinished projects in Rotterdam, which still 
requires more experiments and work to be concluded, but certainly will result in 
future publications. It has been a long road so far, and I have learned considerably. 
My objective is not only to be a nephrologist, but also to become a skillful scientist,
with high expertise, able to contribute to the scientific research on the RAS field, and 





O benefício do bloqueio do sistema Renina Angiotensina (RAS) em doenças 
cardiovasculares e renais é incontestável, mas o que ainda é controverso, é o grau 
ideal deste bloqueio. Um alto grau de bloqueio do RAS pode ter efeitos benéficos 
adicionais, entretanto, também pode resultar em maior incidência de efeitos 
colaterais. Este bloqueio pode ser estimado a partir do aumento da renina circulante, 
representando o "recrutamento" de novas células produtoras de renina (RPC) ao 
longo das arteríolas aferentes. As consequências a longo prazo deste processo 
ainda são desconhecidas, bem como sua contribuição para insuficiência renal no 
futuro. Além da produção de renina, RPCs participariam diretamente na hipertrofia 
vascular concêntrica dos vasos renais, apesar do adequado controle dos níveis de 
pressão arterial. Esta tese enfoca os RPCs, seu conhecimento atual, novos 
aspectos, e uma nova abordagem para entender sua fisiologia. Além disso, 
analisamos o conceito de sítios extrarrenais de produção de renina, e a liberação de 
pró-renina ativa pelos rins. Nossos dados suportam o conceito de que as células 
Juxtaglomerulares, do aparato Juxtaglomerular, são a única fonte de renina no 
organismo, na qual depende a geração de angiotensina. A compreensão completa 
do "recrutamento" das RPCs e suas conseqüências adicionais, combinadas com 
uma compreensão completa da produção de angiotensina local (renal), em última 
análise, permitirão terapias anti-hipertensivas mais efetivas, além de melhores 
resultados em pacientes com patologias cardiovasculares e renais. 
 






The benefit of Renin-Angiotensin System (RAS) blockade in cardiovascular and renal 
disease is undisputed, but what is still controversial is the optimal degree of RAS 
blockade. A high degree of RAS blockade may have additional beneficial effects, but 
also results in a higher incidence of side effects. The degree of blockade can be 
estimated from the increase in circulating renin, depicting the “recruitment” of new 
renin-producing cells (RPC) along the afferent arterioles. The long-term 
consequences of this process are still unknown, nor do we know if it contributes to 
renal impairment in the future. Besides renin production, RPC would participate 
directly in the concentric vascular hypertrophy, despite the control of the blood 
pressure levels. This thesis focuses on the RPCs, their current knowledge, novel 
aspects, and a new approach to understand these cells biology. Furthermore, we 
have analyzed the concept of extrarenal sites of renin production, and the active 
prorenin release by the kidney. Our data support the Juxtaglomerular cells, in the 
Juxtaglomerular Apparatus, as only source of renin in the body, on which angiotensin 
generation depends. The complete understanding of the RPCs “recruitment” and its 
further consequences, combined with a full comprehension of local (renal) 
angiotensin production will ultimately allow more effective anti-hypertensive 
therapies, and better outcomes in patients with cardiovascular and renal pathologies. 
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A2M - Alpha-2-macroglobulin 
AA - Afferent arterioles 
AC - Adenylate cyclase 
ACE - Angiotensin converting enzyme 
ACEi - Angiotensin converting enzyme inhibitor 
ACTA2 - Actin, alpha 2, smooth muscle, aorta 
ADCY3 - Adenylate cyclase 3 
AGA - Angiotensin-generating activity 
Akr1b7 - Aldo-keto reductase family 1, member B7 
AMP - Adenosine monophosphate 
ANG - Angiotensin 
Aog - Angiotensinogen 
ARB - Angiotensin receptor blocker 
AT - Angiotensin receptor 
ATP - Adenosine triphosphate 
ATP1B2 - ATPase, Na+/K+ transporting, beta 2 polypeptide 
BGN - Biglycan 
BSA - Bovine serum albumine  
C4A - Complement component 4A (Rodgers blood group) 
CALD1 - Caldesmon 1 
cAMP - Cyclic AMP 
CBLN4 - Cerebellin 4 precursor 
CBP - CREB-binding protein 
CD - Collecting duct 
CD248 - CD248 molecule, endosialin 
CD34 - CD34 molecule 
cDNA - Complementary deoxyribonucleic acid 
CFP - Cian fluorescent protein 
ciPTEC - Conditionally immortalized proximal tubule epithelial cells  
COL6A1 - Collagen, type VI, alpha 1 
COL6A2 - Collagen, type VI, alpha 2 
CPA3 - Carboxypeptidase A3 (mast cell) 
CPE - Carboxypeptidase E 
CRE - cAMP response element 
CREB - cAMP response elemento binding protein 
CRIP1 - Cysteine-rich protein 1 (intestinal) 
CSRP2 - Cysteine and glycine-rich protein 2 
CXCL12 - Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
DBNDD2 - Dysbindin (dystrobrevin binding protein 1) domain containing 2 
DCT - Distal convolute tubule 
DMEM - Dulbecco’s modified Eagle medium 
DOCA - Deoxycorticosterone acetate 
EA - Efferent arterioles 
ECV - Extracellular volume 
EDTA - Ethylenediamine tetraacetic acid 
EKA - Enzyme kinetic assay 
ELISA - Enzyme-linked immunosorbent assay 
ERK - Extracellular signal-regulated kinase 
FCS - Fetal calf serum 
FISH - Fluorescent 
FKBP10 - FK506 binding protein 10, 65 kDa 
FLNA - filamin A, alpha (actin binding protein 280) 
FOXD1 - Forkhead box D1 
FPKM - Fragments per kilobase of transcript per million 
FXYD1 - FXYD domain containing ion transport regulator 1 
GC - Guanylate cyclase 
GJA4 - Gap junction protein, alpha 4, 37kDa 
GNAS - GNAS complex locus 
GPC1 - Glypican 1 
GPR124 - G protein-coupled receptor 124 
GPRC - G protein-coupled receptor 
GTP - Guanosine triphosphate 
HAT - Histone acetyltransferase 
HBSS - Hank’s Balanced Salt Solution 
HCFC1R1 - Host cell factor C1 regulator 1 (XPO1 dependent) 
HEK - Human embryonic kidney 
HIF - Hypoxia inducible factor 
HMC - Human mastocitoma cells 
HSPB6 - Heat shock protein, alpha-crystallin-related, B6 
icREN - Intracelular renin 
IFITM1 - Interferon induced transmembrane protein 1 (9-27) 
IFITM2 - Interferon induced transmembrane protein 2 (1-8D) 
IFITM3 - Interferon induced transmembrane protein 3 (1-8U) 
IGF2 - Insulin-like growth factor 2 (somatomedin A) 
IL - Interleukin 
IRMA - Immunoradiometric assay 
ISYNA1 - Inositol-3-phosphate synthase 1 
ITGA7 - Integrin, alpha 7 
JAG1 - Jagged 1 (Alagille syndrome) 
JG - Juxtaglomerular 
JGC - Juxtaglomerular cells 
KISS1 - KiSS-1 metastasis-suppressor 
KO - Knock-out 
LBH - Limb bud and heart development homolog (mouse) 
LGALS1 - Lectin, galactoside-binding, soluble, 1 
LH - Loop of Henle 
LM - Loose mesenchyme 
LRO - Lysosome related organeles  
LXR - Liver X receptor 
M6P - Mannose 6-phosphate 
MAPK - Mitogen-activated protein kinases 
MCAM - Melanoma cell adhesion molecule 
MDK - Midkine (neurite growth-promoting factor 2) 
MEF2C - Myocyte enhancer factor 2C 
MFGE8 - Milk fat globule-EGF factor 8 protein 
miRNA - Micro ribonucleic acid 
MM - Metanephric mesenchyme 
MrgD - Mas-related G-protein coupled receptor D 
MSC - Mesenchymal stem cells 
MTT - (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
MXRA8 - Matrix-remodelling associated 8 
MYL9 - Myosin, light chain 9, regulatory 
NEP - Neutral endopeptidase 
NO - Nitric oxide 
NOTCH3 - Notch homolog 3 (Drosophila) 
NPPC - Natriuretic peptide precursor C 
NRARP - NOTCH-regulated ankyrin repeat protein 
NT5DC2 - 5'-nucleotidase domain containing 2 
OAZ2 - Ornithine decarboxylase antizyme 2 
PBS - Phosphate buffer saline 
PCP - Prolyl carboxipeptidase 
PCT - Proximal convolute tubule 
PDE - Phosphodiestarase 
PDGFB - Platelet derived growth fator β 
PDGFRβ - Platelet-derived growth factor receptor, beta polypeptide 
PEP - Prolyl endopeptidase 
PKA - Protein kinase A 
PLEKHH3 - Pleckstrin homology domain containing, family H (with MyTH4 
domain) member 3 
PRA - Plasma renin activity 
PTEC - Proximal tubule epithelial cells 
PTP4A3 - Protein tyrosine phosphatase type IVA, member 3 
PVDF - Polyvinylidene fluoride 
qPCR - Quantitative polimerase chain reaction 
RAAS - Renin angiotensin aldosterone system 
RAP-GST - Receptor-associated protein glutathione S-transferase 
RAS - Renin angiotensin system 
RBPJ - Recombination signal binding protein for immunoglobulin kappa J 
REN - Renin 
RGS5 - Regulator of G-protein signaling 5 
RNA - Ribonucleic acid 
RPC - Renin-producing cells 
RPMI - Roswell park memorial institute 
SERPINI1 - Serpin peptidase inhibitor, clade I (neuroserpin), member 1 
SFRP4 - Secreted frizzled-related protein 4 
SHR - Spontaneous hypertensive rats 
SLIT3 - Slit homolog 3 (Drosophila) 
SM-MHC - Smooth muscle myosin heavy chain 
SMA - Smooth muscle actin 
SPARC - Secreted protein, acidic, cysteine-rich (osteonectin) 
SPARCL1 - SPARC-like 1 (hevin) 
sREN - Secreted renin 
SRGN - Serglycin 
TAGLN - Transgelin 
TBC1D1 - TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 
TBX2 - T-box 2 
TGFBI - Transforming growth factor, beta-induced, 68kDa 
TGM2 -	 Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
TIMP1 - TIMP metallopeptidase inhibitor 1 
TINAGL1 - Tubulointerstitial nephritis antigen-like 1 
TPM1 - Tropomyosin 1 (alpha) 
TPM2 - Tropomyosin 2 (beta) 
TPSB2 - Tryptase alpha/beta 1; tryptase beta 2 
TUBA1A - Tubulin, alpha 1a 
UB - Ureteric bud 
VIM - Vimentin 
VSMC - Vascular smooth muscle cells 
WB - Western blot 
WD - Wolfian duct 
WT - Wild type 
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1.1 CLASSICAL RENIN ANGIOTENSIN SYSTEM 
 
In 1898, Robert Tigerstedt and Per Bergman performed a set of experiments, 
where they observed a rise in blood pressure after injecting rabbit kidney extracts in 
the jugular vein of rabbits. They characterized the substance as derived from the 
renal cortex, soluble in water and alcohol, thermolabile, and named it “renin" (1). This 
discovery remained dormant for more than 30 years, when Goldblatt et al. focus the 
research on hypertension, by renal artery clamping in dogs. They suggested the 
presence of a substance released by the kidney as the cause of hypertension, and 
they associated this substance with the renal hypoperfusion. Posteriorly, 2 
independent groups, using the same aforementioned animal model, confirmed this 
concept. Furthermore, they also isolated a vasoconstrictor compound, later known as 
“angiotensin”, and concluded that the substance released by the kidney was renin, 
capable of enzymatically act on a plasmatic protein to generate angiotensin (2). 
The renin-angiotensin system (RAS) plays a central role in blood pressure 
regulation and fluid-electrolyte homeostasis. It involves an array of enzymes, 
peptides and receptors, whose actions are able to correct small extracellular volume 
(ECV) variations by increasing or decreasing RAS activity. According to the classical, 
endocrine view of the RAS, also known as the systemic or intravascular RAS, renin, 
synthesized in the kidneys, catalyzes cleavage of a 10-amino acid peptide, 
angiotensin I (Ang I), from the N-terminus portion of the circulating angiotensinogen, 
a protein produced by the liver. This decapeptide is subsequently hydrolyzed by 
angiotensin I-converting enzyme (ACE), a dicarboxyl-peptidase ubiquitously present 
on the plasma membrane of endothelial cells, yielding the octapeptide angiotensin II 
(Ang II), the active endproduct of the RAS cascade, which is responsible, among 
others functions, for sodium reabsorption in the proximal convolute tubule of the 
nephron, and vessel constriction, especially arterioles within the renal and systemic 
circulation (3, 4). This traditional axis was completed later, with the discovery of 
aldosterone. Angiotensin II stimulates the zona glomerulosa in the adrenal cortex to 
release aldosterone, which promotes sodium reabsorption coupled with potassium 
exchange in the distal convolute tubule of the nephron. The whole axis, named renin-
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angiotensin-aldosterone system (RAAS), is now firmly linked to ECV adjustment and 
blood pressure regulation (4, 5). 
 
 
Figure 1. Schematic illustration of the classical RAS. Aog: Angiotensinogen; Ang: Angiotensin; ACE: 
Angiotensin converting enzyme. Modified from (4). 
 
1.2 RENIN, PRORENIN AND THEIR RECEPTORS 
 
Renin represents the first and the rate-limiting step of the RAS cascade. 
Overproduction and underproduction of renin result in severe disturbances of body 
fluid homeostasis. Precise regulation of renin release is therefore indispensable for 
proper RAS functioning (3, 6). Renin is an aspartyl protease synthesized as pre-
prorenin protein. Following its synthesis, the pre-part, which represents the signal 
peptide, is cleaved off inside the endoplasmic reticulum. The resulting molecule, 
prorenin, enters the Golgi apparatus to be glycosylated, and then proceeds to one of 
two different pathways. The first one involves clear vesicles containing prorenin 
which are secreted constitutively, while the second pathway involves prorenin 
tagging for regulated secretion, which is accompanied by proteolytic prorenin-renin 
conversion, and renin storage in dense cytoplasmic granules (7), awaiting release in 
response to various stimuli, such as sudden fall in blood pressure, low salt diet, or β-
adrenergic stimulation (8). 
The kidney secretes both renin and prorenin, but plasma levels of prorenin 
are, under normal conditions, about 10-fold higher than the plasma levels of renin (9). 
Renin consists of 2 homologous lobes, with a cleft in between, which contains the 
active site. Prorenin has a 43-amino acid N-terminal propeptide, the pro-segment, 
which covers the enzymatic cleft between the 2 lobes, thereby preventing the access 
of its specific and unique substrate, angiotensinogen (10). Prorenin is a glycoprotein, 
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which can be activated in 2 ways: proteolytically or non-proteolytically. The former is 
irreversible and involves removal of the pro-segment by a processing enzyme inside 
cytoplasmic granules, while the latter is reversible, inducible by certain conditions 
such as low temperature and pH, and results from a conformational alteration, i.e., 
unfolding of the propeptide from the enzymatic cleft (10). The proteases responsible 
to activate the prorenin enzymatically are not clearly known, although some 
candidates, like cathepsin B, have emerged (11). 
Prorenin and renin (together denoted (pro)renin) are able to bind to the 
mannose-6-phosphate/insulin-like growth factor II (M6P/IGFII) receptors, which  
contain binding domains for IGFII and phosphomannosylated ligands such as 
(pro)renin. Following binding, (pro)renin is internalized, and the prorenin is 
enzymatically converted to renin (12). Interestingly, despite internalization, and the 
subsequent prorenin to renin conversion, no intracellular angiotensin generation has 
been demonstrated. Instead, their binding to the M6P receptors has led them to slow 
degradation, and hence, these receptors are currently accepted as clearance 
receptors for (pro)renin (12-14). 
In 2002, a receptor that binds specifically to renin and prorenin was cloned: 
the (pro)renin receptor (15). Oppositely to the M6P receptor, the (pro)renin is not 
internalized or degraded. Instead, binding increases the renin catalytic activity, and 
surprisingly, it activates the prorenin non-proteolytically (16). Therefore, angiotensin 
generation would be feasible on cell surface, and the tissues would be able to uptake 
(pro)renin from the circulation. Interestingly, the (pro)renin receptor also plays some 
roles independently of Ang II generation. The (pro)renin binding triggers the 
activation of the MAPK (mitogen-activated protein kinases)/ERK (extracellular signal-
regulated kinase) 1/2 signaling pathway, which result in the upregulation of genes 
related to inflammation, fibrosis and cell proliferation (17). Nevertheless, the receptor 
has a low affinity for both renin and prorenin, what implies that their binding to the 
receptor in vivo will most likely occur only in sites where (pro)renin levels are 
sufficiently high (18). 
One question that still remains puzzling is the role of prorenin in modulating 
RAS system. Since prorenin is not an active enzyme, and does not generate 
angiotensin, why JGCs secret more prorenin in the bloodstream than renin? In any 
circumstance, does prorenin contribute to Ang II generation or can displays a specific 
pharmacological effect that is Ang II independent? In spite of the fact that different 
 
27 
studies have shown that prorenin has two different receptors, their role in the 
pharmacological action of (pro)renin is still unknown. Yet, the (pro)renin receptor 
gene has important role in the development of the brain, and it is considered an 
embryonic-essential gene. A specific mutation on this gene, which results in frame 
deletion of exon 4, has been associated to X-linked mental retardation and epilepsy 
in humans and mice (19). 
 
1.3 AXES OF RENIN ANGIOTENSIN SYSTEM 
 
The understanding of the RAS has built up with the aggregation of new 
peptides, receptors and enzymes to the system. Furthermore, novel functions 
associated with these recently described components allowed the inclusion of new 
axis in the RAS. It is no longer possible to conceive and accept the RAS as a linear, 
limited-proteolysis cascade, represented by a single and straightforward axis. 
On the classical axis, the Ang II generated from the participation of renin and 
ACE binds to the angiotensin receptors type 1 (AT1) to exert the typical actions 
related to the blood pressure regulation. Furthermore, the axis ACE/Ang II/AT1 is also 
linked to inflammation, proliferation and fibrosis (20). Nevertheless, many Ang II-
derived peptides and angiotensin receptors have been described afterward. Indeed, 
Ang II can be hydrolyzed by different “angiotensinases”, such as aminopeptidases, 
carboxipeptidases, endopeptidases, neprilysin and angiotensin converting enzyme 
type 2 (ECA2). They are all proteolytic enzymes that cleaves the angiotensin 
molecules, yielding smaller fragments that may have similar or opposite effects to 
Ang II, according to the angiotensin receptor they bind (21). For instance, besides 
AT1 receptor, at least 3 other more angiotensin receptors were described: angiotensin 
receptor type 2 (AT2), type 4 (AT4) and Mas receptor (22). 
The first novel axis of the RAS involves the angiotensin (1-7), or Ang (1-7), 
pathway. Curiously, Ang (1-7) is the most studied angiotensin peptide since the 
seventies (23). It is an active heptapeptide that can be formed directly from Ang I by 
endopeptidases (neutral-endopeptidase (NEP) or prolyl-endopeptidase (PEP)), or 
from Ang II by PEP, prolyl-carboxipeptidase (PCP) or ACE2 (24). The latter is a 
transmembrane glycoprotein, homologue to ACE, but with a single active site domain 
that works as a monocarboxypeptidase, removing one amino acid not only from Ang 
II to yield Ang (1-7), but also from Ang I, resulting in Angiotensin (1-9), which can be 
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hydrolyzed to Ang (1-7) by ACE or NEP (25). Interestingly, the ACE inhibitors (ACEi) 
can not block the ACE2, only ACE, thereby favoring Ang II degradation and Ang (1-7) 
generation (26). 
Ang (1-7) binds to the G protein-coupled receptor Mas, which is associated 
with cardiac, renal and cerebral protective responses (27). In fact, this angiotensin 
presents vasodilator and antihypertensive actions by stimulation of prostaglandins 
and nitric oxide (NO) (28). Furthermore, Ang (1-7) has been assumed to blunt 
important processes such as cell proliferation, hypertrophy, fibrosis and thrombosis 
(29). Thereupon, the discovery of the ACE2/Ang (1-7)/Mas axis depicts the 
complexity of the RAS, and the pathways involved in its regulation. The balance 
between the axes, displayed by ACE/Ang II vs. ACE2/Ang (1-7), will determine the 
subsequent outcomes, with the former promoting vasoconstriction/proliferation, while 
the latter upholds vasodilation/antiproliferation. 
Angiotensin (2-8), or angiotensin III (Ang III), is another heptapeptide derived 
from Ang II by the aminopeptidase A, whose actions are similar to Ang II (30). The 
hydrolysis of Ang III by aminopeptidase N yields the angiotensin (3-8), or angiotensin 
IV (Ang IV). This angiotensin binds preferentially to the AT4 receptor, recently 
identified as the transmembrane enzyme, the insulin-regulated membrane 
aminopeptidase, which can be found in adrenal gland, heart, brain, kidney and lung 
(31). Curiously, Ang IV also presents a wide range of effects, specially in the brain, 
where it enhances learning and memory recall and protects against cerebral 
ischemia (32). Conversely, Angiotensin A (Ang A) is another Ang II-derived fragment, 
which can be hydrolyzed by EAC2 to generate an heptapeptide known as 
Alamandine. Interestingly, this novel peptide has similar effects to Ang (1-7), by 
acting through the Mas-related G-coupled receptor type D (MrgD), representing 
another important counter-regulatory mechanism within RAS (33). 
Another axis that has been described in the last decade is the 
(pro)renin/(pro)renin receptor/MAPK ERK1/2 pathway. Again, all the aforementioned 
actions related to this axis would be dependent upon the receptor binding, what is 
limited to specific tissue sites. The complexity involved in all these axes exposes 







Figure 2. Schematic illustration of RAS axes. Aog: angiotensinogen; PR: prorenin; PRR: (pro)renin 
receptor; Ang: angiotensin; ACE: angiotensin converting enzyme; NEP: neutral-endopeptidase; PEP: 
prolyl-endopeptidase; AT: angiotensin receptor; Mas: ang 1-7 receptor Mas; MrgD: Mas-related G-
protein coupled receptor D. AP: aminopeptidase; APA: aminopeptidase A; APN: aminopeptidase N; 
MAP: mitogen activated protein; ERK: extracellular signal-regulated kinase. Modified from (34).    
 
1.4 LOCAL/INTRARENAL RENIN ANGIOTENSIN SYSTEM 
 
In the last three decades, the RAS has assumed an even bigger role. Besides 
its known functions as an endocrine system responsible to adjust blood pressure, 
RAS has emerged as a paracrine and intracrine regulator with pleiotropic effects 
related to inflammation, cell proliferation and fibrosis (35, 36). Hence, RAS 
participates in the pathophysiology of renal and cardiovascular diseases, and 
consequently, the RAS blockade is the current cornerstone in the treatment of renal 
and cardiovascular diseases (37, 38). The RAS also contributes to normal and 
abnormal growth processes and, evolutionary, the growth-promoting actions of 
angiotensin precede its endocrine and paracrine effects, representing one of its most 
highly conserved functions (39). Even though the role of circulating RAS has been 
strongly associated with cardiovascular disease, the local or tissue RAS, which is 
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characterized by the generation of Ang II in situ has also emerged as an important 
pathway involved in the pathogenesis of CV disease (40). Local RAS has been 
demonstrated in tissues such as heart, adrenal gland (24, 41), kidney (23, 24), brain 
(42), vascular endothelium (24, 43) and reproductive system (44). 
The best-described local RAS system is located in the kidneys, known as the 
intrarenal RAS. It harbors all the RAS components necessary for Ang II generation. 
Interestingly, the level of Ang II in the renal tissue is much higher than in plasma, 
sometimes 1000 times higher, what suggests selective local regulation, in a manner 
distinct from circulating RAS (23). 
Traditionally, Ang II has a negative feedback loop on the renin release into the 
circulation, what leads to the subsequent decrease in the circulating Ang II (45). 
Notwithstanding, in Ang II-induced hypertension model, the tissue Ang II content is 
increased, possibly by 2 mechanisms: the AT1 receptor-mediated uptake of 
circulating Ang II; and the presence of a positive feed-forward loop, in which 
circulating Ang II leads to the magnified production of local Ang II (23). Posteriorly, in 
that same experimental hypertension model, Navar et al. have demonstrated an 
augmented local expression of RAS components, including (pro)renin, 
angiotensinogen, and ACE (23). In 2010, Pohl et al. have shown the participation of 
the endocytotic receptor megalin in the uptake and internalization of RAS 
components such as angiotensinogen and renin in the proximal convolute tubule 
(PCT), thereby providing a novel aspect to the intrarenal RAS (46). Conversely, using 
an angiotensin receptor knockout (KO) mice, renal Ang II was located only 
extracellularly, which points toward the angiotensin production either in the interstitial 
space or bound to the cell surface (47). 
The local production of angiotensins in different tissues is undisputed. 
Nevertheless, the expression of local RAS components does not prove their 
functional significance and/or clinical relevance (40). There is still no consensus 
whether intrarenal RAS could participate in hypertension etiology independently from 
the circulating RAS. To address this question, Gonzalez-Villalobos et al. generated a 
mouse model specifically lacking kidney ACE, and studied them under experimental 
hypertension. They have demonstrated that absence of intrarenal ACE blunts the 
hypertension under either low (nitric oxide synthesis inhibition) or high Ang II (Ang II 
infusion) circulating levels (48). In other words, that would be a robust evidence 
linking the participation of renal tissue RAS in the physiopathology of hypertension. 
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However, some caveats require better evaluation. The findings have been 
questioned, especially in what concerns the pattern of Ang II metabolism in the ACE 
KO mice. In these animals, the ACE-free tissues might exhibit alternative upregulated 
angiotensinases, resulting in reduced Ang II half-life. If so, the KO animals would 
have been exposed to lower Ang II concentrations, due to a diminished half-life, 
resulting in more modest hypertensive and renal responses compared to the control 
group (49). Additionally, Matsusaka et al., making use of either kidney-specific or 
liver-specific angiotensinogen knockout mice, have shown that renal Ang II 
production relies utterly on the hepatic angiotensinogen (50, 51). Further studies are 
required to elucidate the participation of the intrarenal RAS as an independent factor 








1) To provide a review in the current literature about the new aspects and 
paradigms of the renin-angiotensin system and its relation with the renin-
producing cells; 
2) To validate a new approach to understand renin-producing cells biology, by 
using transcriptome analysis of human renin-producing tumors (reninoma); 
3) To evaluate the occurrence of a brain renin-angiotensin system, and 
subsequently, the potential participation of renin-producing cells in this 
process; 
4) To assess whether prorenin in an “open” conformation at the site of its release 
from renin-producing cells is capable of generating angiotensin locally; 
5) To investigate renin and prorenin reabsorption in megalin-expressing human 






3 JUXTAGLOMERULAR CELLPHENOTYPIC PLASTICITY 
 
3.1 JUXTAGLOMERULAR CELLS 
 
The JGC of the kidney are the only source of renin and the main source of 
prorenin in the circulation (3, 7). Several extrarenal tissues, such as the adrenal 
gland, ovary, testis, placenta and retina, additionally produce and secrete prorenin 
(9). Indeed, after a bilateral nephrectomy, prorenin, but not renin, can still be 
detected at low levels in blood (52). 
JGC are part of the juxtaglomerular apparatus, a tight structure situated on the 
kidney glomerular hilum, composed mainly of specialized epithelial cells (macula 
densa cells of the ascending limb of the nephron loop), extraglomerular mesangial 
cells, the terminal portion of the afferent arterioles and the proximal portion of the 
efferent arterioles. JGC are within these vessels and exhibit an epithelioid 
appearance, with a prominent endoplasmic reticulum, Golgi apparatus, and renin 
granules, but also containing myofibrils and adhesion plaques, typical of smooth 
muscle cells (53). 
Efforts to characterize JGC have historically been hampered by several 
factors: JGC lose their secretory granules and, concomitantly, their ability to 
proteolytically activate prorenin when placed in culture (54); JGC make up 
approximately 1/1000 of the total cell mass of the kidney, making it difficult to isolate 
sufficient quantities of pure cells for further characterization (55). 
 
3.2 JUXTAGLOMERULAR CELLS PROGENITORS AND THEIR EMBRYOLOGY 
 
JGC represent one type of the so-called repertoire of renin-producing cells 
(RPC), a group of cells that at some moment in their lifespan produce renin. During 
kidney ontogeny in mammals, renin expression changes according to a pattern 
(Figure 3). It first appears in the undifferentiated metanephric blastema before vessel 
formation has begun. Once the vascularization begins, around the 14th embryonic 
day in mice and rats, RPC are distributed along the walls of the arteriolar vessels. As 
the process evolves, renin starts to be expressed in other cells along the distal 
portions of the newly formed vessels. Gradually, RPC disappear from the larger 
vessels, shifting toward the afferent arterioles, and, finally, assuming their position on 
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the juxtaglomerular apparatus (8). Gomez et al. showed that the ontogeny of renin 
expression by RPC depicts its own phylogenetic evolution pattern (56). 
The expression of the renin gene is tissue-specific and developmentally 
regulated (57). Renal renin concentrations are high in early life, decreasing 
progressively as kidney maturation evolves (58). During this process, RPC are 
associated with assembling and branching of the developing kidney vasculature (59), 
and the ablation of these cells in mice during development results in a distinct kidney 
phenotype with peculiar vascular abnormalities (60). In vivo, vascularization of the 
kidney is synchronized with epithelial nephrogenesis (61). Epithelial branching 
morphogenesis is critical for the formation of various organs, including the 
vasculature and kidneys (62). The definitive kidney in mammals originates from a 
complex interaction between the ureteric bud and the metanephric mesenchyme, 
both derived from the intermediate mesoderm. These reciprocal actions lead the 
ureteric bud to elongate and bifurcate toward the metanephric mesenchyme, forming 
on its tip, an aggregate of mesenchyme cells, the cap mesenchyme. This condensate 
of cells generates a vesicle, which continues to form a comma-shaped body and 
later, a S-shaped body that gives rise to most of glomerulus and tubular epithelia. As 
nephrogenesis progresses, the newly formed S-shaped body is fused to the ureteric 
bud, from which the collecting ducts and ureter originate (63, 64). 
Cap mesenchyme expresses the transcriptional factors Six2 and Cited1 and 
gives rise to Bowman’s capsule, podocytes, the proximal and distal convolute tubules 
and the loop of Henle. There is an outer layer of loose mesenchyme cells, adjacent 
to the cap mesenchyme, which expresses different transcriptional factors: cKit 
(endothelial precursors) or forkhead box D1 (FoxD1, stromal cells). The latter factor 
is responsible for the generation of RPC, mesangial cells and all mural cells, 












Figure 3. Schematic illustration of nephrogenesis. The ureteric bud (UB) interacts with the 
methanephric mesenchyme (MM), resulting in the subsequent formation of the cap mesenchyme (CM) 
and loose mesenchyme (LM). The CM harbors the transcription factors Six2 and Cited1 (in orange), 
and will give rise to the tubular system (proximal convolute tubule (PCT), loop of Henle (LH) and distal 
convolute tubule (DCT); the LM harbors the transcriptions factor FoxD1 (depicted in green), and will 
give rise to most of the glomeruli and vascular cells from the afferent arteriole (AA) and efferent 







3.3 THE RECRUITMENT PHENOMENON 
 
JGC lineage involves differentiation of the above metanephric mesenchymal 
cells. This complex process generates hemangioblasts, which will evolve to 
endothelial cells, and RPC precursors, the latter harboring the transcriptional factor 
FoxD1. During kidney ontogeny, these precursors will give rise to JGC and a subset 
of VSMC (65, 67). In the adult, stress events that threaten body homeostasis, such 
as hypotension or extracellular fluid depletion, are normally corrected through renin 
release by JGC. Nevertheless, if this response does not suffice, or if renin expression 
is chronically stimulated, VSMC along the preglomerular arterioles undergo 
metaplasia to a renin cell phenotype in order to also synthesize renin, a phenomenon 
known as “recruitment” (69) (Figure 4). Importantly, the upregulation of renin 
synthesis and release following a homeostasis threat is due to a rise in the number of 
RPC (hyperplasia) rather than an elevation on the renin production per cell 
(hypertrophy) (70, 71). 
The recruitment phenomenon is an indispensible mechanism to maintain 
homeostasis. In the 1970s, Cantin et al. observed metaplasia of VSMC into JGC in 
the arteries and arterioles of ischemic kidneys (72). Nowadays, it is known that this 
transformation involves differentiation of a non-renin-expressing cell into a phenotype 
that is able to synthesize renin, and occurs in the descendants of cells that previously 
expressed renin during development (73). Interestingly, once the stimulation 
perpetuates, the recruitment intensifies, and RPC may occur all along the extension 
of preglomerular arterioles, larger vessels, in the extraglomerular and intraglomerular 
mesangium, in a pattern that resembles the development of the embryonic kidney 
(73). In a recent review, Gomez emphasized that recruitment does not involve 
migration or replication of cells, but solely concerns a phenotype switch toward renin 
expression by cells whose capability to produce renin is latent, and re-acquired 
following appropriate stimulation (68). 
Nevertheless, Dzau et al. identified liver X receptor alpha (LXRα), a nuclear 
receptor, as an important player in the induction of renin expression in JGC. They 
showed that LXRα exerts its activity as a cAMP-responsive regulator, binding to a 
unique upstream region of the renin promoter (74). LXRα activation additionally 
upregulated a set of genes (e.g., c-myc) that are involved in cellular differentiation, 
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proliferation and migration. Accordingly, LXRα would induce JGC hypertrophy and 
hyperplasia, through its coordinate interaction on the renin and c-myc promoters (70). 
 
 
Figure 4. The ‘‘recruitment’’ phenomenon, illustrated by a schematic ilustration (panels A and C) and 
immunofluorescence and fluorescent in situ hybridization data from control and captopril-treated mice 
(panels B and D, modified from (75)). In adult kidneys, renin is produced by the juxtaglomerular (JG) 
cells located within the afferent arterioles at the entrance of the glomeruli. However, under chronic 
renin stimulation (e.g., following captopril treatment), renin lineage cells (like the vascular smooth 
muscle cells (VSMC)) along the afferent arterioles may convert into a renin-producing cell (RPC) 
phenotype in order to maintain the homeostasis.  
 
Moreover, mesenchymal stem cells (MSC) have also been suggested to play 
a pivotal role in the recruitment phenomenon. Matsushita et al. demonstrated that 
human and murine MSC are capable of synthesizing renin following LXRα activation. 
Indeed, MSC overexpressing LXRα and under continuous cAMP stimulation 
underwent differentiation to a RPC phenotype, which could also express α-smooth 
muscle actin (αSMA) (76). Thus, on the basis of these findings, it was speculated that 
MSC, which are normally resident within the glomerulus, might be the origin of the 
RPC (76). Wang et al. used cell lineage tracking models to further study the role of 
MSC in RPC recruitment. First, they isolated MSC from the adult mouse kidney and 
verified the expression of typical tissue stem/progenitor cell markers, including CD44, 
and of metanephric mesenchymal cell markers, such as FoxD1. CD44-positive MSC-
like cells differentiated into RPC following exposure to an LXRα agonist, cAMP or a 
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phosphodiesterase inhibitor (77). Furthermore, mice submitted to a low salt diet and 
captopril treatment, conditions well-established to induce JGC recruitment, exhibited 
an expansion of RPC in the kidney, accompanied by CD44 cells, with co-localization 
of MSC markers and renin. These results could not be reproduced with bone marrow 
MSC, suggesting that only MSC resident in the adult kidney contribute to JGC 
recruitment (77). The prostaglandin E2/E-prostanoid receptor 4 pathway, also known 
for its involvement in tubuloglomerular feedback, played a key role in the activation of 
renal CD44-positive MSC during conditions of JGC recruitment (78). 
However, the participation of adult renal MSC in JGC recruitment has been 
questioned. Gomez et al. reported that MSC at most have a very minor contribution 
in comparison with the already existing pool of arteriolar cells undergoing a 
phenotype switch (68). The latter authors ascertained that JGC also express CD44, 
so that it is questionable whether MSC truly represent a different cell group in the 
recruitment process, or are just simply descendants of the renin cell lineage, capable 
of switching their renin phenotype back and forth. Moreover, CD44 expression on 
MSC might be an in vitro artifact, since  primary MSC from bone marrow lacked such 
expression, while it did occur after culturing the cells (79). Further studies are needed 
to unravel the precise role of MSC in JGC recruitment. 
 
3.4 cAMP PATHWAY AND RECRUITMENT 
 
Renin is a cAMP-inducible gene. In all species tested, there is a functional 
cAMP response element on the renin promoter (8). Among all the intracellular 
second messengers that control renin secretion, the cAMP signaling cascade 
appears to be the core pathway for the exocytosis of renin (7, 80, 81) (Figure 5). 
Thus, prostaglandins, kinins, and β-adrenergic agonists have a stimulatory effect on 
renin release, in all cases because they increase cAMP generation (82). 
cAMP regulates a wide range of biological processes in cells. The binding of 
an extracellular signal molecule to a G-protein coupled receptor activates adenylyl 
cyclase (AC), an enzyme that generates cAMP from ATP, increasing its intracellular 
levels. This rise activates cAMP-dependent protein kinase A (PKA). PKA translocates 
to the nucleus to phosphorylate the gene regulatory protein CREB (cAMP responsive 
element binding protein). CREB recognizes a specific DNA sequence, called the 
cAMP response element (CRE), found in the regulatory region of many genes. Once 
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phosphorylated, CREB recruits the coactivator CBP (CREB-binding protein), which 
stimulates gene transcription (83). 
 
 
Figure 5. Simplified scheme showing how cAMP and cGMP regulate renin (modified from (68)). ATP, 
adenosine-triphosphate; GTP, guanosine-triphosphate; cAMP, cyclic adenosine-monophosphate; AC, 
adenylate cyclase; CBP, CREB-binding protein; CRE, cAMP response element; CREB, cAMP 
response element binding protein; cGMP, cyclic guanosine-monophosphate; PDE, 
phosphodiesterase; NO, nitric oxide; pGC, particulate guanylate cyclase; sGC, soluble guanylate 
cyclase; GPRC, G-protein-coupled receptor; Gsα, stimulatory G protein α-subunit; Gβ, inhibitory G 
protein β-subunit; Gγ, inhibitory G protein γ-subunit; PKA: protein kinase A; cGKII, cGMP-dependent 
protein kinase type II. 
 
Interestingly, conditional deletion of G-protein subunits in RPC has a great 
impact on their function. Indeed, mice with protein Gsα (stimulatory subunit α) 
deficiency in JGC have very low plasma renin concentrations, with resulting low 
levels of aldosterone and arterial blood pressure. Moreover, such deletion also 





Elegant evidence on the regulation of renin production by cAMP was obtained 
by Gomez et al., who labeled cells of renin lineage with cyan fluorescent protein 
(CFP), and cells producing renin with yellow fluorescent protein (YFP) (86). This 
yielded suitable amounts of cells which could still produce renin after several 
passages. CFP-labeled cells expressed VSMC markers like α-SMA and smooth 
muscle myosin heavy chain (SM-MHC or Myh11), but not renin. However, after 
stimulation with forskolin (an AC stimulator) or cAMP analogs, they began to express 
YFP and renin, and decreased α-SMA and Myh11 expression. This response was 
even bigger with more intense or longer stimuli, suggesting that the recruitment 
response is graded (86). 
 
3.5 ROLE OF CALCIUM AND CGMP 
 
Calcium plays an important role in the biology of secretory cells. In general, a 
rise in cytosolic calcium leads to the release of their content. However, the opposite 
occurs in parathyroid cells and JGC, where calcium inhibits renin exocytosis. This is 
known as the "calcium paradox”, and it remained as a mystery for decades (82, 87). 
JGC harbor 2 isoforms of AC (types V and VI), which are inhibited by cytosolic 
calcium. Thus, particularly in JGC, a decrease in cytosolic calcium would stimulate 
AC, resulting in cAMP synthesis and, consequently, renin release (88, 89). Initially, it 
had been reported that calcium inhibits renin gene transcription and destabilizes 
renin mRNA (90). More recently, it became clear that calcium stimulates, via the 
calcium sensing receptor, a calcium calmodulin-activated phosphodiesterase 1C 
(PDE1), an enzyme that degradates cAMP, thereby providing an additional 
explanation of the calcium paradox (91). 
The contribution of cGMP to renin release is more complex, with both 
stimulatory and inhibitory effects (87). The cGMP and cAMP pathways are cross-
linked. Nitric oxide (NO) activates soluble guanylate cyclase (GC) to generate cGMP, 
which in turn inhibits phosphodiesterase 3, a cAMP-degrading enzyme. 
Consequently, cAMP levels will go up, and renin release will rise (87, 92). However, 
ligands that increase cGMP via activation of particulate GC (like atrial natriuretic 
peptide) inhibit renin exocytosis through activation of cGMP-dependent protein 
kinase type II (7, 87). Interestingly, Neubauer et al. recently demonstrated that RPC 
recruitment is dependent on NO availability and the NO-GC signaling pathway (93). 
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3.6 EPIGENETIC MECHANISMS AND MICRORNA 
 
Acetylation and deacetylation of histones are important epigenetics 
mechanisms involved in gene transcription regulation. Acetylation is mediated by 
histone acetyltransferase (HAT), which leads to the transfer of an acetyl functional 
group to histone molecules, promoting nucleosomal relaxation and transcriptional 
activation. Deacetylation is mediated by histone deacetylase (HDAC), and results in 
chromatin condensation and transcriptional repression (94). 
Using the double-fluorescent reporter mouse model described above, Gomez 
et al. observed that chromatin remodeling contributes to the recruitment process, at 
the cAMP level, through histone H4 acetylation (86). The underlying mechanism 
involved the CREB-recruited cofactors CBP and p300, which exhibit HAT activity 
and, in the CRE region, promote nucleosomal relaxation and, consequently, 
transcriptional activation. In support of this concept, forskolin increased histone H4 
acetylation in the CRE region (86). Studies carried out in mice with conditional 
deletion of CBP and p300 in RPC revealed that individual deletion of one of these 
cofactors did not affect renin expression, while simultaneous deletion reduced renin 
in adult life, and resulted in renal interstitial fibrosis (95). CBP/p300 were also 
indispensable for re-expression of renin in the arteriolar VSMC of mice exposed to 
low sodium + captopril (96). Taken together, RPC have a poised chromatin 
landscape suitable to respond properly to threats, allowing these cells to switch the 
renin phenotype on and off (68). 
In addition to the epigenetic control mechanisms, microRNAs (miRNAs) also 
control JGC activity. miRNAs are endogenous small non-coding RNA molecules, 
containing around 18-22 nucleotides. They exert their function by targeting mRNA, 
inducing decay or translational repression (97). miRNA genes are phylogenetically 
conserved, and are involved in many cell processes such as developmental timing, 
death and proliferation (98). miRNA transcription, usually by RNA polymerase II, 
results in a long transcript, whose structure will be cleaved by the RNase III 
endonuclease Drosha and the cofactor DGCR8, yielding a miRNA precursor (pre-
miRNA). This precursor is processed by the RNase III enzyme Dicer, and the product 





Gomez et al. established the importance of Dicer for the JGC and, even 
further, for the morphologic and physiologic integrity of the kidney. They discovered 
that conditional deletion of Dicer in cells of the renin lineage in mice reduced the 
number of JGC and decreased renin gene expression, thus leading to reduced 
plasma renin and blood pressure levels. The animals also presented kidneys with 
vascular abnormalities and striped fibrosis (100). Noteworthy, this vascular pattern 
was quite similar to that found in mice with ablation of the RPC, through the 
expression of diphtheria toxin A chain driven by the renin promoter (60). Surprisingly, 
kidney vessels exhibited normal wall thickness and lumen size, in contrast to the 
concentric hypertrophy and thick vessel walls seen when RAS genes are deleted, 
including renin. Apparently, RPC are responsible for arterial wall thickening, by 
producing angiogenic and trophic factors (60, 61). 
Furthermore, Medrano et al. identified two miRNA, miR-330 and miR-125b-5p, 
whose opposite actions are crucial for the recruitment phenomenon. miR-125b-5p is 
normally expressed in the VSMCs of the afferent arteriole, and responsible for 
sustaining a contractile phenotype. Yet, it is also expressed in JGC, in order to 
preserve their contractile function. However, under a homeostasis threat, miR-125b-
5p expression diminishes in VSMC, allowing them to undergo a metaplastic 
transformation into a renin phenotype, and remains unaltered in JGC. miR-330 is 
expressed in JGC only, and inhibits contractile features, thus favoring renin 
production (101). 
 
3.7 JGC SIGNATURE: THE MYO-ENDOCRINE PROFILE 
 
Although several factors have been identified that regulate renin production 
and secretion, RPC-specific markers were limited to renin itself, and the gene Zis 
transcript (54). To overcome this problem, Brunskill at al. targeted YFP to mouse 
JGC and used fluorescence-activated cell sorting (FACS) to enrich tagged cells for 
transcriptome analysis. This approach yielded a set of 369 core genes, responsible 
for the JGC gene regulatory network (102). Furthermore, this distinct array of genes 
that governs JGC identity is unique when compared to other cell types in the kidney. 
Mainly, it encompasses genes highly expressed in both smooth muscle and 




Among the genes identified in the transcriptome analysis, renin was the 
highest transcribed gene. The second highest one was aldo-keto reductase family 1, 
member B7 (Akr1b7), responsible for detoxification of steroidogenesis products. 
Akr1b7 is a member of aldo-keto reductase superfamily, which reduces harmful 
aldehydes and ketones produced from the breakdown of lipid peroxides to their 
respective alcohols (103). Remarkably, despite its high expression on JGC, mice with 
Akr1b7-deficient kidneys had no abnormalities in renin production and secretion, 
while renin deletion also did not affect Akr1b7 expression (102, 104). Therefore, 
Akr1b7 gene might function as a novel JGC marker, independently of renin. Other 
highly expressed transcripts involved genes related to the smooth muscle phenotype, 
like α-SMA, Myh11 and calponin (Cnn1) (102). 
Interestingly, the aforementioned genetic regulatory network allows RPC to 
possess either an endocrine or a contractile phenotype. Hence, this bivalent profile 
sustains the ability of RPC to switch phenotype, depending on the situation. 
Therefore, during a homeostasis challenge, renin lineage cells have the gene 
program to differentiate into an endocrine cell, synthesizing and releasing renin, in 
order to reestablish the homeostasis. Moreover, due to their position, at the 
glomerular hilum, JGC should also retain contractile properties, allowing them to 
contract or relax and, subsequently, to adjust renal blood flow and glomerular 
filtration rate (68, 102). 
 
3.8 NOTCH SIGNALING PATHWAY 
 
The Notch signaling pathway is a highly conserved system, present in all 
animal species, which plays a pivotal role in local cell-cell communication, 
determining cell fate decisions and controlling patterns formation during ontogenesis. 
Its dysfunction is linked to severe developmental defects and pathologies (105). The 
Notch signaling cascade starts with the binding of specific ligands to the Notch 
transmembrane receptor, leading to cleavage of the intracellular Notch receptor 
domain (NIC). NIC translocates to the nucleus, where it binds to RBPJ 
(recombination signal binding protein for Ig-κJ region), a transcription factor that 
normally represses Notch target genes by recruiting a co-repressor complex. 
However, once it is coupled to NIC, RBPJ recruits cofactors that activate the 
transcriptional machinery (106). 
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Interestingly, among the 369 core genes that confer the JGC identity 
according to the approach performed by Brunskill et al., there are members of the 
Notch pathway, including RBPJ (102). In fact, RBPJ had already been related to 
RPC plasticity by Castellanos Rivera et al. (107). They generated a conditional 
knockout (cKO) of RBPJ in renin lineage cells. This resulted in a striking reduction in 
the JGC number and renin expression, with subsequently low plasma renin levels 
and a low blood pressure. Furthermore, under conditions that trigger the recruitment 
phenomenon, such as sodium depletion and captopril treatment, RBPJ-cKO mice 
were unable to exhibit renin expression along the afferent arterioles, i.e., the ability of 
their VSMCs to regain the renin phenotype was impaired. 
Additionally, mice with RBPJ-cKO in renal cells of FoxD1 lineage displayed 
significant renal abnormalities, including a decline in the arteries and arterioles 
number, with a thinner smooth muscle cell layer and renin depletion, further 
upholding the concept that RBPJ is a major determinant of the transformation of 
FoxD1 cells progenitors into a healthy kidney vasculature (108). Experiments in 
transgenic renin reporter zebrafish fully support the essential role of the Notch 
signaling pathway for developmental renin expression and its association with proper 
angiogenesis (109). 
RBPJ also has a pivotal role in the maintenance of the JGC myo-endocrine 
gene program. Using a bacterial artificial chromosome reporter, it was observed that 
RBPJ activates the renin promoter directly (55). A double-fluorescent mice reporter 
model subsequently revealed that RBPJ deletion does not affect RPC endowment. 
RPC were at their proper location, although unable to express renin and Akr1b7, and, 
surprisingly, also did not express the VSMC markers α-SMA, Myh11 and Cnn1. Yet, 
they displayed an upregulation of genes related to the immunological system, such 
as lipocalin-2, lysozyme-2, chemokine ligand-9 and interleukin-6 (55). Furthermore, 
Belyea et al. identified renin progenitors in mouse bone marrow, and found that in the 
presence of RPBJ-cKO in the renin cell lineage, those progenitors gave rise to a very 
aggressive lymphoblastic leukemia (110). 
JGC are surrounded by multiple cell types, including pericytes, endothelial 
cells, epithelial cells, VSMCs, mesangial cells, and macula densa cells. Direct cell-to-
cell interaction will undoubtedly contribute to normal RPC functioning. It is therefore 
not surprising that, among the highly expressed transcripts identified by Brunskill et 
al. in JGC, is connexin 40 (102). Connexins are transmembrane proteins, six of 
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which assemble to mold a hemichannel. When 2 hemichannels of adjacent cells 
align, a channel is formed which allows the cytoplasma of both cells to connect. A set 
of these channels in parallel builds a gap junction, a structure that permits the cells to 
share small molecules and, therefore, to respond to extracellular signals in a 
coordinated way (56). Unexpectedly, in mice lacking connexin 40, RPC were found in 
the periglomerular interstitium, and not at their normal juxtaglomerular location. 
Besides, the recruitment phenomenon (following severe sodium depletion) did not 
occur at its usual location, i.e., in the wall of the upstream preglomerular arterioles 
(111). Apparently therefore, cell-to-cell communication via gap junctions is essential 
for the correct juxtaglomerular positioning and recruitment of RPC. 
 
3.9 PLASTICITY AND REGENERATION 
 
More than 100 years have passed since renin’s discovery, and the RAS now 
turns out to have multiple effects beyond its role in blood pressure regulation. As 
outlined in this review, renin cells function as pluripotent progenitors for other kidney 
cells types (73, 112). Normally, a low perfusion pressure leads to an expansion of 
RPC. Kurt et al. investigated to what degree this relates to hypoxia per se, by 
deleting the von Hippel-Lindau protein in JGC, i.e., the negative regulator of the 
hypoxia-inducible transcriptional factor-2 (HIF-2α). Remarkably, following the 
upregulation of HIF-2α by this procedure, RPC started to express erythropoietin 
instead of renin, and the normal renin upregulation after low salt was no longer seen. 
In fact, JGC were reprogrammed into fibroblast-like cells, expressing collagen I and 
PDGF receptor β (PDGFRβ) (113, 114). Clearly therefore, hypoxia-inducible genes 
are essential for normal development and physiologic adaptation of RPC. The 
upregulated PDGFRβ expression in these cells is in full agreement with the results 
from the human reninoma studies showing that the PDGFB- PDGFRβ pathway 
downregulates renin expression (115). 
Pippin et al. proposed that cells of renin lineage present alongside the 
preglomerular arteries participate in the glomerular regeneration after podocyte injury 
(116). In support of this concept, renin cells from the juxtaglomerular apparatus were 
shown to migrate to the glomerular tuft, in order to replace podocytes (117). This is 
 
46 
quite striking, since podocytes are normally derived from a different embryonic 
structure, the cap mesenchyme cells. 
Easier to understand is the participation of renin progenitors in glomerular 
mesangium regeneration, since mesangium cells, considered as specialized 
pericytes, are derived from FoxD1 stromal cells present at the loose mesenchyme. 
Indeed, in a mesangiolysis murine model, renin lineage cells repopulated the 
intraglomerular mesangium (118). Interestingly, these cells stopped producing renin 
and expressed PDGFRβ, i.e., the receptor linked to renin downregulation (115). 
Furthermore, Stefanska et al. established that pericytes are RPC in the human 
kidney (119). Traditionally, pericytes are perivascular cells that wrap around blood 
capillaries. They are highly plastic cells contributing to multiple processes like 
angiogenesis, tumorigenesis and vasculopathy progression (120). The concept that 
RPC are or derive from pericytes is very interesting, since pericytes possess 
regenerative potential and are additionally known for the fact that they express the 
PDGFRβ (119). In fact, in zebrafish, Rider et al. observed that renin cells express this 
marker (121). 
 
3.10 CONCLUDING REMARKS 
 
How exactly renin cells are able to differentiate into many different phenotypes 
remains to be clarified. The signals allowing RPC to shift phenotype, or to migrate to 
an injury site are now only beginning to be unraveled. Many questions still need to be 
answered, most importantly, whether regeneration would eventually allow a 
restoration of normal function. This is of particular relevance in chronic 
glomerulopathies, where glomerular cells are destroyed, with subsequent 
overproduction of extracellular matrix, fibrosis and architectural disruption, all leading 
to physiological impairment. Apparently, under such severe pathological conditions, 
tissue regeneration by RPCs either does not occur of is insufficient. One possibility is 
that RPCs under pathological conditions transform to fibroblast-like cells, thus 
contributing to renal fibrosis themselves. Currently, RAS blockade is the cornerstone 
of renal and cardiovascular diseases. Simultaneously, it is well known that RAS 
blockers, like most anti-hypertensive drugs, induce RPCs recruitment. The long-term 
effect of this chronic activation is still unknown, nor do we know to what degree it 
contributes to (further) impairment of renal function. Detailed knowledge of this 
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process would lead to better treatment options and more favorable outcomes. 
Clearly, this whole area not only illustrates the complexity of the renin cell, but also 






4 TRANSCRIPTOME ANALYSIS OF HUMAN RENINOMAS AS AN APPROACH 




The aspartyl protease renin catalyzes the rate-limiting step in the renin-
angiotensin system (RAS). Renin is produced almost exclusively by so-called 
juxtaglomerular (JG) cells that line the afferent arterioles at their point of entry into 
the kidney glomeruli. JG cells convert renin from its inactive precursor (prorenin) by 
proteolysis and store the resulting active renin in lysosome-like dense cytoplasmic 
granules whose content can be rapidly released in response to such stimuli as a 
sudden drop in the perfusion pressure of the afferent arteriole or beta-adrenergic 
stimulation. During kidney development, renin-producing cells are more broadly 
distributed along the lumen of the nascent arterioles (59) and gradually become 
restricted to the glomerular poles after birth. Prolonged exposure to stimuli, such as 
blood pressure-lowering medication, a low-salt diet or ischemia results in an apparent 
recruitment of new renin-producing cells along the afferent arterioles (122), which 
has been proposed to represent a partial return to the developmental pattern of JG 
cell distribution. Altogether, renin-producing JG cells display many unique biological 
features and because of their central role in modulating blood pressure and fluid 
balance, there has been long-standing interest in obtaining a better understanding of 
their origins and biology. 
Efforts to characterize JG cells have historically been hampered by two 
factors: First, JG cells rapidly de-differentiate when placed in culture, losing their 
secretory granules and, concomitantly, their ability to proteolytically activate prorenin. 
As a result, attempts to immortalize both mouse and human renin-producing cells 
have resulted in the establishment of cell lines that have lost the ability to secrete 
renin (123, 124). Second, JG cells make up only approximately 1/1000 of the cell 
mass of the kidney, making it difficult to isolate sufficient quantities of pure cells for 
further characterization. As an alternative approach, Brunskill et al. (102) targeted 
yellow fluorescent protein to mouse JG cells and used fluorescence-activated cell 
sorting (FACS) to enrich tagged cells for expression analysis. The resulting study 
proposed a 369 gene “signature” that characterizes mouse JG cells, although few of 
these have been verified in subsequent studies. 
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In an effort to extend these studies and to determine if the genes identified in 
the mouse also characterize human renin-producing cells, we have catalogued the 
gene expression pattern of biopsies derived from 4 human renin-producing tumors, 
or reninomas. Reninomas are rare, benign tumors arising from a proliferation of JG 
cells in the kidney cortex (125, 126) and are often detected due to the appearance of 
fulminant hypertension in relatively young patients (mean age under 30 years) with 
no obvious explanatory risk factors. RNA sequencing (RNA-Seq) revealed a set of 54 
highly expressed genes that are common to all four tumors and another 30 
expressed in 3 of the 4 biopsies tested. In situ hybridization of mouse kidney sections 
subsequently confirmed JG cell expression of 44 of these genes, the vast majority of 
which  have not previously been reported to be expressed in JG cells. Finally, 
hypothesizing that the highly expressed reninoma genes affect renin-synthesizing 
capacity, we selected 10 ligands (based on known relevance for blood pressure and 
kidney disease) and studied their effects on (pro)renin release by As4.1 cells. These 
cells are derived from a transgene-induced mouse kidney tumor, and do not store 
renin. They may thus be considered as de-differentiated JG cells which have lost 
their capacity to secrete lysosomes. Consequently, As4.1 cells might serve as a 
model to study the effect of reninoma-specific ligands on JG cell plasticity. Results 







The mice used in this study were housed in a 10/14 hour light/dark cycle with 
free access to normal mouse chow and water.  All of the experiments described 
herein were approved by the institutional Animal Ethics Committee and are in 
compliance with guidelines issued by the Canadian Council on Animal Care (CCAC). 
C57BL/6 mice were obtained commercially from Harlan Teklad (Lachine, Quebec, 
Canada) and bred in a specific pathogen free facility. Where indicated, 10-12 week 
old male mice were treated for 7 days with the ACE inhibitor captopril (Sigma-Aldrich, 




4.2.2 Preparation and Sequencing af Reninoma RNA 
 
These studies were approved by the Human Ethics committee of the IRCM 
(protocol 2013-31). Biopsies of histologically proven reninomas from patients with 
history of severe hypertension associated with high plasma active and inactive renin 
(i.e., renin and prorenin) concentrations were obtained at surgery from 4 anonymous 
patients (Paris1, Paris2, Montreal, Rotterdam) and snap frozen in liquid nitrogen. 
Total RNA was isolated using Trizol (Invitrogen) from 10 mg pieces of each tumor or 
biopsy, and was further purified using RNeasy MinElute Cleanup spin (#74204, 
Qiagen, Toronto, Canada) according to manufacturer’s instructions and eluted in a 
final volume of 10 µL. Eight µL of RNA was used as input, and library preparation 
conducted according to manufacturer’s instructions (“Low-Throughput (LT) Protocol” 
TruSeq RNA Sample Preparation Guide, Illumina). Resulting library preps were 
assessed for quality and concentration using the Agilent 2100 Bioanalyzer (Agilent 
Technologies). Fifty base pair paired end sequencing was conducted by the McGill 
University Genome Quebec Discovery Center using the HiSeq2000 (Illumina). 
 
4.2.3 Mapping and Transcript Quantification 
 
Low quality bases (any leading or trailing base with a quality below 3, and any 
window of 4 bases with an average quality below 15) were removed with 
Trimmomatic (v0.22) (128). After trimming, the sequences were aligned mapped to 
the human reference genome hg19 using Tophat (v2.0.6) (129), with a reference 
annotation downloaded from the UCSC Genome Browser (http://genome.ucsc.edu/). 
Transcript assembly and abundance were determined computed using Cufflinks 
(v2.0.2). The gene expression levels are represented as Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM). The normalized data are deposited in 
<http://www.ncbi.nlm.nih.gov/qeo/query/acc.cgi?acc=GSE57401>. 
 
4.2.4 Immunofluorescence/Fluorescent In Situ Hybridization 
 
iFISH was carried out as described (130). Mice (5 day old, 10-12 week old and 
10-12 week old treated with captopril for 7 days) were sacrificed and kidneys were 
rapidly removed and de-capsulated before being snap frozen in isopentane on dry 
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ice. Eight to ten micron sections were cut on a cryotome, and slide-mounted sections 
were post-fixed with 4% paraformaldehyde for 1 hour at room temperature. Total 
cDNA was generated from C57BL/6 mouse kidney and an approximate 1000 bp 
fragment for each of the targeted transcripts was amplified by polymerase chain 
reaction (PCR) using the oligonucleotides shown in Table S4, and subsequently 
sequenced to verify identity. An engineered T7 polymerase promoter on the double-
stranded cDNAs was used as a template to transcribe a cRNA containing UTP 
labeled with disoxygenin (DIG). The cRNAs were hybridized to the kidney sections 
and after washing the slides were incubated with biotin-conjugated mouse 
monoclonal anti-DIG (0.25 µg/slide) and rabbit anti-mouse renin (Molecular 
Innovation), diluted 0.15 µg in 100 µL. After thorough washing, the slides were 
incubated with streptavidin- HRP (Biolegend # 405210) diluted 1/100 and goat anti-
rabbit IgG conjugated to Alexa 488 (Invitrogen, A11008) diluted 1/400 followed by 
incubation with Cyanine3-tyramide reagent pack (PerkinElmer) and mounted in 
Mowiol. All samples were scanned with an LSM700 confocal laser scanning 
microscope (Carl Zeiss, Inc) linked to an AxioObserver Z.1 (Carl Zeiss, Inc) set with 
the same parameters. We used a 40x oil objective with a numerical aperture of 1.3. 
The 488 laser (reflected on the main beam splitter 405/488/555/639) was used to 
excite the Alexa-Fluor 488 probe and the fluorescent signal was detected by filter 
through the low-pass adjustable dichroic set to 542nm. The 555 laser (reflected on 
the main beam splitter 405/488/555/639) was used to excite the Alexa-fluor 555 
probe and the fluorescent signal was detected by filter through the high-pass portion 
of the adjustable dichroic set to 559nm. The image pixel size was 0.078µm collected 
with 2048x2048 pixels at 8bit depth with a pixel dwell time of 0.39µs and averaging 
lines 16 times. The DIC image was acquired using the transmitted photo-multiplier 
tube (PMT). 
 
4.2.5 Cell Culture Studies 
 
Human Embryonic Kidney (HEK) 293 cells and the mouse kidney tumor cell 
line As4.1 (ATCC, Manassas, VA) were cultured in 75 cm2 culture flasks using 
Dulbecco’s Modified Eagle Medium (DMEM Media - GlutaMAX™-I; Thermo Fisher 
Scientific, The Netherlands), supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS; Thermo Fisher Scientific), 100 U/mL penicillin and 100 U/mL 
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streptomycin (Lonza Benelux, The Netherlands), and maintained in a humidified 




Ten highly expressed reninoma genes encoding for ligands were selected 
from the 100 most upregulated genes present in the transcriptome analysis, focusing 
on genes involved in blood pressure regulation and renal disease. Their 
corresponding mouse cDNAs were cloned with a c-myc epitope. One Shot® TOP10 
Chemically Competent E. coli (Thermo Fisher Scientific) cells were used for plasmid 
propagation, according to the manufacturer’s instructions. The plasmid extraction 
was achieved using the Qiagen® Plasmid Mini Kits (Qiagen). 
 
4.2.7 Transfection and Ligand Exposure af As4.1 Cells 
 
HEK293 cells were transfected with the mammalian expression vector 
pcDNA3, containing each of the 12 selected mouse cDNAs. The transfection was 
performed with X-tremeGENE™ 9 DNA Transfection Reagent (Sigma-Aldrich, The 
Netherlands), according to the manufacturer’s  instructions. Once HEK293 and As4.1 
cells were confluent in the culture flasks (90-100%), they were trypsinized and 
resuspended in 10 mL of  DMEM, supplemented with 10% FBS, 100 U/mL penicillin 
and 100 U/mL streptomycin. Then, HEK293 and As4.1 cell suspensions (500 and 
200 µL of each, respectively) were transferred to a 6-well plate with 1.5 mL of DMEM. 
Twenty-four hours later, the medium of the HEK293 cells was refreshed with 900 µL 
of DMEM, and the transfection mix prepared in a proportion of 1 µg of plasmid to 3 
µL of transfection reagent. The final volume was adjusted to 100 µL, and this was 
added to the HEK293 6-well plates. Forty-eight hours later, the conditioned medium 
from the transfected HEK293 cells was transferred to the 6-well plates seeded with 
As4.1 cells, and incubated for another 48 hours. Thereafter, medium and cells were 
collected, cells were lysed with RIPA buffer (50 mmol/L Tris HCl, 150 mmol/L NaCl, 
1% Triton X-100, 0.5% sodium deoxylcholate, 0.1% SDS and 1 mmol/L EDTA) 
supplemented with protease inhibitor (Phospathase Inhibitor Cocktail 3 plus 
cOmplete™, Mini Protease Inhibitor Cocktail, Sigma-Aldrich), and all samples were 
stored at -80°C. 
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4.2.8 Western Blot 
 
In order to test the HEK293 transfection efficiency for each of the cDNAs, WB 
experiments were carried out with the medium obtained at 24 or 48 hours after 
transfection. The medium was collected and treated with protease inhibitor 
(Phosphatase Inhibitor Cocktail 3 plus cOmplete™, Mini Protease Inhibitor Cocktail, 
Sigma-Aldrich), and protein measurements were performed using the PierceTM BCA 
Protein Assay Kit (Thermo Fisher Scientific). Samples were prepared with a 4X 
Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromphenol blue and 0.125 mol/L Tris HC; Bio-Rad, Veenendaal, The Netherlands) 
and heated at 95°C for 5 minutes. The protein electrophoresis was performed with 
Mini-PROTEAN® Precast Gels (Bio-Rad), with a 16-µL of final volume for all 
samples. The bands were transferred by electroblotting to a PVDF membrane, which 
was blocked thereafter in a 5% Blotting Grade Blocker casein solution (Bio-Rad) for 1 
hour, and then incubated overnight with the primary antibody (anti-Mouse c-myc-tag 
monoclonal antibody, 1:1500; Cell Signaling Technology, Leiden, The Netherlands) 
under agitation at 4°C. On the next day, the secondary antibody was applied for 1 
hour at room temperature (Goat anti-mouse IgG (H+L-HRP conjugate, 1:8000; Bio-
Rad). The membrane was then washed and incubated with home-made peroxidase 
substrate for enhanced chemiluminescence for 2 minutes, and pictures were taken 
with the ImageQuant LAS 4000 (GE Healthcare Life Sciences, Eindhoven, The 
Netherlands). 
 
4.2.9 (Pro)renin Measurement and Determination of Cell Viability 
 
Renin and prorenin were determined in medium and cell lysates 48 hours after 
the treatment of the As4.1 cells with the conditioned medium from the transfected 
HEK293 cells, making use of an in-house enzyme-kinetic assay, applied both before 
and after prorenin activation with trypsin (131). 
As4.1 cell viability following PDGFB exposure was evaluated by (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma Aldrich) 
assay according to the manufacturer’s instructions. In brief, confluent cells were 
trypsinized, resuspended in DMEM at a density of 3 x 106 cells/mL, and incubated in 
96-well plates at 100 µL/well with or without PDGFB (Sigma-Aldrich). Twenty hours 
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later, 10 µL MTT (5 mg/mL in PBS) was added to each well, and incubated for 4 
hours. Then, the medium was replaced by 230 µL 0.04 mol/L HCl in isopropanol, and 
following 30 min of agitation at room temperature, absorbance was determined at 
570 nm, with background subtraction determined at 650 nm. 
 
4.2.10 Quantitative PCR 
 
To extract total RNA from As4.1 cells, cells were washed twice with cold PBS, 
and homogenized with 500 µL of TRI reagent (Sigma-Aldrich). Next, 200 µL 
chloroform (Sigma-Aldrich) was added, and centrifugation was performed at 14000 
rpm. Supernatants were collected and mixed with 250 µL isopropanol (Sigma-
Aldrich), centrifuged, and the pellet was washed in 500 µL of 75% ethanol, re-
centrifuged and suspended in diethylpyrocarbonate (Invitrogen, Groningen, The 
Netherlands) water. RNA concentration and purity were determined by NanoDrop 
2000 Spectrophotometer (Thermo Fisher Scientific). RNA was stored at -80°C. cDNA 
was generated using the QuantiTect Reverse Transcription Kit (Qiagen) according to 
the manufacturer’s instructions. The amount of RNA used per reaction was up to 1 
µg, and the final cDNA concentration was assessed by NanoDrop 2000 
Spectrophotometer. cDNAs were stored at -20°C. Primers for the genes of interest 
were designed in the Ensembl genome browser (<http://www.ensembl.org>) or 
obtained from public database (<http://www.rtprimerdb.org>). Sequences were 
evaluated with the Blast tool in the NCBI platform 
(<http://www.ensembl.org/Multi/Tools/Blast>). Primers (see Table S5) were ordered 
from Integrated DNA Technologies (IDT, Belgium). Reactions were prepared in 384-
well plates, with the reagents: 7.5 µL KAPA SYBR® Green FAST (KapaBiosystems), 
0.3 µL of each primer (Forward and Reverse), 0.3 µL High ROX, and 10 ng of cDNA. 
Nuclease-free water (IDT) was added to set the final volume reaction at 15 µL. The 
reaction protocol was identical for all qPCR experiments: 3 minutes at 95°C for DNA 
polymerase activation, 40 cycles of 95°C for 3 seconds for denaturation, and 60°C for 
25 seconds for primer annealing and extension. Standard curves were constructed 
on the Applied Biosystems StepOnePlus™ Real-Time PCR Systems, and data were 
analyzed with the Software StepOne v2.2. Gene expression quantification 
experiments were carried out on the Bio-Rad CFX384™ IVD Real-Time PCR 
Systems, and data analyzed with the Bio-Rad CFX Manager 3.0. 
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4.2.11 Statistical Analysis 
 
Results are expressed as mean±SEM. Data were analyzed for normal 
distribution using a Shapiro-Wilk’s test (P>0.05). Differences were tested using one-
way or two-way ANOVA, followed by Holm-Sidak’s or Dunnett’s multiple comparison 




Deep sequencing of RNA (RNA-Seq) was performed on three biopsies of a 
first reninoma from Paris (Par1B1-B3), one biopsy from a reninoma from Montréal 
(Mon), two biopsies from a reninoma from Rotterdam (RotB1, B2), and a second 
reninoma from Paris (Par2) along with a biopsy from adjacent supposedly normal 
tissue from the same patient (Par2N) (Table S1). We obtained from 45-100 million 
reads per sample (Table 1) with comparable overall sample quality (Figure S1). 
Remarkably, the Fragments Per Kilobase of transcript per Million (FPKM) mapped 
reads values for renin were quite similar in the four tumor samples and, in each 
tumor, renin was expressed at 15-41 times the level of the next most abundant 
transcript, confirming the diagnosis of bona fide reninomas (Table 2). 
 












Par1B1 88058080 83611860 94.95 0.811 
Par1B2 88713782 84187709 94.90 0.803 
Par1B3 74683086 71782557 96.12 0.813 
Mon 76131363 73212125 96.17 0.760 
Rot1B1 117331030 109192033 93.06 0.753 
Rot1B2 95468148 88616034 92.82 0.766 
Par2 55053372 47536436 86.35 0.766 






Table 2 – Ratio of the number of renin reads (FPKM) obtained in the various biopsies versus those for 
the next most abundant transcript. Also shown is the ratio of renin reads obtained between the 
putative tumor and normal adjacent tissue (Par2N) biopsies for the Par2 samples. Data are drawn 
from Table S1. 
Sample Par1 (ave.) Mon Rot (ave.) Par2 Par2N Par2/Par2N 













Ratio 33.53 41.49 16.11 14.53   
 
Results obtained from the three independently analyzed biopsies of the Paris1 
reninoma demonstrated an inter-sample Spearman correlation of >0.98 (Figure S2, 
red outlines) and similar results were obtained with the two biopsies of the reninoma 
from Rotterdam (Figure S2, green outlines) suggesting that the sample preparation 
and results obtained were reliable and reproducible. In the one case in which we had 
biopsies of both tumor and adjacent tissue from a single patient (Paris 2), there was 
a 217-fold increase in the number of renin reads in the reninoma versus the “normal” 
sample (Table 2) although the samples overall were very highly correlated (0.92 for 
all genes; see Figure S2, blue outlines). By limiting the gene set analyzed in all the 
samples to those that were expressed at least 4-fold higher in the reninoma versus 
the “normal” biopsies for Paris 2, we reduced the gene set to just over 1000 (Table 
S2) and this resulted in the removal of low reads (which are commonly unreliable) 
and many “housekeeping” genes from the analysis. Using this limited gene set, we 
identified the 100 most-expressed genes in each biopsy (Table S3). Re-calculation of 
the Spearman correlation using these highly expressed genes revealed a higher 
discrimination between samples (Figure S3). Although the repeat biopsies continued 
to exhibit a correlation >0.98, the correlation between the reninomas varied between 
a low of 0.46 (Par1 versus Par2) and a high of 0.74 (RotB1 and Par2). Surprisingly, 
the highest correlation is between the Par2 and Par2N samples (0.81, Figure S3), 
raising the possibility that the supposedly normal sample from this patient contains 
some reninoma. A Venn diagram reveals that 54 of the 100 most expressed genes 
were common to all 4 reninomas (Table S3 and Figure S4) and another 30 genes 
were highly expressed in 3 out of 4 of the tumors analyzed. Functional annotation 
clustering analysis (DAVID) did not reveal any statistically significant correlation for 
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cellular function using the genes most commonly expressed in the reninomas (data 
not shown). 
To test if these reninoma-enriched genes were also expressed in JG cells, we 
performed iFISH for 71 of the above 84 common reninoma transcripts (excluding, 
among others, genes that have no mouse equivalent) in kidney sections from 
C57BL/6 mice using the equivalent mouse probes (Table 3 and Figure S5). As 
expected, combined in situ hybridization and immunofluorescence for renin reveals 
perfect co-localization in the JG cells of adult mice (Figure 6A-1D). Furthermore, 
treatment of the mice with captopril for one week resulted in the expected recruitment 
of JG cells along the afferent arterioles (Figure 6E), while co-localization was also 
observed throughout the maturing arterioles of 5 day-old mice (Figure 6F). These 
results confirm the validity of this approach to assess the co-localization of the 
transcripts from the reninoma in the mouse JG cells. 
 
 
Figure 6. iFISH for renin in mouse kidney. Where possible, glomeruli are outlined in red and vessels in 
light blue. (a) Immunofluorescence for renin in adult mouse kidney is shown in blue; (b) In situ 
hybridization for renin in the same section is shown in yellow; (c) merged image from panels a and b, 
including phase contrast microscopy showing that renin is expressed at the base of the glomeruli as 
expected; (d) iFISH overlay for renin in kidneys from adult; (e) 5 day-old mouse, and (f) adult mouse 




In order to obtain a semi-quantitative comparison of gene expression levels in 
renin-producing cells, all confocal microscopy images were taken using the same 
parameters and a ranking from 0 (for no expression observed) to 4 (highly 
expressed) was assigned for each gene under each condition tested (Table 3). 
Among the 71 genes tested, 44 genes are expressed in both reninomas and mouse 
JG cells. Twenty-four of these were detected in all three conditions (5 day-old, adult 
and adult treated with captopril kidneys) while the remainder showed preferential 
expression in one or more of the conditions (Figure S5 and Table 3). Functional 
annotation clustering analysis using the 44 genes expressed in both the reninomas 
and mouse JG cells identified “developmental processes” as the most likely gene 
ontology (data not shown). 
From the top 100 highly expressed genes, focusing on blood pressure 
regulation and renal disease, we selected 10 genes coding for ligands (FSTL1, IGF2, 
LGALS1, MDK, MFGE8, NPPC, PDGFB, SPARC, SPARCL1, WFDC2) in order to 
investigate their potential role in JG recruitment. The corresponding mouse cDNAs 
were cloned with a c-myc epitope and transfected into HEK293 cells to obtain high 
concentrations of these ligands in the supernatant of the culture medium. WB 
experiments confirmed the presence of the proteins of each of the transfected genes 
in the HEK293 cell medium at 48 hours after transfection (Figure S6). Since all 

















Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (to be continued) 
Gene symbol Gene ID 
Expression in Mouse Renin-









Present in all 4 Reninomas 
REN*# Renin 4 2 4   
KISS1 KiSS-1 metastasis-suppressor 1 0 2   
GNAS GNAS complex locus 4 1 4   





IVA, member 3 
1 0 4   






0 1 2   








NOTCH3 Notch homolog 3 (Drosophila) 1 1 2   
MFGE8 milk fat globule-EGF factor 8 protein 2 2 4   









Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (continuation) 
Gene symbol Gene ID 
Expression in mouse renin-









Present in all 4 Reninomas 
JAG1 jagged 1 (Alagille syndrome) 0 1 1 
mostly in 
arterioles 
adjacent to JG 
SERPINI1* 
serpin peptidase 
inhibitor, clade I 
(neuroserpin), 
member 1 
0 0 1   
TBC1D1 
TBC1 (tre-2/USP6, 
BUB2, cdc16) domain 
family, member 1 
0 0 1   
CXCL12 
chemokine (C-X-C 
motif) ligand 12 
(stromal cell-derived 
factor 1) 
3 0 1 
mostly in cells 
adjacent to RPC 
in developing 
arterioles 
TPM2 tropomyosin 2 (beta) 1 0 1   
SLIT3 slit homolog 3 (Drosophila) 3 0 1 
only in some 








3 2 2   




protein 1) domain 
containing 2 
3 2 2   




Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (continuation) 
Gene symbol Gene ID 
Expression in mouse renin-









Present in all 4 Reninomas 
ISYNA1 inositol-3-phosphate synthase 1 1 1 2   
CALD1 caldesmon 1 4 2 4 also mesangial cells? 
NRARP NOTCH-regulated ankyrin repeat protein 0 1 1   










0 0 1   
ADCY3 adenylate cyclase 3 1 1 0   
LBH 
limb bud and heart 
development homolog 
(mouse) 





1 2 4  
IGF2 
insulin-like growth 
factor 2 (somatomedin 
A) 




protein 3 (1-8U) 
 0  0 0    




Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (continuation) 
Gene symbol Gene ID 
Expression in mouse renin-









Present in all 4 Reninomas 




protein 1 (9-27) 
0 0 0   
COL6A2 collagen, type VI, alpha 2 0 0 0   
CPE carboxypeptidase E 0 0 0   
LGALS1 lectin, galactoside-binding, soluble, 1 0 0 0   
TGM2 




0 0 0   
CBLN4 cerebellin 4 precursor 0 0 0   
SRGN serglycin 0 0 0   
TBX2 T-box 2 0 0 0   





NT5DC2 5'-nucleotidase domain containing 2 0 0 0 
weak expression 
in cells adjacent 
to JG 
TPM1 tropomyosin 1 (alpha) 0 0 0   




Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (continuation) 
Gene symbol Gene ID 
Expression in mouse renin-









Present in all 4 Reninomas 
HSPB6 
heat shock protein, 
alpha-crystallin-
related, B6 
0 0 0   
CD34# CD34 molecule 0 0 0   
HCFC1R1 
host cell factor C1 
regulator 1 (XPO1 
dependent) 




family H (with MyTH4 
domain) member 3 
0 0 0   





1 1 4   
CPA3 carboxypeptidase A3 (mast cell) 1 2 0  
RGS5* regulator of G-protein signaling 5 4 4 2   
ACTA2 actin, alpha 2, smooth muscle, aorta 4 0 2 
mostly in VSMC 
in adult 




protein 2 (1-8D) 
0 0 1   
TUBA1A tubulin, alpha 1a 2 3 4   




Table 3 – Summary of the iFISH analysis on mouse kidney for the genes most highly expressed in the 
reninomas. The genes found to express in renin-producing cells (RPC) are listed in their order of 
expression in the reninomas from highest to lowest (see Table S1) and their relative expression in 
each sample is estimated on a scale of 0 (no detectable expression) to 4 (highest expression), based 
upon the data in Figure S5. *Described as part of a 369 gene list that makes up a renin-producing cell 
signature, according to Brunskill et al. (102); #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells. (conclusion) 
Gene symbol Gene ID 
Expression in mouse renin-









PRESENT IN 3 OUT OF 4 RENINOMAS 
ATP1B2* 
ATPase, Na+/K+ 
transporting, beta 2 
polypeptide 
2 2 2   
MCAM melanoma cell adhesion molecule 2 2 3   
TAGLN transgelin 3 2 3 also in adjacent arterioles 
CRIP1* cysteine-rich protein 1 (intestinal) 0 1 4   





0 0 0   
TPSB2 tryptase alpha/beta 1; tryptase beta 2 0 0 0   
NPPC natriuretic peptide precursor C 0 0 0   
GPC1 glypican 1 0 0 0   




transport regulator 1 
0 0 0   
 
After adding the 48-hour conditioned HEK293 medium (containing the highest 
level of the desired protein) to (pro)renin-producing As4.1 cells for 2 days, we studied 
As4.1 cell morphology and quantified (pro)renin in the medium. Only PDGFB altered 
As4.1 cell morphology, in that the cells after exposure to this ligand displayed a more 
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elongated densely packed and aligned shape (Figure S7). Moreover, PDGFB also 
induced parallel decreases in the medium and cellular (pro)renin levels, by 64±5% 
and 53±10%, respectively (n=11), although only the former was significant (P=0.03; 
Figure 7A). Under control conditions, the medium contained predominantly (>95%) 
prorenin. In contrast, the cell lysate contained renin only, at levels corresponding to 
<1% of the total amount of renin+prorenin in the medium. qPCR experiments 
revealed that the reduction in (pro)renin also occurred at the expression level, 
decreasing its level by 84±5% (P=0.005, n=5; Figure 7A). Furthermore, when 
applying commercially obtained PDGFB directly to As4.1 cells, it lowered (pro)renin 
concentration-dependently (Figure 7B), and from these data, it could be estimated 
that the PDGFB level in the conditioned HEK293 medium was >100 ng/mL. MTT 
assays confirmed that the effect of PDGFB was not due to a reduction in cell viability 
(Figure 7B). Moreover, PDGFB did not affect total protein content, suggesting that its 
effect was also not due to a decrease in cell number (data not shown). 
Finally, we evaluated the effect of PDGFB-containing HEK293 medium on the 
expression of markers that illustrate the occurrence of a smooth muscle, endocrine 
and/or immunological phenotype, i.e., aldo-keto reductase family 1, member B7 
(Akr1b7), α-smooth muscle actin (Acta2), interleukin-6 (IL-6), and Recombination 
signal binding protein for immunoglobulin kappa j (Rbpj). Figure 7C illustrates that 
PDGFB upregulated IL-6 (P<0.0001, n=4), and downregulated Acta2 (P=0.01, n=6) 
in As4.1 cells. Non-significant increases in Akr1b7 (P=0.06, n=4) and Rbpj (P=0.06, 




The aim of this study was to gain insight into human JG cell biology. Given 
their rapid de-differentiation in culture, such knowledge is currently lacking. Instead, 
information on renin synthesis is largely derived from renin-producing tumor-derived 
cell lines, like As4.1 (mouse), Calu-6 (human) and human mastocytoma cells (HMC-
1). In an attempt to catalogue the genes expressed in JG cells, Brunskill et al. (102) 
used a f luorescent reporter mouse model, in which they have used cell sorting 
to enrich for gene-tagged renin-expressing cells in the mouse kidney. Comparison of 
gene expression arrays from the sorted cells versus the whole kidney led to the 
identification of 369 core genes whose expression was proposed to constitute a 
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“gene signature” for the mouse JG cell. In the current study, we have used direct 
RNA sequencing (RNA-Seq) of human reninomas to independently quantify gene 
expression levels in each of the biopsies we obtained, and to test for correlation of 
the gene expression patterns between mouse and human renin-expressing cells. 
This approach has the additional advantage that a control tissue to which expression 
can be compared was not required. This was an important consideration since our 
samples were derived from frozen pathology specimens, and only one of them had a 
corresponding biopsy of adjacent, presumed non-tumor, tissue. The high 
reproducibility and sequence “depth” achieved confirm that this approach is valid, 
robust and applicable to archival samples and the comparison of the reninoma 
transcriptomes allowed us to derive a gene expression “fingerprint” for the tumors. In 
addition, the high expression of renin, CD34, and vimentin, all of which have been 
previously reported as markers of reninomas (126, 132), confirms the diagnosis of 
bona fide reninoma in all of the tumors. 
At least 3 of the 4 reninomas expressed genes at relatively high levels that 
were also reported to be highly expressed in mouse renin-expressing cells (102) 
including, in addition to renin, RGS5, CRIP1, and ATP1B2. Conversely, a number of 
the most highly expressed transcripts previously identified in the mouse JG cell 
preparations were not detected in the 100 most-expressed genes in the reninomas 
including Syne2, Plac9, Myh11, Jph2, Myo18, Akr1b7 and Mgp. Interestingly, 
Akr1b7, a member of the alpha-keto reductase gene family was previously found to 
be highly enriched in mouse JG cell preparations and to serve as a specific marker 
for JG cells in the mouse kidney (102). Even though Akr1b7 does not have a 
homologue in humans, its closest human analogues, AKR1B10 and AKR1B15, are 
not expressed at detectable levels in the reninomas (data not shown). Since more 
recent results have shown that targeted deletion of Akr1b7 in mouse JG cells does 
not affect renin production (133), it is possible that the expression of Akr1b7 in 
mouse JG cells is unrelated to renin synthesis. 
Indeed, of the extended list of 369 core genes previously reported to be 
enriched in the mouse renin cell preparations (102), only 8 were among the 84 genes 
expressed in at least 3 of the 4 reninomas (Table 3 and Table S3). Although the 
exact reason for these differences is unclear, they could be due to several factors. 
First, some of the highly-expressed transcripts in the reninomas might be related to 
the tumoral transformation of the renin-producing cells. For example, the expression 
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of neither CD34, a commonly reported marker of reninomas and myelo-lymphopoetic 
precursors, nor insulin-like growth factor 2 (IGF2) was detected in the mouse JG 
cells. IGF2 also did not affect (pro)renin release by As4.1 cells. Alternatively, the 
differences could be due to the fact that in both the current study and that of Brunskill 
et al. (102), the gene expression patterns were obtained from impure populations of 
renin-producing cells and could reflect expression of a gene in a contaminating non-
JG cell. Finally, they could reflect true differences between mouse and humans. 
To overcome some of these limitations, we used iFISH to test whether the 
commonly expressed genes in the reninomas were also expressed in mouse JG cells 
(Figure S5). Even though the sensitivity of this analysis is limited by the level of 
expression of the candidate genes, it nevertheless confirmed that 44 of the gene 
transcripts expressed in the reninomas were also detected in mouse JG cells (Table 
3) and thereby significantly extends the list of potential markers for this unique cell 
type. 
Previous studies have reported that JG cells express contractile proteins, are 
related to pericytes (134) and, like pericytes, are derived from FoxD1-expressing 
lineages (135). Simultaneously, renal CD44(+) mesenchymal stem cell-like cells, 
whose differentiation is triggered by LXR stimulation (136), have been suggested to 
differentiate into JG-like renin-expressing cells (77). The current analysis confirmed 
the expression of a number of contractile proteins in both reninomas and JG cells, 
including myosin light chain 9 (MYL9), tropomyosin 2 (TPM2), transgelin (TAGLN), 
myocyte enhancer factor 2C (MEF2C), caldesmon (CALD1) and very low levels of 
ACTA2, as well as some pericyte markers including RGS5 and osteonectin (SPARC). 
We also confirmed the expression of vimentin (VIM), a marker of mesenchyme-
derived cells, in both the reninomas and JG cells, but did not detect expression of 
either LXR receptor or CD44 in the tumors. 
Our data also call into question the model that “recruited” JG cells (e.g., after 
captopril treatment) represent a return to the embryonic stage of renin-producing 
cells. The ACTA2 gene codes for α-smooth muscle actin, a marker for smooth 
muscle cells. Consistent with what has been previously reported (137) there is a 
demarcation in Acta2 expression with the expected higher expression in smooth 
muscle cells of the afferent arteriole and very low expression in adjacent JG cells of 
adult mice (Figure 8A). This demarcation persists after recruitment of new JG cells 
following captopril treatment (Figure 8B). In contrast, there appear to be 2 
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populations of renin-expressing cells in the developing kidney: one population that 
exists in clusters similar to the JG apparatus in adult kidney (Figure 8C, arrow) and 
which express only very low levels of ACTA2 and others which line the vessels of the 
developing kidney and exhibit significant overlap of renin staining and ACTA2 
expression (Figure 8C, light blue outline). Other genes whose expression was 
detected almost exclusively in renin-producing cells of the developing kidney include 
A2m, Slit3 and Cxcl12. Conversely, a number of genes appeared to be preferentially 
expressed in the JG cells of adult control and captopril-treated mice including 
Ptp4a3, C4a, Tinagl1, Lbh, Mdk, Bgn and Crip1. Taken together, these results 
suggest that JG recruitment does not simply involve a return to the embryonic renin-
producing cell, but may rather reflect differentiation of smooth muscle to either an 
intermediate or alternative phenotype. 
KISS1, which codes for a metastasis suppressor and is the second to third 
most abundant transcript in each of the four of the reninomas (Table 3), also 
presents a major difference in expression in the reninomas and mouse kidney. The 
KISS1 gene is located immediately adjacent to the renin gene on chromosome 1 in 
both mice and humans (http://www.ncbi.nlm.nih.gov/gene/3814). When large 
chromosomal fragments containing both genes are used to generate transgenic 
mice, coordinate expression of renin and KISS1 is detected in brain, kidney, lung and 
placenta (138). While we detected some expression of Kiss1 in the JG cells of 
captopril-treated mice (Figure S5), we did not detect its expression in adult mouse JG 
cells, raising the possibility that the neighboring Kiss1 gene is expressed only in 
conditions of very high renin gene expression. Whether it explains the fact that intra-






































Figure 7. A) Total renin (i.e., renin + prorenin) levels in the medium, and renin levels in the cell lysate 
obtained from As4.1 cells incubated for 48 hours with medium obtained from HEK293 cells transfected with 
10 genes expressing ligands that were upregulated in the 4 reninomas. Renin gene expression is also 
provided. Data are mean ±SEM of 5-11 experiments and have been expressed as a percentage of the 
levels in cells exposed to medium of control-transfected cells, i.e., cells treated with the transfection mix, but 
without cDNA. *P<0.01. B) Cell viability and total renin levels in the medium of As4.1 cells exposed to 
PDGFB for 24 or 48 hours. Data are mean ±SEM of 3 experiments and have been expressed as a 
percentage of the levels in cells not exposed to PDGFB (’control’). *P<0.01, #P<0.05 vs. 100%. C) Aldo-
keto reductase family 1, member B7 (Akr1b7), α-smooth muscle actin (Acta2), interleukin-6 (IL-6), and 
recombination signal binding protein for immunoglobulin kappa j (Rbpj) expression in As4.1 cells incubated 
for 48 hours with medium obtained from HEK293 cells transfected with 10 genes expressing ligands that 
were upregulated in the 4 reninomas. Data are mean ±SEM of 4-6 experiments and have been expressed 
as fold change versus the levels in cells exposed to medium of control-transfected cells, i.e., cells treated 




Also among the most highly expressed genes in all 4 reninomas is DBNDD2 
(Table S3), a paralog of the gene DTNBP1, which is a component of the BLOC-1 
complex that is required for normal biogenesis of lysosome-related organelles (LRO), 
such as platelet dense granules and melanosomes. Thus, DBNDD2 might be an 
interesting candidate to explain the high content of LROs found in the JG cells. 
A number of ligands and receptors were also found to be highly expressed in 
the reninomas and in mouse renin-producing cells, some of which might play a role in 
either the maintenance of the JG cell phenotype or in JG cell recruitment. Of 
particular interest is the high level of expression of the Notch3 receptor and PDGF 
receptor β (PDGFR) in the reninomas and JG cells. Indeed, RBPJ, the main effector 
involved in Notch receptor signaling, activates the myo-endocrine program of the JG 
cell, and conditional deletion of Rbpj in renin-producing cells results in a dramatic 
decrease in the number of JG cells seen in adult mice (55). Yet, in humans mutations 
in NOTCH3 have been identified as the underlying cause of cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 
with no known effects on renin. In the current study we observed that PDGFB 
suppressed (pro)renin synthesis in As4.1 cells, and altered their morphology. The 
concomitant suppression of Acta2 and upregulation of IL-6 suggests an As4.1 
phenotype change from myo-endocrine to inflammatory. IL-6 upregulation by PDGFB 
is well-known, and occurs in a RBPJ-independent manner (139). No significant 
alterations were observed in Akr1b7 and Rbpj, nor did PDGFB affect cell viability. 
Classically, endothelium-derived PDGFB recruits pericytes and promotes VSMC 
proliferation (140). Importantly, pericytes in the human kidney were recently reported 
to produce renin (119). Hypoxia transforms renin-producing cells into erythropoietin-
producing cells (114), and erythropoietin-expressing cells are assumed to be derived 
from capillary pericytes (141). Finally, following severe mesangial injury, renin-
positive precursor cells moved into intraglomerular sites and differentiated into (renin-
negative), PDGFRβ-expressing mesangial cells (118). As shown in Figure 8 (panels 
D-F), PDGFRβ modestly overlapped with renin in kidneys of adult, young, and 
captopril-treated adult mice, in addition to its well-known expression in interstitial 
cells. Moreover, Rider et al. observed that renin cells in the zebrafish kidney express 
both Acta2 and Pdgfrβ (121). Given the well-known role of endothelial PDGFB as a 
facilitator of mesangial cell proliferation and migration, an additional effect of PDGFB 
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might now be suppression of renin expression. Here it should be mentioned that 
neither conditional deletion of the PDGFRβ in renin-producing cells nor deletion of 
endothelial PDGFB production affected the normal development of renal renin-
expressing cells (142). This may not be too surprising, given the fact that PDGFB 
actually is a negative regulator of renin expression, possibly coming into play only 
under pathological conditions. 
 
 
Figure 8. iFISH showing renin immunofluorescence in blue and in situ hybridization for Acta2 or 
PDGFβ in yellow in kidneys from adult (A,D), 5 day-old (B,E) and captopril-treated (C,F) mice. Note 
the existence of 2 types of renin-producing cells in the 5 day-old mouse: those that co-express Acta2 
(outlined in the vessel in light blue) and those that don’t (arrow). Original magnification X 40. Scale 
bar=50µm. 
 
Besides the high level of PDGFRβ expression in the reninomas and the JG 
cells, both also express the genes for SPARC, SPARCL1 (SPARC-like 1 or hevin) 
and MFGE8 (lactadherin) at relatively high levels. It has been reported that SPARC 
can both prevent the binding of PDGF to its receptor (143) and potentiate its 
profibrotic effects (142), while lactadherin potentiates PDGFRß signaling (144). This 
raises the possibility that a more complex interplay between SPARC, SPARCL1, 
MFGE8 and PDGF regulates either the recruitment or other physiological responses 
of JG cells in their natural setting. In agreement with this concept, the current study 
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revealed no effect of either SPARC, SPARCL1 or MGE8 alone on (pro)renin 
synthesis by As4.1 cells. Additionally,  ligands that are known to be involved in blood 
pressure regulation (NPPC, or natriuretic peptide precursor C), diabetic nephropathy 
(LGALS1 or galectin-1) (145), nephrogenesis (MDK or midkine)(146), renal fibrosis 
(WFDC2, or WAP four-disulfide core domain protein 2)(147), and renal injury 
prevention (FSTL1, or follistatin-related protein 1) (148) also did not directly affect 
(pro)renin synthesis by As4.1 cells. 
Somewhat surprisingly, no proteases were included in the 100 most 
expressed genes in the reninomas (Table S3) where we might have expected to find 
one or more candidate prorenin processing enzymes (PPE) necessary for proteolytic 
activation of the renin secreted by these tumors. However, examination of the gene 
lists before subtraction of the genes expressed in the Par2N “normal” biopsy (Table 
S1) reveals that the rank of Cathepsin B (CTSB) expression varies from the 8th 
(Par1B1) to the 78th (Par2) position in the reninomas, although these expression 
levels did not appear to correlate with the apparent renin expression levels in each 
sample (not shown). However, because CTSB was only expressed 1.1-fold more in 
the Par2 reninoma than in the Par2N control kidney biopsy, it was eliminated from 
our gene list. Nevertheless, because CTSB has been co-localized with renin in JG 
cells secretory granules (149) and shown to accurately process human prorenin in 
vitro (150), it is quite possible that it fulfills the role of the PPE in the reninomas, even 
though it is a ubiquitously distributed protease. This analysis also reveals one of the 
potential shortcomings of our approach since by focusing on genes whose 
expression was consistently enriched in tumor biopsies we may have eliminated 
consideration of genes that play an important functional role in the biology of the JG 
cell, but whose expression is more widely distributed. 
The present study is the first to use a reninoma transcriptome analysis as an 
approach to understand human JG cell biology. It has yielded multiple new 
candidates that might play a role in the developmental plasticity of these cells and, 
among them, raises the PDGFB-PDGFRβ signaling pathway as a promising novel 
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Figure S2. Spearman pairwise comparison of the gene expression levels in the raw (unsubtracted) 
reads (FPKM) for each sample analyzed. The sample displayed on the X-axis is shown above the 
graphs, while that displayed on the Y-axis is shown at left. The correlation coefficient for overlap is 
shown in each reciprocal position. Par1B1-3 are biopsies 1-3 of the Paris 1 reninoma (bordered by a 
red box). Mon; Montreal. RotB1, 2 are the 2 biopsies analyzed from the Rotterdam reninoma 
(bordered by a green box). Par2 is the second Paris reninoma and Par2N is a biopsy of supposedly 







Figure S3. Repeat Spearman pairwise comparison of the sample analyzed in Figure S2 after 
subtracting genes that differed less than 4-fold between the Par2 and Par2N samples. See Figure S2 






Figure S4. Venn diagram representing the overlap of the 100 most-expressed genes in the reninomas 






Figure S5. Representative iFISH results showing renin immunofluorescence (in blue) and in situ 
hybridization for the indicated mouse mRNA (in yellow) in kidneys from 5 day-old mice (upper panel) 
10-12 week adult control mice (middle panels) and adult mice treated for 7 days with the ACE inhibitor 
captopril (lower panels). The results from each probe is presented on one page in alphabetical order. 
Where possible, glomeruli are outlined in red and vessels in light blue. Overlapping expression of 
renin and any of the corresponding genes in renin-producing cells (RPC) of the 5 day old (developing) 
kidney or juxtaglomerular (JG) cells of the adult kidney is seen as white dots. Signal in the tubules 
represents some degree of non-specific background. Results are summarized in Table 3 of the text. 
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Figure S6. WB experiments confirmed the presence of each of the transfected genes in the HEK293 
cells medium at 48 hours after transfection.  
 
 
Figure S7. PDGFB altered As4.1 morphology, in that the cells after exposure to this ligand displayed a 














Table S3 – Rank order of the 100 most highly expressed genes in each of the reninomas. Genes in 
yellow are part of a 369 gene list that makes up a renin-producing cell signature, according to Brunskill 
et al. (102) (to be continued) 
Rank Par1 Mon Rot Par2 
1 REN REN REN REN 
2 GNAS GNAS KISS1 KISS1 
3 KISS1 KISS1 GNAS GNAS 
4 IGF2 IGF2 IGF2 IFITM3 
5 IFITM3 A2M C4A PTP4A3 
6 A2M IFITM3 PTP4A3 IGF2 
7 SFRP4 SPARCL1 CSRP2 CSRP2 
8 PTP4A3 PTP4A3 IFITM3 ACTA2 
9 SPARCL1 TGFBI A2M A2M 
10 TGFBI C4A MYL9 MYL9 
11 CSRP2 CSRP2 TPM2 TPM2 
12 C4A JAG1 SPARCL1 IFITM1 
13 VIM NOTCH3 C10orf116 TAGLN 
14 TPSB2 PDGFRB TAGLN C10orf116 
15 MYL9 IGLL5 ACTA2 C4A 
16 IFITM1 SERPINI1 ISYNA1 SPARCL1 
17 MDK WFDC2 TPSB2 VIM 
18 TPSAB1 IFITM1 TPSAB1 LGALS1 
19 COL6A2 SRGN COL6A2 SPARC 
20 CPE HSPB6 HSPB6 LBH 
21 NOTCH3 ISYNA1 JAG1 SFRP4 
22 MFGE8 NPPC SRGN COL6A2 
23 LGALS1 SFRP4 MYBPH TPM1 
24 PDGFRB LBH CPE JAG1 
25 TGM2 ECEL1 CALD1 CPE 
26 SPARC GPC1 IFITM1 ISYNA1 
27 JAG1 MXRA8 LGALS1 TBX2 
28 CBLN4 TBC1D1 NOTCH3 TPSB2 
29 SRGN ADCY3 VIM IFITM2 
30 SERPINI1 VIM LBH CALD1 
31 TBC1D1 ITGA7 TBX2 SRGN 
32 ECEL1 TBX2 FLNA MCAM 
33 TBX2 CPE IFITM2 TBC1D1 




Table S3 – Rank order of the 100 most highly expressed genes in each of the reninomas. Genes in 
yellow are part of a 369 gene list that makes up a renin-producing cell signature, according to Brunskill 
et al. (102) (continuation) 
Rank Par1 Mon Rot Par2 
35 TPM2 COL6A1 TPM1 MDK 
36 CPA3 ATP1B2 COL6A1 COL6A1 
37 RGS5 CALD1 ITGA7 C11orf96 
38 ACTA2 CBLN4 TBC1D1 CXCL12 
39 NPPC SPARC MXRA8 TGFBI 
40 SLIT3 NT5DC2 TGM2 OAZ2 
41 CD248 LGALS1 CPA3 NOTCH3 
42 FABP5 APLP1 BCKDHB PDGFRB 
43 IFITM2 MDK C1QB BGN 
44 ITGA7 FLNA HCFC1R1 TPSAB1 
45 TUBA1A SLIT3 NRIP2 GJA4 
46 LBH C20orf27 TM4SF1 WFDC2 
47 C20orf27 HRC TINAGL1 RERGL 
48 BGN TUBA1A SFRP4 NT5DC2 
49 COL6A1 C1QB C1QA TINAGL1 
50 ATP1B2 COL6A2 ADCY3 COL13A1 
51 GPC1 CXCL12 GJA4 CRIP1 
52 CD55 DBNDD2 SPARC TUBA1A 
53 MXRA8 PDE4C C20orf27 SERPINI1 
54 MCAM GPR133 C1QC ADCY3 
55 C10orf116 FSTL1 PDGFRB TM4SF1 
56 FKBP10 RASAL1 SLC5A7 UBA2 
57 FXYD1 WISP1 ATP1B2 MFGE8 
58 OAZ2 C10orf116 NR2F1 C1QA 
59 NT5DC2 OAZ2 WFDC2 C1QB 
60 FSTL1 GJA4 COL13A1 NRARP 
61 GJA4 TPM2 C11orf96 TPM4 
62 DBNDD2 FABP5 FLRT2 FLNA 
63 TAGLN NRARP DBNDD2 HCFC1R1 
64 FLNA CD34 UBA2 CBLN4 
65 IGLL5 HCFC1R1 NT5DC2 NRIP2 
66 ISYNA1 MMP7 SLC7A2 ENO3 
67 CALD1 GPAT2 OAZ2 CPA3 




Table S3 – Rank order of the 100 most highly expressed genes in each of the reninomas. Genes in 
yellow are part of a 369 gene list that makes up a renin-producing cell signature, according to Brunskill 
et al. (102) (conclusion) 
Rank Par1 Mon Rot Par2 
69 CRIP1 C1QC FXYD1 DBNDD2 
70 PLTP MYL9 CASQ2 C1QC 
71 KLHDC8B UBA2 PEAR1 NPPC 
72 ADCY3 ADAMTS9 SLIT3 CD248 
73 TPM1 C1QA ADAM33 CD34 
74 RERGL CD248 MFGE8 HSPB6 
75 GPR124 MFGE8 MYOM2 C10orf10 
76 TIMP1 HES4 MCAM ITGA7 
77 HSPB6 FABP4 NRARP PLEKHH3 
78 COX4I2 PLEKHH3 CD34 HES4 
79 FABP4 TIMP1 PDLIM7 SEPT4 
80 DAAM2 DDIT4 HES4 COX4I2 
81 HRC ADAM33 TIMP1 NR2F1 
82 RET LIMCH1 MYH11 CCR10 
83 PCOLCE KLHDC8B LEFTY1 BCKDHB 
84 TINAGL1 TBX3 BGN FKBP10 
85 CSPG4 TNFRSF1B MEIS1 TGM2 
86 DKK3 PEAR1 LMOD1 CCL14 
87 CD34 TINAGL1 TYROBP SGCA 
88 GUCY1B3 CRIP1 CBLN4 TIMP1 
89 UNC5B TPM1 MEF2C PPP1R12C 
90 HCFC1R1 PPP1R12C GPR124 NDUFA4L2 
91 PLEKHH3 GRK5 TNFRSF1B C20orf27 
92 TPM4 TPM4 GUCY1B3 DKK3 
93 COL15A1 COL13A1 GPC1 GPR124 
94 NRARP NRIP2 SEPT7 GRK5 
95 ADRA2C HIC1 PLEKHH3 GUCY1B3 
96 MEF2C EMILIN1 ENO3 FXYD1 
97 ARHGEF17 GPR124 RGS5 SLIT3 
98 EMILIN1 MEF2C DDIT4 PDE4C 
99 NDUFA4L2 NPTX1 ARHGEF17 PTPN12 






Table S4 – Oligonucleotide sequences used to amplify the C57BL/6 mouse cDNA fragments for 
generation of the FISH probes. F; forward. R; reverse. Shown in the right-hand column is the expected 
length of the amplified fragment. (to be continued) 
Gene Sense Sequence size (bp) 
A2m F ATGGAGTCTGTCCGTGGGA 1066bp 
  R GTTAGGGACGTGCCCATGAT 
Acta2 F GCTATGTGTGAAGAGGAAGA 1028bp 
  R CCAGACAGAGTACTTGCGT 
Adcy3 F CAAAATGGCCTCAACGGCTC 1014bp 
  R AGTACTTGGAAGGCACCAGG 
Atp1b2 F CCCCTTTCTATCGCAGTCGG 1088bp 
  R ATCCGGAGTTTGAAGGCCAC 
Bgn F GCATCAATGACTTCTGTCCTA 1017bp 
  R ACCTTCCAGCTTCCTCCAG 
C4a F CCCGGGGCGAAGGTCACAGACGCTGTG 1007bp 
  R GGCCGCGGCTGCTGAACTCCATCAGGA 
Cald1 F TGCCTATCAGAGAAATGATGAT 982bp 
  R CGATCTCTTCCTTTAACCTC 
Cbln4 F CTAGCCACCTTTGCTAGCGT 1063bp 
  R CATCACGGAGAAGTCGGGTT 
Cd34 F ATGCAGGTCCACAGGGAC 959bp 
  R CCTTTCTCCTGTAGGGCTC 
Cd248 F CCCGGGGCGTGATCTCTGCCACTCGACC 1012bp 
  R GGCCGCGGTGTGGTCTCAGCCATGTGTC 
Col6a1 F GGTGAAGCTGGAGCAGAC 999bp 
  R GCGCTTCTCCGGTGAATG 
Col6a2 F ACATGGGTGAACCAGGAGA 999bp 
  R CAGCATCCACAGGTCTCC 
Cpa3 F CCCGGGGCCATCCTGAGATGGTTTCAAG 996bp 
  R GGCCGCGGCTGTTGGGAGTAAATAGAAAC 
Cpe F GCTGTCATTCACTGGATCAT 1015bp 
  R CGGTTGACTTCTTCATGGC 
Crip1 F GGTCCCTGAAAAGCGCGG 443bp 
  R TTCCAAAGATCAGGTTTATTAA 
Csrp2 F AGTCTCCGGATCCGCCC 840bp 
  R TAAGAGGTGGTACCCAAATC 
Cxcl12 F GCCATGGACGCCAAGGTC 1064bp 




Table S4 – Oligonucleotide sequences used to amplify the C57BL/6 mouse cDNA fragments for 
generation of the FISH probes. F; forward. R; reverse. Shown in the right-hand column is the expected 
length of the amplified fragment. (continuation) 
Gene Sense Sequence size (bp) 
Dbndd2 F GCTGACATGGACCCAAATC 1054bp 
  R CAATGCCTTGCGGAGATGAA 
Fkbp10 F CATGTTCCTTGTGGGGTCCTC 1056bp 
  R CCATTCTCCCCGTAGGCA 
FlnA F TATGGTGGTCACCAAGTGCC 1055bp 
  R CTGGTCACATCCAGCCCATT 
Fxyd1 F GGGTGGAGCATCCAGTTCT 559bp 
  R TTATCAAGAAGGAAAACCGAG 
Gja4 F AGCACACCCACCCTGATCTA 1006bp 
  R AGTCAAGAGCACTCCCACCT 
Gnas F GCGATGGTGAGAAGGCCA 1022bp 
  R CTATGGTGGGTGACCAACT 
Gpc1 F GCCATGGAACTCCGGACC 1008bp 
  R CTGTGAGTGTGTCCTTGTTG 
Gpr124 F TGGGAGGCCCAACATTTCTC 1006bp 
  R AATCAACGCCACCGGTATGT 
Hcfc1r1 F CCCGGGGCGAGCCGTAATGATCCTGCAA 858bp 
  R GGCCGCGGTTATTGTGGGGATAATGTTTGG 
Hspb6 F CAGCGTAGGAACAGGATGGAG 1098bp 
  R TTGAGTTTGGGGTTCCTGGT 
Ifitm1 F TTAACTCCGCAGCCCCTAA 700bp 
  R GGCAGAAAGTCACAGCACG 
Ifitm2 F CCAGAGTCAGTACCATGAGCC 589bp 
  R CCACCCCGTGCACTTTATTGA 
Ifitm3 F GGAAACTTCTGAGAAACCGA 640bp 
  R GGTGGTTATCAAGTGCACTT 
Igf2 F GAAGTCGATGTTGGTGCTTC 1017bp 
  R CCAAGTCTTAGCCAATTTGAC 
Isyna1 F GTGGTCTACAGCCCCGAAAC 1043bp 
  R TCCACCACACTGCTCTTTGT 
Itga7 F GCAGACCTGATTGTGGGTG 999bp 
  R TGGGCAGAGCCTGGAACT 
Jag1 F GAGATCCTGTCCATGCAGA 1036bp 




Table S4 – Oligonucleotide sequences used to amplify the C57BL/6 mouse cDNA fragments for 
generation of the FISH probes. F; forward. R; reverse. Shown in the right-hand column is the expected 
length of the amplified fragment. (continuation) 
Gene Sense Sequence size (bp) 
Kiss1 F CCTGGAAGGAGACTGTAGA 496bp 
  R GACGGCAGCATTGCTTTTAT 
Lbh F GAAGCTGGCTAGCGGGCT 1005bp 
  R CTCAGACAGCACATGGTTG 
Lgals1 F GTCTCTCGGGTGGAGTCT 800p 
  R TTAGTGGTTTCTGGCTTTTATT 
Mcam F ATATGAGCACCGCCTTAGCC 1040bp 
  R CCATCCATGGGGACCCAAAA 
Mdk F CCCGGGGCGCTCCCTGCCACATCAGA 997bp 
  R GGCCGCGGCTTAATAACAAGTATCAGGGT 
Mef2c F CCCGGGGCGTCTGATGGGCGGAGATC 1019bp 
  R GGCCGCGGCTCAAGTGCTAAGCGTATCT 
Mfge8 F CTACACAGCTGGGCATGGAA 1047bp 
  R AAGGTCGTCAGCCACAGAAG 
Mxra8 F TGTGGACCCAAGACCGGC 999bp 
  R ACAGCAAACTCCACCATGT T 
Myl9 F GGCAAGATGTCGAGCAAGA 1013bp 
  R CAGCCTTGTATTAAGAGACTG 
Notch3 F GCTGCCAGTGTCCTCTTG 1050bp 
  R CTGACGGCTATGAGTGTCG 
Nppc F GCACAGCAGTAGGACCTGT 961bp 
  R CATTACAATGGTTGGCTTCTT 
Nrarp F CCCGGGGCGCAACATGAGCCAAGCCG 1038bp 
  R CCCGGGGCGCAACATGAGCCAAGCCG 
Nt5dc2 F AAGTGATCGACCTGTACGGC 1000bp 
  R CGCGGGTAGAAGGTGAAGTC 
Oaz2 F AGAGCCACCGAGGATGATAAA 1046bp 
  R AAAGCCTATACTCAGGAGCCC 
Pdgfrb F GACACCAGCTCTGTTCTCT 1018bp 
  R CTATCACAGGCGTGGACAA 
Plekhh3 F CATGGTTACTCCCACGCAGA 1024bp 
  R GCTCCTCGCTGCTCATACAA 
Ptp4a3 F GGACCTGAAGAAGTACGGG 1014bp 




Table S4 – Oligonucleotide sequences used to amplify the C57BL/6 mouse cDNA fragments for 
generation of the FISH probes. F; forward. R; reverse. Shown in the right-hand column is the expected 
length of the amplified fragment. (continuation) 
Gene Sense Sequence size (bp) 
Ren F ACATGACCAGGCTCAGTGC 1004bp 
  R ACTTGCGGATGAAGGTGGC 
Rgs5 F ATGTGTAAGGGACTGGCAG 1008bp 
  R CTAACCAAATTCTGAAGCCAT 
Serpini1 F GCACAGCTGATCGAAGAATG 1071bp 
  R CATGTGGCATATTGGTTCA 
Sfrp4 F GCTCCATCCTGGTGGCGT 1064bp 
  R CCATCACAGAAAGTAATTAGCT 
Slit3 F GAACCTCTGTCAGCACGAG 1000bp 
  R CTGCAGCTGTGACCAAGG 
Sparc F GTCCTGGTCACCTTGTACG 1018bp 
  R CCTAAGAGTCGAGAAGACAG 
Sparcl1 F GAGCAACCTGTAAGTGACTC 1015bp 
  R CAAGCTCCGAAGTAATCCAG 
Srgn F GCTAATCCAGAGGCTGAGT 894bp 
  R GAGGCCACTGTGTTTCACT 
Tagln F TTTAAACCCCTCACCCAGCC 1003bp 
  R TCGATATCAAGGACAGTGGGC 
Tbc1d1 F ATGGAGGCAATCACATTCAC 994bp 
  R GAGCACTCTCGGCAGATGA 
Tbx2 F CACCCAGGACAATTCGCCAT 1024bp 
  R TCCTGGGATGCTTTCCGAAG 
Tgfbi F GTATGTGCTGTGCAGAAGG 1029bp 
  R CAGTGGAGACGTCAGATTC 
Tgm2 F GGAGAGGTGTGATTTGGAGA 995bp 
  R TCCACCCAGCAGTGGAAGT 
Timp1 F TGGGTGGATGAGTAATGCGT 800bp 
  R AGGCTTCAGTTTTTCCTGGGG 
Tinagl1 F GAAGTGCTACCCACTGCCTT 1033bp 
  R CTGCAGTTTCCAAACAGGGC 
Tpm1 F CACCATGGACGCCATCAAGA 1003bp 
  R TAGAAAGCAGTCTGTGCCTGG 
Tpm2 F TGGACGCCATCAAGAAGAAG 863bp 




Table S4 – Oligonucleotide sequences used to amplify the C57BL/6 mouse cDNA fragments for 
generation of the FISH probes. F; forward. R; reverse. Shown in the right-hand column is the expected 
length of the amplified fragment. (conclusion) 
Gene Sense Sequence size (bp) 
Tpsb2 F GCAGCTAAGATGCTGAAGCG 1009bp 
  R GAACCGGAATGGCTAGGGAC 
Tuba1a F GTCTCCAGGGCTTCTTGGTTT 1000bp 
  R CATCCCTGTGGAAGCAGCAC 
Vim F GAGCTCGAGCAGCTCAAG 1026bp 
  R CTGTTGCACCAAGTGTGTG 
 
Table S5 – Primer sequences used in quantitative real-time PCR. 
Gene Primer Forward Primer Reverse 
renin AGCTACATGGAGAACGGGTC  TTCCACCCACAGTCACCGAG 

















GTGTAATTAAGCCTCCGACTT   
 
recombination signal binding 
















Since the discovery of renin in the brain nearly 50 years ago (151), numerous 
studies have proposed that a so-called brain renin-angiotensin system (RAS) exists. 
Given the presence of the blood-brain barrier, brain RAS activity should depend on 
the local synthesis of (pro)renin in the brain rather than uptake from blood. In support 
of this concept, an intracellular, non-secreted form of renin (icREN) has been shown 
to occur exclusively in the brain. This renin isoform is derived from an alternative 
transcript of the renin gene, lacking the signal peptide and part of the prosegment 
(152, 153). To what degree this truncated prorenin truly generates angiotensin (Ang) 
I remains elusive. Lee-Kirsch et al. detected low Ang I-generating activity (AGA) 
levels in cell lysates of AtT20 cells transfected with icREN during incubation with 
excess angiotensinogen, but failed to demonstrate to what degree this AGA was 
renin-mediated (e.g., by making use of a renin inhibitor). Peters et al. showed 
increased AGA in cardiac homogenates of transgenic rats overexpressing icREN and 
were able to block this with the renin inhibitor CH732 (154). Yet, unexpectedly, the 
AGA increase was observed only after prosegment removal with trypsin, in 
disagreement with the fact that truncated prorenin does not require prosegment 
removal to display activity (155). Moreover, icREN overexpression in the heart, if 
anything, resulted in effects that were unrelated to angiotensin formation (156). 
DOCA-salt treatment is widely believed to stimulate brain RAS activity. 
Confusingly, it lowers icREN expression, but increases the expression of the 
classical, secreted form of renin in brain tissue (sREN) (157), possibly because, 
icREN, via an unknown mechanism, inhibits sREN expression (158). Li et al. 
proposed that DOCA-salt selectively increases brain prorenin, which, in the absence 
of a prosegment-cleaving enzyme in the brain, requires interaction with the (pro)renin 
receptor to allow Ang I generation locally (159, 160). The underlying assumption of 
this concept is that prorenin binding to the (pro)renin receptor results in a 
conformational change in the prorenin molecule, allowing it to display enzymatic 
activity without prosegment cleavage (161). Yet, the low (nanomolar) affinity of the 
(pro)renin receptor implies that very high prorenin levels are required for receptor 
binding (161), for which there currently is no evidence (160). 
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Given these uncertainties, in the present study we set out to re-evaluate the 
occurrence of (pro)renin in the brain. We quantified brain (pro)renin in a wide variety 
of brain regions, derived from control mice, mice exposed to DOCA-salt or Ang II, 
and renin-deficient mice. Under all conditions, a comparison was made with plasma 
(pro)renin, and the renin inhibitor aliskiren was applied in the assay to evaluate 
whether AGA was truly renin-mediated. Mice were studied given the fact that their 
(pro)renin levels are several orders of magnitude higher than those in humans or 
rats, thereby facilitating the detection of renin-dependent AGA, even in areas with low 
(pro)renin levels. To obtain a more complete understanding of the brain RAS, we 
also quantified brain angiotensinogen, and we studied the changes in brain 
angiotensin generation making use of brainstem tissue obtained from control 
spontaneously hypertensive rats (SHR) and SHR treated with the AT1 receptor 




All animal experiments were performed under the regulation and permission of 
the Animal Care Committee, conforming to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 8523, revised 1985). 
 
5.2.1 Brain Renin, Prorenin and Angiotensinogen Levels in Wild-Type Mice, 
Mice Treated with DOCA-Salt or Angiotensin II and Renin-Deficient Mice 
 
Male and female C57BL/6J mice (wild-type, WT) were obtained by in-house 
breeding or purchased from Charles River (Sulzfeld, Germany). Mice (age 3-4 
months) were either untreated, treated with deoxycorticosterone acetate (DOCA)-salt 
(150 mg, 60-day release pellet [Innovative Research of America, Sarasota, USA]) for 
4 weeks, or infused with Ang II (490 ng/kg/min by osmotic minipump [Alzet, model 
2004, DURECT, Cupertino, USA](162)) for 2 weeks. Ren1c homozygous null mice 
(Ren1c-/-; 3 females and 1 male) were generated as described before (C57BL/6J 
background) (163) and sacrificed at the age of 3-6 months. All mice were housed 
under standard laboratory conditions (temperature 23±1°C, 12-hour light-dark cycle) 
and maintained on standard chow (Special Diets Services, Essex, UK) with ad libitum 
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access to tap water. DOCA-salt-treated mice had ad libitum access to 0.15 mol/L 
(0.9%) NaCl solution. At the end of the treatment period, mice were sacrificed with an 
overdose of isoflurane and blood was collected by cardiac puncture into EDTA-
coated tubes. Blood was centrifuged at 4600 rpm for 10 minutes and plasma was 
stored at -80ºC until analysis. Five untreated mice were perfused transcardially with 
PBS to wash away blood from the brain vasculature. Brains were rapidly removed 
from all mice and the desired regions (cerebellum, brainstem, cortex, hippocampus, 
midbrain, striatum and thalamus) were dissected, frozen in liquid nitrogen, and stored 
at -80ºC until analysis. 
 
5.2.2 Brain and Plasma Angiotensin Levels in Spontaneously Hypertensive 
Rats 
 
Male 10-week old SHR (Janvier Labs, Le Genest St. Isle, France) were 
treated with either vehicle (tap water), the ACE inhibitor lisinopril (15 mg/kg body 
weight; Sigma-Aldrich, Darmstadt, Germany) or the AT1 receptor blocker olmesartan 
(10 mg/kg body weight, Daiichi Sankyo Co., Ltd., Japan) once daily per gavage for 
four weeks. Animals were housed under standard laboratory conditions (temperature 
23±1°C, 12-hour light-dark cycle), they were fed a standard pellet diet (1.8% NaCl; 
Velaz, Prague, Czech Republic), and drank tap water ad libitum. At the end of 
treatment period, the animals were sacrificed in terminal isoflurane anesthesia (2-
3%) by being bled out. Blood was collected in the presence of an inhibitor cocktail 
containing ethylenediaminetetraacetic acid (EDTA), pepstatin A, p-
hydroxymercuribenzoic acid, phenanthroline and specific inhibitors for renin and 
aminopeptidases to a final concentration of 5% v/v (Attoquant Diagnostics, Vienna, 
Austria) and immediately cooled on ice.(164) Plasma was isolated by centrifugation 
at 4°C and frozen at -80°C until analysis. Brains were sampled via scull trepanation 
followed by removal of the hemispheres and cerebellum. The brainstem was isolated, 








5.2.3 Angiotensinogen Synthesis by Rat Primary Cortical Astrocytes 
 
Rat primary cortical astrocytes (Invitrogen, Thermo Fisher, Waltham, USA) 
were grown in 6-well plates (Corning Incorporated, Corning, USA) in DMEM medium 
(85% Dulbecco’s Modified Eagle Medium containing high glucose 4.5 g/L, 15% FCS 
(Gibco, Thermo Fisher) and L-glutamine (600 mg/L; Flow Lab, UK)) in an incubator at 
37°C and 5% CO2 until confluency. Medium and cells were collected after 24, 48, 72 
or 96 hours. For the determination of angiotensinogen, the culture medium was 
removed and stored at -80°C, while cells were gently washed with PBS, lysed with 
RIPA buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% Triton x-100, 0.5% sodium 
deoxylcholate, 0.1% SDS, 1 mmol/L EDTA), and frozen at -80°C until analysis. 
 
5.2.4 Measurement of Renin, Prorenin and Angiotensinogen 
 
Mouse plasma renin and prorenin were measured as described before (165). 
Brain tissue was homogenized in 0.01 mol/L phosphate buffer, pH 7.4, containing 
0.15 mol/L NaCl, and the homogenates were used to measure renin, total renin (i.e., 
renin plus prorenin), and angiotensinogen. AGA was measured by enzyme-kinetic 
assay in the presence of excess sheep angiotensinogen, both without and with the 
renin inhibitor aliskiren (10 pmol/L-10 µmol/L) (166). Total renin was measured 
identically after conversion of prorenin to renin by acidification (166). 
Angiotensinogen was measured in mouse plasma, mouse brain homogenate, rat 
astrocyte cell culture medium and astrocyte cell lysate (after its centrifugation at 8000 
x g for 10 min) as the maximum quantity of Ang I that was generated during 
incubation with excess recombinant rat renin (161). 
 
5.2.5 LC-MS/MS Based Quantification of Angiotensin Metabolites 
 
Plasma was thawed on ice, and samples were spiked with 200 pg of stable 
isotope-labeled internal standards for Ang I, Ang II, Ang-(1-7) and Ang-(2-8). 
Following C18-based solid-phase-extraction, samples were subjected to LC-MS/MS 
analysis using a reversed-phase analytical column (Acquity UPLC® C18, Waters, 
Milford, USA) operating in line with a XEVO TQ-S triple quadrupole mass 
spectrometer (Waters) in MRM mode. Internal standards were used to correct for 
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peptide recovery of the sample preparation procedure for each angiotensin 
metabolite in each individual sample. Angiotensin peptide concentrations were 
calculated considering the corresponding response factors determined in matrix 
calibration curves, on condition that integrated signals exceeded a signal-to-noise 
ratio of 10. Brain tissue samples were grinded under liquid nitrogen (pestle and 
mortar) and the resulting frozen tissue powder was rapidly dissolved in ice cold 6 
mol/L guanidine hydrochloride supplemented with 1 % (v/v) TFA at a concentration of 
100 mg tissue/mL (167). Resulting homogenates were spiked with 200 pg of stable 
isotope-labelled internal standard for each angiotensin metabolite analyzed and 
subjected to solid phase based peptide extraction and subsequent LC-MS/MS 
analysis. The lower limits of quantification for Ang I, Ang II, Ang-(1-7) and Ang-(2-8) 
in plasma were 2.1, 0.9, 1.9 and 1.1 pg/mL, and in brain 8.1, 6.7, 12.7 and 8.0 pg/g 
tissue, respectively. 
 
5.2.6 Renin and Angiotensinogen Expression 
 
Total RNA was isolated from kidney and liver tissue, using Tri Reagent 
(Sigma-Aldrich, Darmstadt, Germany), and from brain tissue (cerebellum, brainstem, 
cortex, hippocampus, midbrain, striatum and thalamus), using the RNeasy Lipid kit 
(Qiagen, Venlo, The Netherlands). RNA concentration was quantified using micro-
spectrophotometry (NanoDrop Technologies, Wilmington, USA). Single stranded 
complementary DNA was synthesized using the genomic DNA-free total RNA using 
the Quantitect Reverse Transcription kit (Qiagen) according to the manufacturer's 
protocol. Quantitative real-time PCRs were conducted in 10 µL and 100 ng of cDNA, 
using the CFX384 Touch™ Real-time PCR detection system (BioRad, Hercules, 
USA), followed by measurement using either IQ™ SYBR® Green Supermix (BioRad) 
or Taqman probes (IDT, Coralville, USA). The exon-exon junction spanning 
oligonucleotide primers for qPCR were designed with NCBI (Primer-BLAST). Primer 
sequences and GenBank accession numbers for the sequences used to design the 
primers are listed in Table S6. Regarding mouse renin, primers were designed to 
selectively detect sREN and icREN, as well as to detect renin independently of its 
signal peptide and prosegment (‘secreted + intracellular renin’; Figure S8A). The 
following cycling conditions were used [95°C for 3 min, (95°C for 3 sec, 60°C for 
25 sec) × 40 cycles] for the KAPA SYBR ® FAST qPCR Master Mix, [95°C for 5 min, 
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(95°C for 10 sec, 59-72°C for 40 sec) × 40 cycles] for the IQ™ SYBR® Green 
Supermix, and [95°C for 3 min, (95°C for 15 sec, 60°C for 1 min) × 45 cycles] for the 
Taqman assay. Expression levels in kidney, liver and brain tissue were normalised to 
the housekeeping genes B2M and TubG2, respectively. The 2−ΔΔCt method was 
used for relative quantification of gene expression. 
Renin expression in brain tissue was also explored by using Ingenuity 
Pathway Analysis (IPA). In IPA, tissue expression datasets were created based on 
expression annotations from the GNF Body Atlas (expression calls were made from 
microarray data from dissection of healthy, adult, untreated C57/BL6 mouse tissues). 
Data was also available in Gene Expression Omnibus 
(<http://www.ncbi.nlm.nih.gov/qeo/query/acc.cgi/acc=GSE1133>). Published (168) 
cases where a gene was marked "Present" in a particular tissue (based upon the 
Affymetrix MAS5 Absence/ Presence call) were used as evidence of mRNA 
expression, and were incorporated into the tissue expression dataset for that 
particular tissue. The criteria used to define a gene as expressed in the body atlas 
data in IPA correspond to an average concentration of 3 transcripts per cell (10 
transcripts per million). Additional mRNA expression calls were derived from findings 
in the Ingenuity Knowledge Base that describes observations of mRNA expression in 
normal, healthy, adult mammalian tissue (human, mouse, rat and mammalian 
orthologs). Only findings where high quality mRNA detection methods were used 
(e.g. Northern Blots, quantitative RT-PCR, etc.) were included. Additional information 
is provided at the following link: 
<http://ingenuity.force.com/ipa/IPATutorials?id=kA250000000TN5CCAW>. 
 
5.2.7 Statistical Analysis 
 
Data are expressed as mean±SEM. To determine the minimum number of 
animals needed for this study, we reasoned that, if renin is synthesized locally in 
certain brain areas, the majority of this renin (>50%) should not be washed away by 
buffer perfusion. Moreover, Grobe et al. (157) have suggested that brain sREN 
expression doubles after DOCA-salt. On the basis of these 2-fold changes, at an SD 
of 40% (as observed in brainstem, see Results), with α = 0.05 and β = 80%, the 
minimum n-number is 3. Univariate linear associations between plasma and brain 
renin levels were assessed by calculation of Pearson’s coefficient of correlation. 
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Differences between groups were evaluated by Student’s t-test or ANOVA, and 
corrected for multiple testing by post-hoc Bonferroni analysis when needed. P<0.05 
was considered significant. Statistical analysis was performed with IBM SPSS 




5.3.1 Aliskiren Inhibits Angiotensin I-Generating Activity in the Mouse Brain 
 
Aliskiren identically inhibited AGA in mouse plasma (n=2), mouse kidney 
homogenate (n=2) and mouse brain homogenate (n=3) (Figure 9). Its IC50 was in the 
nanomolar range, as has been reported before for mouse renin.(169, 170) These 
data suggest that AGA in mouse brain homogenates is due to renin. All subsequent 
AGA measurements were performed both in the absence and presence of 10 µmol/L 
aliskiren in order to correct for non-renin (i.e., non-aliskiren-inhibitable) AGA. 
 
 
Figure 9. Concentration-dependent inhibition of angiotensin I-generating activity (AGA) by aliskiren in 
mouse plasma (n=2), mouse kidney homogenate (n=2) and mouse brain homogenate (n=3, 







5.3.2 Buffer Perfusion Reduces Mouse Brain Renin by >60% 
 
Renin-dependent (i.e., aliskiren-inhibitable) AGA was readily detectable in 
brain regions, the highest AGA being present in brainstem (>thalamus ≈cerebellum 
≈striatum ≈midbrain >hippocampus ≈cortex) (Figure 10, n=5/group). AGA increased 
in each individual brain region after prorenin activation, but only when analyzing all 
brain regions together by multivariate ANOVA did this increase reach significance 
(P<0.05). Applying the prorenin activation procedure to 3 mouse brain homogenates 
(cortex, midbrain and brainstem, respectively) to which recombinant human prorenin 
had been added yielded values in a renin IRMA (211±12 pg/mL) that were similar to 
those when activating the same amount of recombinant human prorenin in buffer with 
aliskiren(171) (169±6 pg/mL). This confirms that our prorenin activation procedure 
was appropriate. PBS perfusion of the mouse brain reduced AGA in all brain areas 
by >60% (Figure 2; P<0.01), and diminished the percentage of AGA that could be 
blocked by aliskiren (Table S7). These data suggest that blood removal 
predominantly washes away renin, but not non-renin enzymes that are also capable 
of reacting with angiotensinogen. Plasma renin (expressed per mL plasma) was 40-
800x higher than brain renin (expressed per g tissue), and, as expected, identical in 
mice that were exposed to buffer perfusion. Plasma prorenin levels were of the same 


















Figure 10. Renin and total renin (=renin + prorenin) levels in plasma and brain regions of mice before 
and after buffer perfusion (wash) of the brain. Data are mean±SEM of n=5. Multivariate ANOVA 
showed that total renin levels were higher than renin levels (P<0.05), and that buffer perfusion 
reduced renin by >60% in all regions (P<0.01).  
 
5.3.3 Comparable Reductions in Brain and Plasma (Pro)Renin after DOCA-Salt 
Treatment, Angiotensin II Infusion and Renin-Deficiency 
 
DOCA-salt (n=6) and Ang II (n=7) suppressed plasma renin versus WT (n=6), 
and parallel decreases were observed for brainstem, midbrain and cortex renin 
(Figure 11), although significance was not reached in all cases. Nevertheless, brain 
renin levels (expressed per g tissue) correlated significantly with plasma renin levels 
(expressed per mL plasma) in all 3 brain regions (Figure 12). The different slopes 
may reflect the different blood content of each brain region. Plasma prorenin levels 
were comparable to plasma renin levels, and prorenin activation in brain regions non-
significantly increased brain AGA. Plasma renin and prorenin were undetectable in 
Ren1c-/- mice (n=4), and renin (i.e., aliskiren-inhibitable AGA) was also undetectable 
in the 3 brain regions obtained from Ren1c-/- mice. However, low levels of aliskiren-
inhibitable AGA were present in brainstem (1 out of 4) midbrain (3 out of 4) and 
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cortex (2 out of 4) after prorenin activation in the Ren1c-/- mice. Since this cannot 
represent prorenin, these data imply that our prorenin activation procedure 
occasionally activated a renin-like enzyme, capable of reacting with angiotensinogen, 
the activity of which can be blocked by 10 µmol/L aliskiren. 
 
 
Figure 11. Renin and total renin (=renin + prorenin) levels in plasma and brain regions of untreated 
mice (WT), mice treated with DOCA-salt, mice infused with Ang II, and Ren1c-/- mice. Data are 
mean±SEM of n=4-7. Differences in renin levels were assessed by one-way ANOVA, followed by 
correction for multiple testing by post-hoc Bonferroni analysis. *P<0.05, #P<0.01, oP<0.001 vs. WT. 
 
5.3.4 Renin Expression in the Brain 
 
Renin (secreted + intracellular), sREN or icREN mRNA expression levels were 
undetectable in all brain regions in WT, DOCA-salt-treated and Ang II-infused mice. 
Primer specificity for renin (secreted + intracellular) and sREN was validated by 
measuring renal renin expression in Ren1c-/- mice (Figure S8B). In the IPA tissue 
expression data sets, renin expression was found in cerebellum, hypothalamus and 





Figure 12. Relationship between renin in plasma and renin in 3 different brain regions in untreated 






5.3.5 Despite Angiotensinogen Expression, Angiotensinogen Protein is 
Undetectable in Mouse Brain and Rat Astrocytes 
 
Mouse plasma contained detectable levels of angiotensinogen (28±5 
pmol/mL). Angiotensinogen mRNA expression was observed in different brain 
regions (Figure 13), at Ct values of 23 (cerebellum), 22 (thalamus), 25 (hippocampus) 
and 27 (striatum) versus ≈18 in the liver. Brain expression levels changed 
inconsistently after DOCA-salt, Ang II and renin deficiency: an increase was 
observed in the thalamus after DOCA-salt (P<0.05), while decreases occurred in the 
cerebellum after DOCA-salt (P<0.05), and in the hippocampus after Ang II (P<0.05). 
Yet, angiotensinogen protein was undetectable (<1 pmol/g) in mouse cortex and 
brainstem (n=4 of each). Angiotensinogen was also undetectable in the medium of 
cultured rat astrocytes (<0.3 pmol/mL), cultured for 24, 48, 72 or 96 hours (n=4 for 
each condition), or the accompanying cell lysates (<0.3 pmol/mg protein). 
 
 
Figure 13. Angiotensinogen mRNA expression in different brain regions in untreated mice (WT), mice 
treated with DOCA-salt, mice infused with Ang II, and Ren1c-/- mice. Data, presented as fold change 
over TubG2 relative to WT levels, are mean±SEM of n=3-6. Differences were assessed by one-way 





5.3.6 Angiotensins in the SHR Brain with and without RAS Blockade 
 
Ang I, Ang-(1-7) and Ang-(2-8) were below detection limit in brain tissue of 
untreated SHR (n=6), while Ang II could be detected in the rat brain at levels 
corresponding with ≈25% of the Ang II levels in blood plasma (Table S8 and Figure 
14). Ang I and Ang-(2-8), but not Ang-(1-7), were detectable in plasma in untreated 
SHR. Brain Ang-(1-7) and Ang-(2-8) remained undetectable after olmesartan (n=6) or 
lisinopril (n=4), while Ang I became detectable in the rat brain after both types of RAS 
blockade (P<0.001 for both). Since plasma Ang I increased ≈20-fold after olmesartan 
and lisinopril (P<0.001 for both), it could be calculated that, during both types of RAS 
blockade, brain Ang I levels corresponded with ≈1% of the Ang I levels in plasma. 
Olmesartan increased brain Ang II ≈5-fold (P<0.001) and plasma Ang II ≈25-fold 
(P<0.001), so that after AT1 receptor blockade, the brain/plasma ratio of Ang II 
decreased by ≈80% (P<0.05). Lisinopril decreased plasma Ang II by >90% 
(P<0.001), and diminished brain Ang II to undetectable levels (P<0.001). Lisinopril 
also decreased plasma Ang-(2-8) to undetectable levels, and greatly increased 
plasma Ang-(1-7), while olmesartan increased both plasma Ang-(2-8) and plasma 
Ang-(1-7). Taken together, given that brain Ang I levels correspond with ≈1% of the 
circulating Ang I levels, 10 µL plasma per g brain tissue is sufficient to explain the 
entire brain Ang I content. Brain Ang II levels, relative to plasma Ang II levels, are 
higher, suggesting either local synthesis or an active uptake mechanism. The 





The present study confirms that renin-dependent AGA can be detected in 
virtually every region of the mouse brain. Yet, as compared to plasma, brain renin 
levels were very low, corresponding with the amount of renin in 1-25 µL blood plasma 
per g brain tissue (≈0.1-2.5 % (v/v)). This volume mimics the amount of blood plasma 
in various brain regions determined with tritiated inulin or Evans blue dye (172, 173). 
Moreover, perfusing the brain with PBS prior to the collection of the various regions, 
reduced brain renin uniformly by >60%. Had local renin synthesis occurred in one or 
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more specific brain regions, the washout percentage should have been much lower 
in these regions, similar to the fact that in the kidney one cannot wash away stored 
renin (165, 174), while this does happen in non-renin producing organs like the heart 
(175). Furthermore, DOCA-salt, like Ang II, reduced circulating renin, and, contrary to 
our expectations, did not increase brain prorenin. In fact, if anything, both DOCA-salt 
and Ang II lowered brain renin in parallel with plasma renin. Aliskiren-inhibitable AGA 
was entirely absent in the brain of Ren1c-/- mice, supporting the validity of our brain 
renin measurement. Taken together, our data do not support the presence of kidney-
independent (pro)renin synthesis in the brain, nor the concept that this occurs 
particularly in the DOCA-salt model. In fact, brain renin levels are so low that the 
accumulation of renin at brain tissue sites outside the blood compartment seems 
unlikely. This greatly differs from other organs (e.g., the heart), where renin diffuses 
freely into the interstitium and/or binds to a receptor, thereby reaching tissue levels 
that are, on a gram basis, at least as high as the renin levels in blood plasma (on a 




Figure 14. Ang I and II levels in plasma and brain of SHR treated with vehicle (control), olmesartan or 
lisinopril. ND, not detectable. Data are mean±SEM of n=4-6. Differences were assessed by one-way 







Prorenin activation resulted in modest AGA increases in all brain regions, and 
significance for this increase was only obtained by analyzing all regions together. 
Applying recombinant human prorenin to brain homogenates prior to the prorenin 
activation procedure (on the basis of acid activation (177)) confirmed that this 
procedure resulted in complete prorenin activation. However, small rises in aliskiren-
inhibitable AGA were also observed in brain homogenates from Ren1c-/- mice after 
their exposure to acid. Since Ren1c-/- mouse brain tissue cannot contain prorenin, 
this implies that the brain contains a non-renin proenzyme, which is activated by acid 
exposure, and which is capable of cleaving Ang I from angiotensinogen in an 
aliskiren-inhibitable manner. A possible candidate is pro-cathepsin D. Indeed, renin 
inhibitors, at high micromolar concentrations, do inhibit cathepsin D (178). Our 
difficulty to demonstrate prorenin in the brain is reminiscent of earlier studies in 
organs not synthesizing prorenin themselves, like the heart (177). Obviously, blood 
plasma contains prorenin, and thus some prorenin should be detected in the blood-
containing homogenates derived from such tissues. Yet only under conditions where 
circulating prorenin levels were greatly elevated, like in heart failure in humans, did 
we reliably detect prorenin in cardiac tissue (166). In mice, in contrast to humans, 
circulating prorenin levels are relatively low (versus renin), making it even more 
difficult to show a rise in AGA on top of already low renin-mediated AGA. A further 
complicating factor is that tissue homogenization per se may result in (partial) 
prorenin activation. In summary, given the presence of prorenin in blood plasma, 
brain homogenates should minimally contain the amount of prorenin present in a few 
µL of blood. The rises in AGA after prorenin activation are consistent with this view, 
but should still be interpreted with caution given the fact that non-renin enzymes also 
came into play after acid activation. Brain-selective prorenin rises, e.g. after DOCA-
salt, were not observed. This implies that prorenin-(pro)renin receptor interaction is 
unlikely to occur in the mouse brain, particularly after DOCA-salt (which lowers brain 
(pro)renin), although it may obviously occur after intracerebroventricular infusion of 
pharmacological prorenin doses into the brain (160). 
Most, if not all, studies on brain renin relied on the detection of renin mRNA in 
the brain, either under normal conditions, or after deleting/overexpressing sREN or 
icREN. Deleting sREN in neurons or glia did not affect blood pressure, heart rate, 
water intake, or metabolic rate (179), while preservation of icREN did not 
compensate for the consequences of whole body sREN-deficiency (hypotension, 
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renal defects, lethality) (180). Surprisingly, brain-selective deletion of icREN even 
caused neurogenic hypertension, possibly because icREN inhibits sREN (158). 
These data seem to argue against icREN as an Ang I-generating enzyme. Yet, 
overexpressing either human icREN or sREN in astrocytes, if combined with human 
angiotensinogen, resulted in Ang II-dependent hypertension and an increase in 
drinking volume (181). Since icREN under the latter conditions was not detectable in 
cerebrospinal fluid (CSF), it was concluded that this phenomenon involved 
intracellular Ang II formation. We attempted to detect renin mRNA, using either 
specific assays for sREN or icREN, or a non-specific assay that detects both sREN 
and icREN. Under no condition were we able to show renin (secreted + intracellular), 
sREN or icREN gene expression in any of the different regions of the brain: the 
expression level was below the detection threshold of the RT-PCR assay, even with 
the use of the highly sensitive Taqman probes. The specificity of our renin primers 
was validated by making use of the kidneys of Ren1c-/- mice. Of course, poor renin 
expression in the brain has been noted before (182-184). Because of the technical 
limitations inherent in any RT-PCR assay, we could not load more than 100 ng of 
total RNA. Our results therefore indicate that, if renin is expressed in the brain, its 
expression is >218-fold lower than that in the kidney (no signal after 40 cycles, with 
renin detection in the kidney at Ct≈22). The IPA expression data sets confirm this 
view. Yet, Kubo et al. observed a blood pressure drop after intraventricular renin 
antisense injection in SHR (185). In their hands only one of three tested antisense 
oligonucleotides acted hypotensive, and this response was accompanied by a 20% 
drop in renin mRNA (detected after 45 cycles of RT-PCR). These authors did not 
measure renin levels in brain or plasma, and were unable to rule out antisense 
leakage to the kidney. Therefore, these data cannot be taken as definitive proof for 
the existence of an independent brain RAS. 
The mouse RAS differs from the human RAS, in that the circulating renin 
levels in mice are up to 1000-fold higher (on a ng Ang I/ml.hr basis) than in humans. 
As a consequence, circulating angiotensinogen levels in mice are far below Km 
range, as confirmed in the present study. Nevertheless, despite these differences, 
mouse angiotensin levels in blood and tissue are comparable to those in humans, 
rats and pigs (164, 186-188). We attempted to measure angiotensinogen in the 
mouse brain, both at the mRNA and protein level. Although we did observe 
angiotensinogen mRNA expression in different regions of the brain, in full agreement 
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with previous work (189, 190), expression was up to 500-fold lower than in the liver. 
Under no condition were we able to detect angiotensinogen protein in the brain. 
Given the detection limit of our assay (1 pmol/g), this implies that brain 
angiotensinogen, if present, occurs at levels (per g tissue) that are <3% of the levels 
in plasma (per mL plasma). Such low levels have been reported before in the rat 
brain, as well as in human and rat CSF (172, 191-193), and thus our data entirely 
agree with the literature. Clearly, mice, given their low angiotensinogen levels, are 
not the optimal species to study brain angiotensinogen. As astrocytes are assumed 
to be the source of brain angiotensinogen (194, 195), we additionally studied 
angiotensinogen synthesis by rat primary cortical astrocytes, but again failed to 
detect any angiotensinogen. Nevertheless, data from Schink et al. (193) do support 
the functional presence of angiotensinogen in the rat brain. These authors artificially 
elevated renin in the brain by either intracerebroventricular renin infusion (in 
Sprague-Dawley rats) or by making use of transgenic hypertensive rats 
overexpressing mouse Ren2. The responses to both approaches (drinking and blood 
pressure reduction, respectively) were greatly diminished after lowering brain 
angiotensinogen by brain-selective expression of an antisense RNA against 
angiotensinogen mRNA. 
Finally, given our observation that brain renin is confined to the plasma 
compartment, while brain angiotensinogen is extremely low (if not also confined to 
the plasma compartment), an urging question is what degree local angiotensin 
generation truly occurs in the brain. We therefore collected brainstem tissue (i.e., the 
brain region with the highest renin level) from SHR under control conditions and 
during RAS blockade with olmesartan or lisinopril. Rats rather than mice were used 
here, because at identical angiotensin levels in both species, the larger rat brainstem 
would allow a more reliable quantification of angiotensins. Without treatment, brain 
Ang I was undetectable, while Ang II occurred at levels that were ≈25% of the levels 
in plasma (per gram tissue weight). This contrasts with other organs where Ang II is 
usually much higher than in plasma, while Ang I is easily detectable (167, 196-198). 
RAS blockade induced the usual rise in Ang I levels in plasma, and now brain Ang I 
became detectable, however, at only 1% (v/v) of its plasma levels. It seems 
reasonable to assume that also in the untreated animals brain Ang I levels were in 
the 1% range of plasma Ang I, and therefore too low to be detected with our assays. 
If so, this implies that under all conditions, brain Ang I at most represented the 
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amount of Ang I that is inherently present in brain tissue because it contains a small 
amount (≈1%) of blood (172). Lisinopril decreased brain Ang II to undetectable levels, 
while olmesartan reduced the brain/plasma Ang II ratio by >80%. The latter finding 
suggests that, normally, circulating Ang II accumulates in brain tissue via binding to 
AT1 receptors. Such uptake occurs in multiple organs (199), and facilitates the 
intracellular accumulation of Ang II (200). Without receptors (i.e., in AT receptor-
deficient mice), tissue Ang II levels drop dramatically (47), suggesting that tissue Ang 
II levels do not originate intracellularly. If Ang II binding to AT1 receptors is the only 
source of Ang II in the brain, one would expect angiotensin metabolites that do not 
(or only with low affinity) bind to this receptor to be undetectable in the brain. This is 
indeed what we observed for both Ang-(2-8) and Ang-(1-7). An olmesartan-induced 
reduction in brain Ang II levels was also observed in Dahl-sensitive hypertensive rats, 
albeit in the absence of an effect on blood pressure (201). Clearly therefore, the 
changes observed in brain Ang II are blood pressure-independent.  
 
5.5 SUPPLEMENT INFORMATION 
 
Figure S8 A. Proposed pathway for secreted renin and intracellular renin. It is hypothesized that in the 
brain, a different mRNA, renin-b, is transcribed that result in a novel transcript lacking exon 1a. This 
renin isoform lacks the signal peptide and part of the prosegment, and is believed to remain 
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Figure S9. B. Renin (secreted or intracellular), sRen and icRen mRNA expression in kidneys of wild-
type (WT, n=6) and Ren1c-/- mice (n=4). icRen was undetectable under all conditions, while renin 
(secreted + intracellular) and sRen were undetectable in kidneys of Ren1c-/- mice. Ct values were 














































Table S6 – Primer sequences and GenBank accession numbers. 
Kidney and Brain Tissue (Mus musculus) 
SYBR green assay 









Renin (secreted + intracellular) AGCTACATGGAGAACGGGTC 
TTCCACCCACAGTCACCGAG 
>NM_031192.3 
Secreted renin (sRen) GCACCTTCAGTCTCCCAACAC 
TCCCGGACAGAAGGCATTTTC 
>NM_031192.3 
Intracellular renin (icRen) CCGGCTGCTTTGAAGATTTGAT 
ATGCCAATCTCGCCGTAGTA 
- 




Beta-2 microglobulin (B2M) Assay ID-Mm.PT.58.10497647 
(IDT) 
NM_009735(1) 





Renin (secreted + intracellular) FW: TCAGCAAGACTGACTCCTGGC 
Rev: GCACAGCCTTCTTCACATAGC 
Probe: TCACGATGAAGGGGGTGTCTGTGGG 
Secreted renin (sRen) FW: GCACCTTCAGTCTCCCAACAC 
Rev: TCCCGGACAGAAGGCATTTTC 
Probe: CCTTTGAACGAATCCC 














Table S7 – Percent inhibition of angiotensin I-generating activity by aliskiren in brain nucleus 
homogenates before and after buffer perfusion. Data are mean±SEM of n=5. 
Brain Nucleus 
Before Buffer Perfusion After Buffer Perfusion 
Renin Total Renin Renin Total Renin 
Brainstem 96±1 91±3 92±3 87±3 
Thalamus 81±6 81±9 18±20 28±19 
Cerebellum 86±4 92±2 73±12 54±18 
Striatum 71±2 60±18 51±16 34±20 
Midbrain 83±10 84±6 37±19 30±19 
Hippocampus 49±6 48±22 47±15 13±13 
Cortex 50±23 36±17 15±17 0±0 
 
Table S8 – Angiotensin (Ang) metabolites in SHR plasma and brain during treatment with placebo, 




(pg/mL or g) 
Ang II 
(pg/mL or g) 
Ang-(2-8) 
(pg/mL or g) 
Ang-(1-7) 
(pg/mL or g) 
Plasma 
Placebo 139±20 39±11 8±2 <2±0 
Olmesartan 2579±497 911±171 223±57 9±2 
Lisinopril 3142±362 2±1 <1±0 58±14 
Brain 
Placebo <8±1 9±2 <9±0 <13±1 
Olmesartan 25±5 50±11 <8±0 <13±1 











Renin belongs to the A1 family of aspartic proteases. Its 3D structure consists 
of two β-sheet domains, the N- and C-domain. Renin has an inactive precursor, 
prorenin, in which the catalytic binding site is covered by the N-terminal part of 
mature renin that, in turn, is covered by the prosegment (202). After removal of the 
prosegment, this N-terminal part becomes part of a six-stranded β-sheet on the back 
of the mature renin molecule, previously occupied by the prosegment. This requires a 
conformational change that fully exposes the active cleft (202). 
Prosegment unfolding occurs in a pH- and temperature-dependent manner, 
and, if not followed by cleavage, results in two prorenin conformations (Figure 15): a 
‘closed’, inactive form, and an ‘open’ form that displays full enzymatic activity (203, 
204). In addition, an intermediate form exists where the prosegment has moved away 
from the cleft, but where the renin part still has to undergo the afore-mentioned 
conformational changes. Under physiological conditions (pH 7.4, 37°C), <2% of 
prorenin is in the open conformation. The renin inhibitor aliskiren binds to prorenin in 
the open conformation as well as to the intermediate form of prorenin (203, 204). 
Binding to the intermediate form induces prorenin unfolding. Due to the tight binding 
of the renin inhibitor, the refolding step (i.e., the return to the closed conformation) is 
now no longer possible, and thus, the equilibrium between the closed and open 
conformation will shift in favor of the open conformation. Eventually, all prorenin 
molecules may be open (‘non-proteolytic activation’), allowing its recognition by the 
active site-directed antibodies used in renin immunoradiometric assays (IRMAs), 
despite the fact that the prosegment is still present and aliskiren is bound to the 
active site (171, 205). 
Unexpectedly, VTP-27999, a new, active site-directed renin inhibitor with an 
IC50 (0.3 nmol/L) that is comparable to that of aliskiren, did not induce prorenin 
unfolding (206). Yet, it blocked the aliskiren-induced unfolding of prorenin. This 
suggest that VTP-27999 does bind to the intermediate form of prorenin, but that such 
binding has no conformational consequences. Furthermore, VTP-27999 increased 
renin immunoreactivity. This may relate to the observation, based on crystallization 
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studies, that there are 2 renin conformations (207). Aliskiren and VTP-27999 bind to 
both conformations, but only in the case of VTP-27999, the conformations of the two 
monomers are nearly identical (206). These conformational differences are likely to 
affect the affinity of the active site-directed antibodies applied in renin IRMAs. As a 
consequence, the renin IRMA yields higher levels in the presence of VTP-27999 than 
without this inhibitor. 
 
 
Figure 15. Model displaying the closed and open prorenin conformations, as well as the assays 
allowing the detection of these prorenin variants. Normally, <2% of prorenin is in the open 
conformation. Aliskiren, acid and low temperature shift the equilibrium to the right, allowing the 
detection of prorenin in a renin IRMA, on the basis of its prosegment (F258 IRMA), or by enzyme-
kinetic assay (EKA). Only a direct prorenin ELISA allows the detection of intact, closed prorenin. 
 
A long-standing question concerns the function of prorenin. As mentioned 
above, it displays limited activity in plasma. Nguyen et al. proposed that it binds to 
the so-called (pro)renin receptor at nanomolar affinity (15). This resulted in a 
conformational change, allowing prorenin to display full activity. Theoretically, this 
would result in angiotensin generation, at least in (pro)renin receptor-expressing 
tissues, by receptor-bound prorenin. Initially, this finding was received with great 
enthusiasm, since it finally provided a role for prorenin: although synthesized in only 
a limited number of organs, given the wide occurrence of the (pro)renin receptor, 
prorenin might now contribute to angiotensin generation in virtually every organ of the 
body. However, although in-vitro studies applying high prorenin concentrations 
confirmed this concept, the prorenin concentrations in vivo are many orders below its 
Kd for the (pro)renin receptor, thereby making this possibility unlikely (161, 208). As a 
consequence, this concept is now being abandoned, and we need alternative 
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hypotheses to explain the function (if any) of prorenin. One possibility is that prorenin 
acts exclusively at its site of synthesis. For this to occur, prorenin-synthesizing cells 
should release prorenin in an open conformation, allowing it to display local activity in 
the immediate vicinity of the cells, before it returns to its inactive, closed 
conformation, e.g., when reaching blood plasma. If true, renin inhibitors capable of 
interfering with open prorenin might have an advantage over other RAS blockers, 
since they can specifically suppress angiotensin generation in prorenin-synthesizing 
tissues. Possibly, novel inhibitors need to be developed to optimally exert this effect. 
To test this concept in the present study, we made use of human prorenin-
synthesizing cells. For comparison, renin-releasing cells were also evaluated. We 
used 3 approaches. First, we incubated the cells with VTP-27999. This inhibitor, like 
aliskiren, would bind to prorenin if it is released in an open conformation, thus 
preventing its return to the closed conformation, allowing its detection in a renin 
IRMA. VTP-27999, unlike aliskiren, would not additionally convert all closed prorenin 
molecules into the open conformation, and thus this renin inhibitor is ideal to quantify 
the percentage of prorenin molecules released in the open conformation. We applied 
renin-, prorenin-, and prosegment-specific assays (available for human (pro)renin 
only) to verify this concept. Second, we studied angiotensin I generation during 
prorenin release by adding angiotensinogen to the medium, the underlying 
assumption being that only open prorenin would be able to display enzymatic activity. 





6.2.1 Human Samples 
 
All studies were approved by the Medical Ethical Review Board, and 
performed in accordance with the Declaration of Helsinki and Good Clinical Practice. 
Informed consent was obtained from each subject. Blood samples were obtained 
from 6 healthy controls (4 men, 2 women; age 23-45 years, mean 31 years). Blood 
was collected in polystyrene tubes containing 6.25 mmol/L EDTA (final 
concentration). The samples were centrifuged at room temperature at 3000 g for 10 
minutes, and plasma was either used immediately or stored at -20°C. Placenta’s 
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were harvested from 7 women after delivery (age 26-41, mean 34 years). Renin- and 
prorenin-synthesizing human mast cells (HMC-1) were a gift from Dr. J.H. Butterfield 
(Mayo Clinic, Rochester, MN, USA) (131). 
 
6.2.2 Cell Culture Studies 
 
Cell culture studies were performed at 37°C in a humidified 5% CO2 incubator 
(Sanyo, Panasonic Biomedical Sales Europe B.V., Etten-Leur, The Netherlands). 
HMC-1 cells were cultured in 75 cm2 culture flasks using Iscove’s modified 
Dulbecco’s medium (Lonza, Verviers, Belgium), supplemented with 10%, iron-
supplemented bovine calf serum (Hyclone, Thermo Fisher Scientific, Breda, The 
Netherlands), 1% Penicillin Streptomycin (PS; Invitrogen, Bleiswijk, The Netherlands) 
and 1.2 mmol/L α-thio-glycerol (Sigma, Zwijndrecht, The Netherlands). 
HEK293 cells were transfected with the mammalian expression vector 
pRhR1100, containing human prorenin (209), a gift from Dr. Reudelhuber (IRCM, 
Montréal, Canada). In short, cells were transfected with Lipofectamine2000 
(Invitrogen), according to the manufacturers protocol, and put on selection using 0.6 
mg/mL G418 (Invitrogen). The clone with the highest expression of prorenin was 
isolated, and used for further experiments. Cells were cultured in DMEM-F12 
(GIBCO, Breda, The Netherlands) medium supplemented with 10% fetal calf serum 
(FCS; Lonza), 1% PS, and 0.6 mg/mL G418. 
Decidua cells were harvested from the maternal side of the placenta according 
to Markoff et al. (210). In short, tissue was chopped and washed twice with DPBS 
(GIBCO), alternated by centrifugation steps of 10 minutes at 700 rpm. The pellet was 
resuspended in 5 mL RPMI-1640 (GIBCO) per gram tissue, supplemented with 1% 
FCS, 0.1% collagenase and 0.1% hyaluronidase (Sigma) in a tissue culture flask, 
and put on an orbital shaker (150 rpm) for two hours at 37°C. This suspension was 
filtered using a sieve with a mesh of 40 µm. The filtered solution was centrifuged for 
10 minutes at 700 rpm, after which the pellet was washed with RPMI-1640, and 
centrifuged again. The pellet was then exposed to 20 mL RBC lysis solution 
(5PRIME, Hilden, Germany) for 10 minutes, followed by another 10 minutes of 
centrifugation. This was followed by another two wash steps with RPMI. Next, cells 
were cultured in RPMI-1640 containing 10% FCS, 12.5 mmol/L HEPES (GIBCO), 50 
 
133 
µg/mL gentamycin (Sigma) and 5 µg/mL fungizone (Sigma). Medium was changed 
every 24 hours in the first 72 hours. 
For experiments verifying the release of open prorenin, cells were seeded in 6- 
or 12-well plates at a concentration of 0.5*106 cells/mL in fresh medium in the 
presence or absence of VTP-27999 (0.1-1000 nmol/L). After 2 to 5 days, medium 
was collected, and spun down 5 minutes at 2500 rpm to remove remaining cells. 
Supernatant was stored at -20°C. 
To study prorenin-induced angiotensin generation, decidua cells were 
incubated for 24 hours in the presence of 150 nmol/L human angiotensinogen 
(Sigma). Cells incubated without angiotensinogen served as control. Medium 
samples (75 µL) for the determination of renin and prorenin were collected at 4, 8 
and 24 hr. Medium samples (500 µL) for the determination of angiotensin I were 
collected at 24 hours with 25 µL inhibitor stock solution (containing 0.1 mmol/L 
aliskiren, 200 mmol/L EDTA and 0.2 mmol/L lisinopril), frozen in liquid N2, and stored 
at -70°C. The first-order rate constant for angiotensin I elimination was determined by 
incubating the cells with 100 nmol/L angiotensin I for maximally 4 hrs in the presence 
or absence of 100 nmol/L captopril. Medium samples (50 µL) for the determination of 
angiotensin I were collected at 0, 0.5, 1 and 4 hr, mixed with 2.5 µL inhibitor stock 
solution, and stored as described above. 
 
6.2.3 Biochemical Assays 
 
Renin and prorenin were determined either indirectly, by enzyme-kinetic assay 
(i.e., quantifying angiotensin I-generating activity) or directly, by IRMA (i.e., 
quantifying renin or prorenin immunoreactively). 
Enzyme-kinetic assays were applied to human plasma samples only, to verify 
prorenin activity. The sample was incubated with excess sheep angiotensinogen in 
the presence of angiotensinase inhibitors, either directly after its removal from the 
patient, after freezing and thawing, or after keeping it for 18 hours at 37°C. Imidazole 






Immunoreactive renin was measured with the Renin III (Cisbio, France) IRMA. 
This assay, which makes use of a monoclonal antibody (4G1) (211) directed against 
renin’s active site, also recognizes intact, open prorenin (203, 212). This implies that 
intact prorenin can be measured with this assay after incubating it with acid (pH=3.3) 
or after exposing it for 48 hours at 4°C to 10 µmol/L aliskiren, since both procedures 
induce the conversion of all prorenin molecules into the open conformation (171). 
Intact, closed prorenin was measured with an enzyme-linked immunosorbent 
assay (ELISA) that recognizes residues 32-39 of the prosegment (Molecular 
Innovations, Novi, MI, USA) (204). This prorenin assay was performed according to 
the instructions of the manufacturer, making use of human recombinant prorenin to 
construct the standard curve. 
In a select set of samples, intact, open prorenin was measured on the basis of 
its prosegment, replacing the 125I-labeled active site-directed monoclonal antibody of 
the Cisbio kit by a prosegment-directed 125I-labeled monoclonal antibody (F258-37-
B1) in the IRMA (‘F258 IRMA’). F258-37-B1 is directed against the C-terminal part 
(p20-p43) of the propeptide and does not react (<0.1%) with renin. F258-37-B1 also 
does not react (<0.1%) with intact, closed prorenin (13). However, it does react with 
prorenin after the converting all prorenin molecules into the open conformation by 
incubation with acid. Thus, the acid-induced non-proteolytic conformational change, 
causing the propeptide to move to the surface of the molecule, allows the recognition 
of prorenin by both the active site-directed antibody of the Cisbio kit, and the 
prosegment-directed antibody of the prorenin IRMA. 
The levels of Angiotensin I and II in the medium were measured by 
radioimmunoassay after SepPak extraction and reversed-phase high performance 
liquid chromatography separation (188). 
 
6.2.4 Data Analysis 
 
Results are shown as mean±SEM. Differences were tested using one-way 
ANOVA, followed by Dunnett’s multiple comparison test; P<0.05 was considered 
significant. Angiotensin I–generating activities obtained in the enzyme-kinetic assay 
were converted to renin concentrations based on the fact that 1 ng of angiotensin I 






6.3.1 Plasma Prorenin Displays Enzymatic Activity 
 
When incubating freshly obtained plasma samples from 6 healthy controls with 
excess angiotensinogen at 37°C, angiotensin I generation was linear over time 
(Figure 16, left panel). Results obtained in the same samples after they had been 
frozen and thawed were identical. However, when performing the assay after the 
samples had been kept for 18 hours at 37°C (to inactivate open prorenin) the degree 
of angiotensin I generation was lower (P<0.05). This was not due to (pro)renin 
degradation, since total renin levels (determined by immunoreactive assay) did not 
change over the 18 hour-period (Figure 16, right panel). The average decrease in 
angiotensin I-generating activity after 18 hours (≈1 ng angiotensin I/mL.hr) 
corresponded with ≈3% of the immunoreactive prorenin levels. This confirms that 
both blood handling/centrifugation (at room temperature) and freezing/thawing induce 
a conformational change in prorenin, allowing a small percentage of the prorenin 
molecules to display enzymatic activity in the enzyme-kinetic assay. Prolonged 




















Figure 16. Left, angiotensin I generation in human plasma during its incubation with excess sheep 
angiotensinogen, either immediately after collecting the plasma samples (fresh), after keeping the 
samples for 18 hours at 37°C, or after freezing and thawing the samples. Right, renin and total renin 
levels measured by renin IRMA after 4 hours of incubation. Data are mean±SEM of n=6.  
 
6.3.2 VTP-27999 Increases Renin Immunoreactivity, but does not Unravel the 
Release of ‘Open’ Prorenin 
 
Open prorenin release was studied in cells that synthesize both renin and 
prorenin (HMC-1 cells) and in cells that exclusively synthesize prorenin (human 
prorenin-expressing HEK293 cells and decidua cells). 
In medium samples obtained from HMC-1 cells incubated without inhibitor, 
renin was measured by renin IRMA, both before and after activating prorenin with 
aliskiren (i.e., converting all closed prorenin molecules to open prorenin molecules). 
Aliskiren exposure increased renin immunoreactivity ≈3-fold (Figure 17, left panel; 
n=7), illustrating that the cells predominantly released prorenin. Total renin 
measurements after aliskiren exposure did not change significantly following 
incubation of the cells with increasing concentrations of VTP-27999, nor did prorenin 
immunoreactivity (determined by prorenin ELISA) change in the presence of this 
inhibitor. This implies that VTP-27999 did not affect (pro)renin release per se. Yet, 
renin immunoreactivity (expressed as a % of the total renin levels without VTP-
27999) almost tripled following incubation of the cells with VTP-27999 (Figure 17 left 
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panel; n=6). Given the absence of changes in the release of (pro)renin, these data 
suggest that VTP-27999 affects the renin assay itself (i.e., yields higher renin levels 
for a given amount of renin). 
Aliskiren increased renin immunoreactivity in the medium of control (i.e., 
incubated without inhibitor) HEK293 and decidua cells >10-fold (Figure 17, middle 
and right panels; n=5). This is in agreement with the fact that these cells exclusively 
release prorenin, and that, at pH=7.4 and 37°C, only a few percent of prorenin is in 
the open conformation (i.e., can be recognized in a renin IRMA). Total renin 
measurements after aliskiren exposure did not change following incubation of the 
cells with increasing concentrations of VTP-27999, nor did prorenin immunoreactivity 
change in the presence of this inhibitor. Thus, as in HMC-1 cells, VTP-27999 did not 
affect prorenin release in either HEK293 cells or decidua cells. Yet, VTP-27999 
doubled renin immunoreactivity in both cell types. 
The latter increase in renin immunoreactivity might be suggestive for the 
release of open prorenin. To verify this further, we first repeated the studies in 
(pro)renin-containing medium (obtained from control cells) incubated with VTP-27999 
in the absence of cells. Results were identical (Figure 18; n=5-7). Second, we 
exposed (pro)renin-containing medium of the 3 cell types to acid, to induce the open 
(renin-like) conformation in all prorenin molecules. Under this condition, the 
prosegment is still present, but folded away from the active site (allowing prorenin 
detection both by renin - and prosegment IRMA). Next, pH was returned to pH=7.4 in 
the absence or presence of either 10 µmol/L aliskiren or VTP-27999. Without renin 
inhibitor, prorenin will rapidly return to its closed conformation, no longer allowing its 
detection by renin - or prosegment IRMA. But with renin inhibitor, prorenin will be 













Figure 17. Renin, total renin (measured following after aliskiren pretreatment) and prorenin in the 
medium of renin+prorenin-secreting HMC-1 cells or exclusively prorenin-secreting HEK293 and 
decidua cells, cultured in the presence of increasing concentrations VTP-27999. Renin and total renin 
were measured by renin IRMA, prorenin was measured by direct prorenin ELISA. Data are 
mean±SEM of n=5-7, and have been expressed as a percentage of the total renin levels without VTP-
27999. 
 
Results show that both renin inhibitors greatly increased renin and prosegment 
immunoreactivity (Figure 19, n=3 for all conditions), confirming their capacity to trap 
prorenin in its open conformation. Importantly, the increases in renin 
immunoreactivity after VTP-27999 were ≈20-fold, i.e. double those seen after 
aliskiren. In contrast, the increases in prosegment immunoreactivity were identical for 
both inhibitors. This implies that VTP-27999 increases renin immunoreactivity, but 
not prosegment immunoreactivity. 
Taken together, these data show that incubation of all 3 cell types with VTP-
27999 yields higher renin immunoreactivity levels in the medium. Yet, this is due to 
the fact that VTP-27999, for a given amount of renin or open prorenin, increases 
renin immunoreactivity in the renin IRMA 2-3 fold. It is not due to the release of open 
prorenin, since a) results were identical in the absence of cells, and b) renin 
immunoreactivity rises in the medium of prorenin-releasing cells were far below the 






Figure 18. Renin and total renin (measured following after aliskiren pretreatment) in medium obtained 
from renin+prorenin-secreting HMC-1 cells or exclusively prorenin-secreting HEK293 and decidua 
cells, incubated without cells in the presence of increasing concentrations VTP-27999. Renin and total 
renin were measured by renin IRMA. Data are mean±SEM of n=5-7, and have been expressed as a 
percentage of the total renin levels without VTP-27999. 
 
6.3.3 Angiotensin Generation in Decidua Cells 
 
The medium prorenin levels of decidua cells continuously rose during a 24 
hour-incubation (Figure 20, left panel; n=3-7). Angiotensin I, when added to these 
cells, disappeared with a half life (t1/2) of 0.45±0.04 hr (n=7). In the presence of 
captopril, the angiotensin I half life increased to 1.41±0.13 hr (P<0.01), implying that 
66±4% of the angiotensin I metabolism was due to conversion by ACE (Figure 21, 
left panel). Importantly, the angiotensin I disappearance was identical when repeating 
these studies in (serum-containing) medium in the absence of cells (n=5), suggesting 
that the majority of the angiotensin I metabolism involved serum-derived ACE (Figure 
21, right panel). In other words, we found no evidence for the presence of decidual 
ACE. Consequently, when investigating angiotensin generation after adding 
angiotensinogen, we only focused on angiotensin I, and not angiotensin II. 
Angiotensin I levels in the medium at 24 hours after adding angiotensinogen were 4-
5 times higher than the (background) levels measured in the absence of 
angiotensinogen (Figure 20, right panel; n=7). Normally, 2.6 pg/mL renin corresponds 
with 1 ng angiotensin I/ml.hr (vmax), at least when activity is determined at 
angiotensinogen levels above Km (=1200 nmol/L). However, our experiments were 
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performed at angiotensinogen levels 8 times below Km (150 nmol/L). This implies that 
angiotensin I generation in our experimental set-up occurred at a rate v 
corresponding with v = 150/(150+1200) x vmax. Given the angiotensin I half life of 0.45 
hr, the expected steady-state level of angiotensin I level can be calculated as v x 
t1/2/ln2. Had all prorenin detected at 24 hours been active, this steady-state 
angiotensin I level would have been 12109±4488 fmol/mL. In reality, the steady-state 
angiotensin I levels at that time point amounted to only 1.3±0.7% of this level. This 
suggests that ≈1% of prorenin displayed enzymatic activity under our experimental 
conditions. This is comparable to the percentage of ‘active’ prorenin in human 




Figure 19. (Pro)renin immunoreactivity, measured by renin IRMA (open bars) or prosegment (F258) 
IRMA (closed bars) in the acid-pretreated medium of HMC-1 cells, HEK293 cells or decidua cells, 
followed by a 1-hour incubation with buffer (control), 10 µmol/L aliskiren (acid+ali), or 10 µmol/L VTP-




The current study, making use of human prorenin-releasing cells, does not 
provide evidence for the concept that such release occurs in an ‘open’ conformation, 
subsequently allowing prorenin to display (full) activity at the site of its release. 
Theoretically, given the low pH conditions under which (pro)renin synthesis/release 
occurs(214), this might have happened, given that a low pH shifts the equilibrium 
between the open and closed conformation of prorenin into the direction of the 
former. Our data in acid-pretreated medium samples (containing 100% open prorenin 
(215)) confirm that the renin inhibitor VTP-27999 would have kept prorenin in this 
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Figure 20. Left, total renin levels in the medium of human decidua cells after 4, 8 and 24 hours 
(mean±SEM of n=3-7) in the absence (open bars) or presence (closed bars) of 150 nmol/L human 
angiotensinogen. Levels were measured by renin IRMA after prorenin activation with aliskiren. Right, 
angiotensin I levels in the medium of human decidua cells after 24 hours (mean±SEM of n=7) in the 
absence (open bars) or presence (closed bars) of 150 nmol/L human angiotensinogen. 
 
The renin inhibitor aliskiren would have done the same. However, this 
inhibitor, unlike VTP-27999, also affects the equilibrium between the open and closed 
conformation by inducing a conformational change in prorenin (171). Therefore, 
aliskiren, if applied at sufficiently high concentrations, would have converted all 
closed prorenin molecules into the open conformation. This would have resulted in 
an overestimation of the number of open prorenin molecules, and thus aliskiren 
cannot be used to quantify the release of open prorenin. 
When applying VTP-27999 to cells that release renin (HMC-1 cells), we 
observed that this inhibitor increased renin immunoreactivity 2-3-fold. This has been 
observed before in human plasma (206), and is related to the existence of 2 renin 
conformations (207), and the different affinity of the active site-directed antibody for 
these 2 conformations. The immunoreactivity increase also occurred when applying 
VTP-27999 to acid-activated prorenin, i.e., prorenin that has the open conformation. 
This confirms that the 3D structure of open prorenin resembles that of renin, despite 
the fact that the prosegment is still present (203). Since VTP-27999 did not affect the 
outcome of the prosegment assay (F258 IRMA), it can be concluded that the binding 






Figure 21. Left, angiotensin I levels in the medium of human decidua cells in the presence (closed 
circles) or absence of 100 nmol/L captopril (open squares) after adding 100 nmol/L angiotensin I at 
t=0. Right, angiotensin I levels in medium alone (i.e., without cells), in the presence or absence of 100 
nmol/L captopril after adding 100 nmol/L angiotensin I at t=0. Data are mean±SEM of n=5-7, and have 
been expressed of the levels of angiotensin I at t=0. 
 
Under physiological conditions, only a small percentage of prorenin is in the 
open conformation (203). This was also the case in the medium of our HEK293 and 
decidua cells (i.e., cells that exclusively released prorenin). Therefore VTP-27999 
should have minimally bound to this percentage of the prorenin molecules, and, 
given its effect on the affinity of the active site-directed antibody, it might 
subsequently marginally have increased renin immunoreactivity in the renin IRMA. 
This is indeed what happened: no substantial rises in renin immunoreactivity were 
observed after VTP-27999, although a >20-fold rise would have been feasible (Figure 
19) in case all prorenin molecules would have been released in an open 
conformation. Moreover, the rises observed in prorenin-containing medium incubated 
with VTP-27999 in the absence of cells were identical to those observed with cells. 
These data therefore strongly argue against the release of open prorenin. 
In addition, our angiotensin measurements after applying human 
angiotensinogen to the medium of human decidua cells also do not support the 
release of open, active prorenin. At most, the generated levels of angiotensin I in the 
medium of these cells support the idea that ≈1% of prorenin displayed activity, i.e., is 
in the open conformation. Such low percentages are in the range occurring in human 
blood plasma, and simply represent the open/closed equilibrium at pH=7.4 and 37°C, 
i.e., our cell culture conditions (10, 215, 216). Lowering temperature will increase this 
percentage, as confirmed by our measurements in human plasma, and only keeping 
the samples for a prolonged time at 37°C allowed prorenin to refold into its closed, 
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inactive conformation. Clearly, depending on the assay conditions, prorenin may be 
detected as renin, and given its much higher levels than those of renin, this should be 
taken into account when quantifying renin in patients with low renin levels (217). 
Decidua cells neither released angiotensinogen themselves, nor generated ACE. 
Yet, these components are present in the 10% FCS added to the medium (218), and 
obviously this should be corrected for when studying angiotensin generation by 
decidua cells. 
In summary, the function of prorenin, if any, remains elusive. The discovery of 
the (pro)renin receptor (15) caused a lot of excitement, but recent studies have 
revealed that its in-vivo function in reality is largely, if not entirely, prorenin-
independent (219-221). All studies investigating prorenin binding to this receptor 
applied highly non-physiological concentrations, which have no relevance in vivo 
(161, 222). Our current studies do not reveal evidence for the release of open, active 
prorenin by prorenin-synthesizing cells. This argues against prorenin activity at the 
site of its release, at least when applying cell culture conditions, but does not exclude 
that there are sites where prorenin may display activity. At such sites, either a 
prorenin-activating enzyme should be present, or conditions favouring prorenin 
unfolding, e.g. a low pH or a novel, high-affinity prorenin-binding receptor. Finally, to 
minimize the contribution of prorenin in renin assays, samples should not be exposed 
to low temperatures and preferably be incubated immediately. However, since this is 
not feasible in daily clinical practice, the best is to centrifuge them at room 
temperature (i.e., not at 4°C), to freeze and thaw the samples only once, and to 







1. Phillips MI, Schmidt-Ott KM. The discovery of renin 100 years ago. News 
Physiol Sci. 1999;14:271-4. 
2. Basso N, Terragno NA. History about the discovery of the renin-angiotensin 
system. Hypertension. 2001;38(6):1246-9. 
3. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical 
Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201-28. 
4. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 
2001;345(23):1689-97. 
5. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol 
Metab. 2003;88(6):2364-72. 
6. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and 
molecular biology of renin secretion. Physiol Rev. 1990;70(4):1067-116. 
7. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology 
(Bethesda). 2007;22:310-9. 
8. Castrop H, Hocherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology 
of kidney renin. Physiol Rev. 2010;90(2):607-73. 
9. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. 
Hypertension. 2008;51(5):1259-64. 
10. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. 
Hypertension. 2005;46:1069-76. 
11. Neves FA, Duncan KG, Baxter JD. Cathepsin B is a prorenin processing 
enzyme. Hypertension. 1996;27(3 Pt 2):514-7. 
12. Saris JJ, Derkx FHM, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser 
AHJ. Cardiomyocytes bind and activate native human prorenin: role of soluble 
mannose 6-phosphate receptors. Hypertension. 2001;37(2 Part 2):710-5. 
13. Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, 
et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes 
proteolytic activation to renin. Am J Physiol. 2001;280(4):H1706-H15. 
14. Saris JJ, van den Eijnden MMED, Lamers JMJ, Saxena PR, Schalekamp 
MADH, Danser AHJ. Prorenin-induced myocyte proliferation: no role for intracellular 
angiotensin II. Hypertension. 2002;39(2 Pt 2):573-7. 
15. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of 
the renin/prorenin receptor in angiotensin II production and cellular responses to 
renin. J Clin Invest. 2002;109:1417-27. 
16. Nguyen G, Contrepas A. The (pro)renin receptors. J Mol Med (Berl). 
2008;86(6):643-6. 
17. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available 




18. Danser AHJ. (Pro)renin receptors: are they biologically relevant? Curr Opin 
Nephrol Hypertens. 2009;18(1):74-8. 
19. Contrepas A, Walker J, Koulakoff A, Franek KJ, Qadri F, Giaume C, et al. A 
role of the (pro)renin receptor in neuronal cell differentiation. Am J Physiol Regul 
Integr Comp Physiol. 2009;297(2):R250-7. 
20. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in 
inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247-57. 
21. Ferrao FM, Lara LS, Lowe J. Renin-angiotensin system in the kidney: What is 
new? World J Nephrol. 2014;3(3):64-76. 
22. Singh KD, Karnik SS. Angiotensin Receptors: Structure, Function, Signaling 
and Clinical Applications. J Cell Signal. 2016;1(2). 
23. Zhuo JL, Ferrao FM, Zheng Y, Li XC. New frontiers in the intrarenal Renin-
Angiotensin system: a critical review of classical and new paradigms. Front 
Endocrinol (Lausanne). 2013;4:166. 
24. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin 
system: potential roles in cardiovascular and renal regulation. Endocr Rev. 
2003;24(3):261-71. 
25. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the 
renin-angiotensin system. Trends Endocrinol Metab. 2004;15(4):166-9. 
26. Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ACE2 is a novel 
mammalian metallocarboxypeptidase and a homologue of angiotensin-converting 
enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol. 2002;80(4):346-53. 
27. Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P, Carretero OA. 
Angiotensin (1-7) induces MAS receptor internalization. Hypertension. 
2011;58(2):176-81. 
28. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. 
Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30(3 Pt 2):535-
41. 
29. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-
converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519-27. 
30. Yugandhar VG, Clark MA. Angiotensin III: a physiological relevant peptide of 
the renin angiotensin system. Peptides. 2013;46:26-32. 
31. Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, et al. The 
angiotensin IV/AT4 receptor. Cell Mol Life Sci. 2004;61(21):2728-37. 
32. Stragier B, De Bundel D, Sarre S, Smolders I, Vauquelin G, Dupont A, et al. 
Involvement of insulin-regulated aminopeptidase in the effects of the renin-
angiotensin fragment angiotensin IV: a review. Heart Fail Rev. 2008;13(3):321-37. 
33. Villela DC, Passos-Silva DG, Santos RA. Alamandine: a new member of the 
angiotensin family. Curr Opin Nephrol Hypertens. 2014;23(2):130-4. 
34. Etelvino GM, Peluso AA, Santos RA. New components of the renin-
angiotensin system: alamandine and the MAS-related G protein-coupled receptor D. 
Curr Hypertens Rep. 2014;16(6):433. 
 
148 
35. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-
angiotensin system. Clin Sci (Lond). 2012;123(5):273-84. 
36. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin 
systems. Physiol Rev. 2006;86(3):747-803. 
37. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and 
the kidney: effects on kidney disease. Am J Med. 2004;116(4):263-72. 
38. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart 
failure. J Renin Angiotensin Aldosterone Syst. 2004;5 Suppl 1:S7-10. 
39. Gomez RA, Norwood VF. Developmental consequences of the renin-
angiotensin system. Am J Kidney Dis. 1995;26(3):409-31. 
40. Campbell DJ. Clinical relevance of local Renin Angiotensin systems. Front 
Endocrinol (Lausanne). 2014;5:113. 
41. De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of 
local cardiovascular and renal Renin-Angiotensin systems. Front Endocrinol 
(Lausanne). 2014;5:16. 
42. Wright JW, Harding JW. The brain angiotensin system and extracellular matrix 
molecules in neural plasticity, learning, and memory. Prog Neurobiol. 
2004;72(4):263-93. 
43. Aroor AR, Demarco VG, Jia G, Sun Z, Nistala R, Meininger GA, et al. The role 
of tissue Renin-Angiotensin-aldosterone system in the development of endothelial 
dysfunction and arterial stiffness. Front Endocrinol (Lausanne). 2013;4:161. 
44. Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive 
system. Front Endocrinol (Lausanne). 2013;4:150. 
45. Kurtz A, Wagner C. Regulation of renin secretion by angiotensin II-AT1 
receptors. J Am Soc Nephrol. 1999;10 Suppl 11:S162-8. 
46. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, et al. 
Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis 
along the proximal nephron. J Biol Chem. 2010;285(53):41935-46. 
47. van Esch JHM, Gembardt F, Sterner-Kock A, Heringer-Walther S, Le T, 
Lassner D, et al. Cardiac phenotype and angiotensin II levels in AT1a, AT1b and AT2 
receptor single, double and triple knockouts Cardiovasc Res. 2010;86:401-9. 
48. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, 
Riquier-Brison AD, et al. The absence of intrarenal ACE protects against 
hypertension. J Clin Invest. 2013;123(5):2011-23. 
49. Lu X, Roksnoer LC, Danser AH. The intrarenal renin-angiotensin system: does 
it exist? Implications from a recent study in renal angiotensin-converting enzyme 
knockout mice. Nephrol Dial Transplant. 2013;28(12):2977-82. 
50. Matsusaka T, Niimura F, Pastan I, Shintani A, Nishiyama A, Ichikawa I. 
Podocyte injury enhances filtration of liver-derived angiotensinogen and renal 
angiotensin II generation. Kidney Int. 2014;85(5):1068-77. 
51. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver 




52. Krop M, de Bruyn JH, Derkx FH, Danser AH. Renin and prorenin 
disappearance in humans post-nephrectomy: evidence for binding? Front Biosci. 
2008;13:3931-9. 
53. Jennette JC, Heptinstall RH. Heptinstall's pathology of the kidney. 6th ed. 
Philadelphia, PA: Lippincott Williams & Wilkins; 2007. 
54. Karginova EA, Pentz ES, Kazakova IG, Norwood VF, Carey RM, Gomez RA. 
Zis: a developmentally regulated gene expressed in juxtaglomerular cells. Am J 
Physiol. 1997;273(5 Pt 2):F731-F8. 
55. Castellanos-Rivera RM, Pentz ES, Lin E, Gross KW, Medrano S, Yu J, et al. 
Recombination signal binding protein for Ig-kappaJ region regulates juxtaglomerular 
cell phenotype by activating the myo-endocrine program and suppressing ectopic 
gene expression. J Am Soc Nephrol. 2015;26(1):67-80. 
56. Sequeira Lopez ML, Gomez RA. Novel mechanisms for the control of renin 
synthesis and release. Curr Hypertens Rep. 2010;12(1):26-32. 
57. Pan L, Gross KW. Transcriptional regulation of renin: an update. 
Hypertension. 2005;45(1):3-8. 
58. Gomez RA, Pupilli C, Everett AD. Molecular and cellular aspects of renin 
during kidney ontogeny. Pediatr Nephrol. 1991;5(1):80-7. 
59. Reddi V, Zaglul A, Pentz ES, Gomez RA. Renin-expressing cells are 
associated with branching of the developing kidney vasculature. J Am Soc Nephrol. 
1998;9(1):63-71. 
60. Pentz ES, Moyano MA, Thornhill BA, Sequeira Lopez ML, Gomez RA. 
Ablation of renin-expressing juxtaglomerular cells results in a distinct kidney 
phenotype. Am J Physiol Regul Integr Comp Physiol. 2004;286(3):R474-R83. 
61. Sequeira Lopez ML, Gomez RA. Development of the renal arterioles. J Am 
Soc Nephrol. 2011;22(12):2156-65. 
62. Michos O. Kidney development: from ureteric bud formation to branching 
morphogenesis. Curr Opin Genet Dev. 2009;19(5):484-90. 
63. Gilbert SF. Developmental biology. 6th ed. Sunderland, Mass.: Sinauer 
Associates; 2000. xviii, 749 p. p. 
64. Hohenstein P, Pritchard-Jones K, Charlton J. The yin and yang of kidney 
development and Wilms' tumors. Genes Dev. 2015;29(5):467-82. 
65. Sequeira Lopez ML, Pentz ES, Robert B, Abrahamson DR, Gomez RA. 
Embryonic origin and lineage of juxtaglomerular cells. Am J Physiol Renal Physiol. 
2001;281(2):F345-F56. 
66. Gomez RA, Belyea B, Medrano S, Pentz ES, Sequeira-Lopez ML. Fate and 
plasticity of renin precursors in development and disease. Pediatr Nephrol. 
2014;29(4):721-6. 
67. Sequeira-Lopez ML, Lin EE, Li M, Hu Y, Sigmund CD, Gomez RA. The 
earliest metanephric arteriolar progenitors and their role in kidney vascular 
development. Am J Physiol Regul Integr Comp Physiol. 2015;308(2):R138-R49. 
68. Gomez RA, Sequeira-Lopez ML. Novel Functions of Renin Precursors in 
Homeostasis and Disease. Physiology (Bethesda). 2016;31(1):25-33. 
 
150 
69. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, et al. 
Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol. 
1990;259(4 Pt 2):F660-F5. 
70. Matsushita K, Zhang Z, Pratt RE, Dzau VJ. Molecular mechanism of 
juxtaglomerular cell hyperplasia: a unifying hypothesis. J Am Soc Hypertens. 
2007;1(3):164-8. 
71. Everett AD, Carey RM, Chevalier RL, Peach MJ, Gomez RA. Renin release 
and gene expression in intact rat kidney microvessels and single cells. J Clin Invest. 
1990;86(1):169-75. 
72. Cantin M, Araujo-Nascimento MD, Benchimol S, Desormeaux Y. Metaplasia of 
smooth muscle cells into juxtaglomerular cells in the juxtaglomerular apparatus, 
arteries, and arterioles of the ischemic (endocrine) kidney. An ultrastructural-
cytochemical and autoradiographic study. Am J Pathol. 1977;87(3):581-602. 
73. Sequeira Lopez ML, Pentz ES, Nomasa T, Smithies O, Gomez RA. Renin 
cells are precursors for multiple cell types that switch to the renin phenotype when 
homeostasis is threatened. Dev Cell. 2004;6(5):719-28. 
74. Tamura K, Chen YE, Horiuchi M, Chen Q, Daviet L, Yang Z, et al. LXRalpha 
functions as a cAMP-responsive transcriptional regulator of gene expression. Proc 
Natl Acad Sci U S A. 2000;97(15):8513-8. 
75. Martini AG, Xa LK, Lacombe MJ, Blanchet-Cohen A, Mercure C, Haibe-Kains 
B, et al. Transcriptome Analysis of Human Reninomas as an Approach to 
Understanding Juxtaglomerular Cell Biology. Hypertension. 2017;69(6):1145-55. 
76. Matsushita K, Morello F, Wu Y, Zhang L, Iwanaga S, Pratt RE, et al. 
Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like 
cells under the control of liver X receptor-alpha. J Biol Chem. 2010;285(16):11974-
82. 
77. Wang H, Gomez JA, Klein S, Zhang Z, Seidler B, Yang Y, et al. Adult renal 
mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am 
Soc Nephrol. 2013;24(8):1263-73. 
78. Yang Y, Gomez JA, Herrera M, Perez-Marco R, Repenning P, Zhang Z, et al. 
Salt restriction leads to activation of adult renal mesenchymal stromal cell-like cells 
via prostaglandin E2 and E-prostanoid receptor 4. Hypertension. 2015;65(5):1047-
54. 
79. Qian H, Le Blanc K, Sigvardsson M. Primary mesenchymal stem and 
progenitor cells from bone marrow lack expression of CD44 protein. J Biol Chem. 
2012;287(31):25795-807. 
80. Della Bruna R, Kurtz A, Schricker K. Regulation of renin synthesis in the 
juxtaglomerular cells. Curr Opin Nephrol Hypertens. 1996;5(1):16-9. 
81. Klar J, Sandner P, Muller MW, Kurtz A. Cyclic AMP stimulates renin gene 
transcription in juxtaglomerular cells. Pflugers Arch. 2002;444(3):335-44. 
82. Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J 
Physiol Renal Physiol. 2010;298(1):F1-F11. 




84. Chen L, Kim SM, Oppermann M, Faulhaber-Walter R, Huang Y, Mizel D, et al. 
Regulation of renin in mice with Cre recombinase-mediated deletion of G protein 
Gsalpha in juxtaglomerular cells. Am J Physiol Renal Physiol. 2007;292(1):F27-F37. 
85. Neubauer B, Machura K, Chen M, Weinstein LS, Oppermann M, Sequeira-
Lopez ML, et al. Development of vascular renin expression in the kidney critically 
depends on the cyclic AMP pathway. Am J Physiol Renal Physiol. 
2009;296(5):F1006-F12. 
86. Pentz ES, Lopez ML, Cordaillat M, Gomez RA. Identity of the renin cell is 
mediated by cAMP and chromatin remodeling: an in vitro model for studying cell 
recruitment and plasticity. Am J Physiol Heart Circ Physiol. 2008;294(2):H699-H707. 
87. Schweda F, Kurtz A. Cellular mechanism of renin release. Acta Physiol Scand. 
2004;181(4):383-90. 
88. Grünberger C, Obermayer B, Klar J, Kurtz A, Schweda F. The calcium 
paradoxon of renin release: calcium suppresses renin exocytosis by inhibition of 
calcium-dependent adenylate cyclases AC5 and AC6. Circ Res. 2006;99(11):1197-
206. 
89. Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. 
Decreased intracellular calcium stimulates renin release via calcium-inhibitable 
adenylyl cyclase. Hypertension. 2007;49(1):162-9. 
90. Klar J, Sigl M, Obermayer B, Schweda F, Kramer BK, Kurtz A. Calcium inhibits 
renin gene expression by transcriptional and posttranscriptional mechanisms. 
Hypertension. 2005;46(6):1340-6. 
91. Ortiz-Capisano MC, Liao TD, Ortiz PA, Beierwaltes WH. Calcium-dependent 
phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells. Am J 
Physiol Regul Integr Comp Physiol. 2009;297(5):R1469-R76. 
92. Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, et al. 
Regulation of renin secretion by renal juxtaglomerular cells. Pflugers Arch. 
2013;465(1):25-37. 
93. Neubauer B, Machura K, Kettl R, Lopez ML, Friebe A, Kurtz A. Endothelium-
derived nitric oxide supports renin cell recruitment through the nitric oxide-sensitive 
guanylate cyclase pathway. Hypertension. 2013;61(2):400-7. 
94. Wang Z, Qin G, Zhao TC. HDAC4: mechanism of regulation and biological 
functions. Epigenomics. 2014;6(1):139-50. 
95. Gomez RA, Pentz ES, Jin X, Cordaillat M, Sequeira Lopez ML. CBP and p300 
are essential for renin cell identity and morphological integrity of the kidney. Am J 
Physiol Heart Circ Physiol. 2009;296(5):H1255-H62. 
96. Pentz ES, Cordaillat M, Carretero OA, Tucker AE, Sequeira Lopez ML, Gomez 
RA. Histone acetyl transferases CBP and p300 are necessary for maintenance of 
renin cell identity and transformation of smooth muscle cells to the renin phenotype. 
Am J Physiol Heart Circ Physiol. 2012;302(12):H2545-H52. 
97. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 
2004;116(2):281-97. 




99. Watson JD. Molecular biology of the gene. Seventh edition ed. Boston: 
Pearson; 2014. xxxiv, 872 pages p. 
100. Sequeira-Lopez ML, Weatherford ET, Borges GR, Monteagudo MC, Pentz 
ES, Harfe BD, et al. The microRNA-processing enzyme dicer maintains 
juxtaglomerular cells. J Am Soc Nephrol. 2010;21(3):460-7. 
101. Medrano S, Monteagudo MC, Sequeira-Lopez ML, Pentz ES, Gomez RA. Two 
microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its 
smooth muscle phenotype. Am J Physiol Renal Physiol. 2012;302(1):F29-F37. 
102. Brunskill EW, Sequeira-Lopez ML, Pentz ES, Lin E, Yu J, Aronow BJ, et al. 
Genes that confer the identity of the renin cell. J Am Soc Nephrol. 2011;22(12):2213-
25. 
103. Liu MJ, Takahashi Y, Wada T, He J, Gao J, Tian Y, et al. The aldo-keto 
reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors 
pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 
2009;76(3):604-11. 
104. Machura K, Iankilevitch E, Neubauer B, Theuring F, Kurtz A. The aldo-keto 
reductase AKR1B7 coexpresses with renin without influencing renin production and 
secretion. Am J Physiol Renal Physiol. 2013;304(5):F578-F84. 
105. Lai EC. Notch signaling: control of cell communication and cell fate. 
Development. 2004;131(5):965-73. 
106. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional 
regulation at Notch target genes. Cell Mol Life Sci. 2009;66(10):1631-46. 
107. Castellanos Rivera RM, Monteagudo MC, Pentz ES, Glenn ST, Gross KW, 
Carretero O, et al. Transcriptional regulator RBP-J regulates the number and 
plasticity of renin cells. Physiol Genomics. 2011;43(17):1021-8. 
108. Lin EE, Sequeira-Lopez ML, Gomez RA. RBP-J in FOXD1+ renal stromal 
progenitors is crucial for the proper development and assembly of the kidney 
vasculature and glomerular mesangial cells. Am J Physiol Renal Physiol. 
2014;306(2):F249-F58. 
109. Rider SA, Mullins LJ, Verdon RF, MacRae CA, Mullins JJ. Renin expression in 
developing zebrafish is associated with angiogenesis and requires the Notch 
pathway and endothelium. Am J Physiol Renal Physiol. 2015;309(6):F531-F9. 
110. Belyea BC, Xu F, Pentz ES, Medrano S, Li M, Hu Y, et al. Identification of 
renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia. Nat 
Commun. 2014;5:3273. 
111. Kurtz L, Schweda F, de Wit C, Kriz W, Witzgall R, Warth R, et al. Lack of 
connexin 40 causes displacement of renin-producing cells from afferent arterioles to 
the extraglomerular mesangium. J Am Soc Nephrol. 2007;18(4):1103-11. 
112. Pippin JW, Kaverina NV, Eng DG, Krofft RD, Glenn ST, Duffield JS, et al. 
Cells of renin lineage are adult pluripotent progenitors in experimental glomerular 
disease. Am J Physiol Renal Physiol. 2015;309(4):F341-F58. 
113. Kurt B, Paliege A, Willam C, Schwarzensteiner I, Schucht K, Neymeyer H, et 
al. Deletion of von Hippel-Lindau protein converts renin-producing cells into 
erythropoietin-producing cells. J Am Soc Nephrol. 2013;24(3):433-44. 
 
153 
114. Kurt B, Gerl K, Karger C, Schwarzensteiner I, Kurtz A. Chronic hypoxia-
inducible transcription factor-2 activation stably transforms juxtaglomerular renin cells 
into fibroblast-like cells in vivo. J Am Soc Nephrol. 2015;26(3):587-96. 
115. Martini AG, Xa LK, Lacombe M-J, Blanchet-Cohen A, Mercure C, Haibe-Kains 
B, et al. Transcriptome analysis of human reninomas as an approach to 
understanding juxtaglomerular cell biology. Hypertension. 2017;69:1145-55. 
116. Pippin JW, Sparks MA, Glenn ST, Buitrago S, Coffman TM, Duffield JS, et al. 
Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in 
experimental glomerular disease. Am J Pathol. 2013;183(2):542-57. 
117. Kaverina NV, Kadoya H, Eng DG, Rusiniak ME, Sequeira-Lopez ML, Gomez 
RA, et al. Tracking the stochastic fate of cells of the renin lineage after podocyte 
depletion using multicolor reporters and intravital imaging. PLoS One. 
2017;12(3):e0173891. 
118. Starke C, Betz H, Hickmann L, Lachmann P, Neubauer B, Kopp JB, et al. 
Renin lineage cells repopulate the glomerular mesangium after injury. J Am Soc 
Nephrol. 2015;26(1):48-54. 
119. Stefanska A, Kenyon C, Christian HC, Buckley C, Shaw I, Mullins JJ, et al. 
Human kidney pericytes produce renin. Kidney Int. 2016;90(6):1251-61. 
120. Bergers G, Song S. The role of pericytes in blood-vessel formation and 
maintenance. Neuro Oncol. 2005;7(4):452-64. 
121. Rider SA, Christian HC, Mullins LJ, Howarth AR, MacRae CA, Mullins JJ. 
Zebrafish mesonephric renin cells are functionally conserved and comprise of two 
distinct morphological populations. Am J Physiol Renal Physiol. 2017;312:F778-F90. 
122. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, et al. 
Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol. 
1990;259(4 Pt 2):F660-5. 
123. Laframboise M, Reudelhuber TL, Jutras I, Brechler V, Seidah NG, Day R, et 
al. Prorenin activation and prohormone convertases in the mouse As4.1 cell line. 
Kidney Int. 1997;51(1):104-9. 
124. Pinet F, Mizrahi J, Laboulandine I, Menard J, Corvol P. Regulation of prorenin 
secretion in cultured human transfected juxtaglomerular cells. J Clin Invest. 
1987;80(3):724-31. 
125. Gottardo F, Cesari M, Morra A, Gardiman M, Fassina A, Dal Bianco M. A 
kidney tumor in an adolescent with severe hypertension and hypokalemia: an 
uncommon case--case report and review of the literature on reninoma. Urol Int. 
2010;85(1):121-4. 
126. Wong L, Hsu TH, Perlroth MG, Hofmann LV, Haynes CM, Katznelson L. 
Reninoma: case report and literature review. J Hypertens. 2008;26(2):368-73. 
127. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. 
Chronic increases in circulating prorenin are not associated with renal or cardiac 
pathologies. Hypertension. 2009;53(6):1062-9. 
128. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina 
sequence data. Bioinformatics. 2014;30(15):2114-20. 
 
154 
129. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: 
accurate alignment of transcriptomes in the presence of insertions, deletions and 
gene fusions. Genome Biol. 2013;14(4):R36. 
130. Legendre F, Cody N, Iampietro C, Bergalet J, Lefebvre FA, Moquin-Beaudry 
G, et al. Whole mount RNA fluorescent in situ hybridization of Drosophila embryos. J 
Vis Exp. 2013(71):e50057. 
131. Krop M, van Veghel R, Garrelds IM, de Bruin RJA, van Gool JMG, van den 
Meiracker AH, et al. Cardiac renin levels are not influenced by the amount of resident 
mast cells. Hypertension. 2009;54:315-21. 
132. Martin SA, Mynderse LA, Lager DJ, Cheville JC. Juxtaglomerular cell tumor: a 
clinicopathologic study of four cases and review of the literature. Am J Clin Pathol. 
2001;116(6):854-63. 
133. Machura K, Iankilevitch E, Neubauer B, Theuring F, Kurtz A. The aldo-keto 
reductase AKR1B7 coexpresses with renin without influencing renin production and 
secretion. Am J Physiol Renal Physiol. 2013;304(5):F578-84. 
134. Berg AC, Chernavvsky-Sequeira C, Lindsey J, Gomez RA, Sequeira-Lopez 
ML. Pericytes synthesize renin. World J Nephrol. 2013;2(1):11-6. 
135. Lin EE, Sequeira-Lopez ML, Gomez RA. RBP-J in FOXD1+ renal stromal 
progenitors is crucial for the proper development and assembly of the kidney 
vasculature and glomerular mesangial cells. Am J Physiol Renal Physiol. 
2014;306(2):F249-58. 
136. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma 
F, et al. Liver X receptors alpha and beta regulate renin expression in vivo. J Clin 
Invest. 2005;115(7):1913-22. 
137. Machura K, Neubauer B, Steppan D, Kettl R, Grobeta A, Kurtz A. Role of 
blood pressure in mediating the influence of salt intake on renin expression in the 
kidney. Am J Physiol Renal Physiol. 2012;302(10):F1278-85. 
138. Nistala R, Zhang X, Sigmund CD. Differential expression of the closely linked 
KISS1, REN, and FLJ10761 genes in transgenic mice. Physiol Genomics. 
2004;17(1):4-10. 
139. Franchimont N, Durant D, Rydziel S, Canalis E. Platelet-derived growth factor 
induces interleukin-6 transcription in osteoblasts through the activator protein-1 
complex and activating transcription factor-2. J Biol Chem. 1999;274(10):6783-9. 
140. Gianni-Barrera R, Bartolomeo M, Vollmar B, Djonov V, Banfi A. Split for the 
cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis. Biochem 
Soc Trans. 2014;42(6):1637-42. 
141. Suzuki N, Yamamoto M. Roles of renal erythropoietin-producing (REP) cells in 
the maintenance of systemic oxygen homeostasis. Pflugers Arch. 2016;468(1):3-12. 
142. Neubauer B, Machura K, Rupp V, Tallquist MD, Betsholtz C, Sequeira-Lopez 
ML, et al. Development of renal renin-expressing cells does not involve PDGF-B-
PDGFR-beta signaling. Physiol Rep. 2013;1(5):e00132. 
143. Johns DW, Carey RM, Gomez RA, Lynch K, Inagami T, Saye J, et al. Isolation 
of renin-rich rat kidney cells. Hypertension. 1987;10(5):488-96. 
 
155 
144. Motegi S, Garfield S, Feng X, Sardy M, Udey MC. Potentiation of platelet-
derived growth factor receptor-beta signaling mediated by integrin-associated MFG-
E8. Arterioscler Thromb Vasc Biol. 2011;31(11):2653-64. 
145. Liu Y, Long L, Yuan F, Liu F, Liu H, Peng Y, et al. High glucose-induced 
Galectin-1 in human podocytes implicates the involvement of Galectin-1 in diabetic 
nephropathy. Cell Biol Int. 2015;39(2):217-23. 
146. Sato W, Sato Y. Midkine in nephrogenesis, hypertension and kidney diseases. 
Br J Pharmacol. 2014;171(4):879-87. 
147. LeBleu VS, Teng Y, O'Connell JT, Charytan D, Muller GA, Muller CA, et al. 
Identification of human epididymis protein-4 as a fibroblast-derived mediator of 
fibrosis. Nat Med. 2013;19(2):227-31. 
148. Hayakawa S, Ohashi K, Shibata R, Kataoka Y, Miyabe M, Enomoto T, et al. 
Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal 
nephrectomy model. J Am Soc Nephrol. 2015;26(3):636-46. 
149. Matsuba H, Watanabe T, Watanabe M, Ishii Y, Waguri S, Kominami E, et al. 
Immunocytochemical localization of prorenin, renin, and cathepsins B, H, and L in 
juxtaglomerular cells of rat kidney. J Histochem Cytochem. 1989;37(11):1689-97. 
150. Wang PH, Do YS, Macaulay L, Shinagawa T, Anderson PW, Baxter JD, et al. 
Identification of renal cathepsin B as a human prorenin-processing enzyme. J Biol 
Chem. 1991;266(19):12633-8. 
151. Ganten D, Minnich JL, Granger P, Hayduk K, Brecht HM, Barbeau A, et al. 
Angiotensin-forming enzyme in brain tissue. Science. 1971;173(3991):64-5. 
152. Lee-Kirsch MA, Gaudet F, Cardoso MC, Lindpaintner K. Distinct renin 
isoforms generated by tissue-specific transcription initiation and alternative splicing. 
Circ Res. 1999;84(2):240-6. 
153. Mercure C, Thibault G, Lussier-Cacan S, Davignon J, Schiffrin EL, 
Reudelhuber TL. Molecular analysis of human prorenin prosegment variants in vitro 
and in vivo. J Biol Chem. 1995;270(27):16355-9. 
154. Peters J. Secretory and cytosolic (pro)renin in kidney, heart, and adrenal 
gland. J Mol Med (Berl). 2008;86(6):711-4. 
155. Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in 
neurons: fact, hypothesis, or fantasy. Physiology (Bethesda). 2008;23:187-93. 
156. Wanka H, Staar D, Lutze P, Peters B, Hildebrandt J, Beck T, et al. Anti-
necrotic and cardioprotective effects of a cytosolic renin isoform under ischemia-
related conditions. J Mol Med (Berl). 2016;94(1):61-9. 
157. Grobe JL, Rahmouni K, Liu X, Sigmund CD. Metabolic rate regulation by the 
renin-angiotensin system: brain vs. body. Pflugers Arch. 2013;465(1):167-75. 
158. Shinohara K, Liu X, Morgan DA, Davis DR, Sequeira-Lopez ML, Cassell MD, 
et al. Selective deletion of the brain-specific isoform of renin causes neurogenic 
hypertension. Hypertension. 2016;68:1385-92. 
159. Li W, Sullivan MN, Zhang S, Worker CJ, Xiong Z, Speth RC, et al. 
Intracerebroventricular infusion of the (pro)renin receptor antagonist PRO20 




160. Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JMG, et al. 
Neuron-specific (pro)renin receptor knockout prevents the development of salt-
sensitive hypertension. Hypertension. 2014;63(2):316-23. 
161. Batenburg WW, Lu X, Leijten F, Maschke U, Müller DN, Danser AHJ. Renin- 
and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the 
human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually 
occur? Hypertension. 2011;58(6):1111-9. 
162. Batenburg WW, van den Heuvel M, van Esch JHM, van Veghel R, Garrelds 
IM, Leijten F, et al. The (pro)renin receptor blocker handle region peptide upregulates 
endothelium-derived contractile factors in aliskiren-treated diabetic transgenic 
(mREN2)27 rats. J Hypertens. 2013;31:292-302. 
163. Takahashi N, Lopez ML, Cowhig JE, Jr., Taylor MA, Hatada T, Riggs E, et al. 
Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are 
indistinguishable from wild-type. J Am Soc Nephrol. 2005;16(1):125-32. 
164. Roksnoer LCW, van Veghel R, de Vries R, Garrelds IM, Bhaggoe UM, 
Friesema ECH, et al. Optimum AT1 receptor-neprilysin inhibition has superior 
cardioprotective effects compared with AT1 receptor receptor blockade alone in 
hypertensive rats. Kidney International. 2015;88:109-20. 
165. Fraune C, Lange S, Krebs C, Holzel A, Baucke J, Divac N, et al. AT1 
antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in 
chronic kidney disease. Am J Physiol Renal Physiol. 2012;303(7):F1037-F48. 
166. Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena 
PR, et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in 
normal and failing human hearts. Evidence for renin binding. Circulation. 
1997;96(1):220-6. 
167. Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting enzyme 
inhibition, and angiotensin peptides. Hypertension. 1993;22(4):513-22. 
168. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of 
the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 
2004;101(16):6062-7. 
169. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. 
Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem 
Biophys Res Commun. 2003;308(4):698-705. 
170. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, et al. Renin 
inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin 
Invest. 2008;118(3):984-93. 
171. Batenburg WW, de Bruin RJA, van Gool JM, Müller DN, Bader M, Nguyen G, 
et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic 
vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1151-7. 
172. Gregory TJ, Wallis CJ, Printz MP. Regional changes in rat brain 
angiotensinogen following bilateral nephrectomy. Hypertension. 1982;4(6):827-38. 
173. Migliarini S, Pacini G, Pelosi B, Lunardi G, Pasqualetti M. Lack of brain 
serotonin affects postnatal development and serotonergic neuronal circuitry 
formation. Mol Psychiatry. 2013;18(10):1106-18. 
 
157 
174. Lange S, Fraune C, Alenina N, Bader M, Danser AHJ, Frenay AR, et al. 
Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. J 
Hypertens. 2013;31(4):713-9. 
175. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, 
Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of 
the isolated perfused rat heart. Local production of angiotensin I. Hypertension. 
1997;29(6):1240-51. 
176. Heller LJ, Opsahl JA, Wernsing SE, Saxena R, Katz SA. Myocardial and 
plasma renin-angiotensinogen dynamics during pressure-induced cardiac 
hypertrophy. Am J Physiol. 1998;274(3 Pt 2):R849-R56. 
177. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw 
PD, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ 
synthesis. Hypertension. 1994;24(1):37-48. 
178. Deinum J, Derkx FHM, Danser AHJ, Schalekamp MADH. Identification and 
quantification of renin and prorenin in the bovine eye. Endocrinology. 
1990;126(3):1673-82. 
179. Xu D, Borges GR, Davis DR, Agassandian K, Sequeira Lopez ML, Gomez RA, 
et al. Neuron- or glial-specific ablation of secreted renin does not affect renal renin, 
baseline arterial pressure, or metabolism. Physiol Genomics. 2011;43(6):286-94. 
180. Xu D, Borges GR, Grobe JL, Pelham CJ, Yang B, Sigmund CD. Preservation 
of intracellular renin expression is insufficient to compensate for genetic loss of 
secreted renin. Hypertension. 2009;54(6):1240-7. 
181. Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, Sigmund CD. Evidence 
supporting a functional role for intracellular renin in the brain. Hypertension. 
2006;47(3):461-6. 
182. Bader M, Ganten D. It's renin in the brain: transgenic animals elucidate the 
brain renin angiotensin system. Circ Res. 2002;90(1):8-10. 
183. Lippoldt A, Fuxe K, Luft FC. A view of renin in the brain. J Mol Med (Berl). 
2001;79(2-3):71-3. 
184. Saavedra JM. Brain angiotensin II: new developments, unanswered questions 
and therapeutic opportunities. Cell Mol Neurobiol. 2005;25(3-4):485-512. 
185. Kubo T, Ikezawa A, Kambe T, Hagiwara Y, Fukumori R. Renin antisense 
injected intraventricularly decreases blood pressure in spontaneously hypertensive 
rats. Brain Res Bull. 2001;56(1):23-8. 
186. Campbell DJ, Duncan AM, Kladis A. Angiotensin-converting enzyme inhibition 
modifies angiotensin but not kinin peptide levels in human atrial tissue. Hypertension. 
1999;34(2):171-5. 
187. van Kats JP, Danser AHJ, van Meegen JR, Sassen LM, Verdouw PD, 
Schalekamp MADH. Angiotensin production by the heart: a quantitative study in pigs 
with the use of radiolabeled angiotensin infusions. Circulation. 1998;98(1):73-81. 
188. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AHJ. The impact of left 
ventricular assist device-induced left ventricular unloading on the myocardial renin-




189. Davisson RL, Yang G, Beltz TG, Cassell MD, Johnson AK, Sigmund CD. The 
brain renin-angiotensin system contributes to the hypertension in mice containing 
both the human renin and human angiotensinogen transgenes. Circ Res. 
1998;83(10):1047-58. 
190. Thomas WG, Sernia C. Immunocytochemical localization of angiotensinogen 
in the rat brain. Neuroscience. 1988;25(1):319-41. 
191. Ito T, Eggena P, Barrett JD, Katz D, Metter J, Sambhi MP. Studies on 
angiotensinogen of plasma and cerebrospinal fluid in normal and hypertensive 
human subjects. Hypertension. 1980;2(4):432-6. 
192. Schelling P, Muller S, Clauser E. Regulation of angiotensinogen in 
cerebrospinal fluid and plasma of rats. Am J Physiol. 1983;244(4):R466-71. 
193. Schinke M, Baltatu O, Bohm M, Peters J, Rascher W, Bricca G, et al. Blood 
pressure reduction and diabetes insipidus in transgenic rats deficient in brain 
angiotensinogen. Proc Natl Acad Sci U S A. 1999;96(7):3975-80. 
194. Intebi AD, Flaxman MS, Ganong WF, Deschepper CF. Angiotensinogen 
production by rat astroglial cells in vitro and in vivo. Neuroscience. 1990;34(3):545-
54. 
195. Milsted A, Barna BP, Ransohoff RM, Brosnihan KB, Ferrario CM. Astrocyte 
cultures derived from human brain tissue express angiotensinogen mRNA. Proc Natl 
Acad Sci U S A. 1990;87(15):5720-3. 
196. van Kats JP, Chai W, Duncker DJ, Schalekamp MADH, Danser AHJ. Adrenal 
angiotensin. Origin and site of generation. Am J Hypertens. 2005;18:1045-51. 
197. van Kats JP, Schalekamp MADH, Verdouw PD, Duncker DJ, Danser AHJ. 
Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney 
Int. 2001;60:2311-7. 
198. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors 
on angiotensin and bradykinin peptides. Hypertension. 1994;23(4):439-49. 
199. van Kats JP, de Lannoy LM, Danser AHJ, van Meegen JR, Verdouw PD, 
Schalekamp MADH. Angiotensin II type 1 (AT1) receptor-mediated accumulation of 
angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. 1997;30(1 
Pt 1):42-9. 
200. van Kats JP, van Meegen JR, Verdouw PD, Duncker DJ, Schalekamp MADH, 
Danser AHJ. Subcellular localization of angiotensin II in kidney and adrenal. J 
Hypertens. 2001;19:583-9. 
201. Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H, Mogi M, et al. Blockade of 
AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-
sensitive hypertensive rats. Am J Hypertens. 2011;24(3):362-8. 
202. Morales R, Watier Y, Böcskei Z. Human prorenin structure sheds light on a 
novel mechanism of its autoinhibition and on its non-proteolytic activation by the 
(pro)renin receptor. J Mol Biol. 2012;421(1):100-11. 
203. Schalekamp MADH, Derkx FHM, Deinum J, Danser AHJ. Newly developed 




204. Krop M, van Gool JM, Day D, Hollenberg NK, Danser AHJ. Evaluation of a 
direct prorenin assay making use of a monoclonal antibody directed against residues 
32-39 of the prosegment. J Hypertens. 2011;29:2138-46. 
205. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. 
Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as 
demonstrated by renin-specific monoclonal antibody. J Biol Chem. 
1992;267(32):22837-42. 
206. Krop M, Lu X, Verdonk K, Schalekamp MADH, van Gool JM, McKeever BM, et 
al. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold 
prorenin. Hypertension. 2013;61(5):1075-82. 
207. Rahuel J, Priestle JP, Grütter MG. The crystal structures of recombinant 
glycosylated human renin alone and in complex with a transition state analog 
inhibitor. J Struct Biol. 1991;107(3):227-36. 
208. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, et 
al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of 
renin and prorenin in rat vascular smooth muscle cells overexpressing the human 
(pro)renin receptor. J Hypertens. 2007;25:2441-53. 
209. Chu WN, Baxter JD, Reudelhuber TL. A targeting sequence for dense 
secretory granules resides in the active renin protein moiety of human preprorenin. 
Mol Endocrinol. 1990;4(12):1905-13. 
210. Markoff E, Zeitler P, Peleg S, Handwerger S. Characterization of the synthesis 
and release of prolactin by an enriched fraction of human decidual cells. J Clin 
Endocrinol Metab. 1983;56(5):962-8. 
211. Galen FX, Devaux C, Atlas S, Guyenne T, Menard J, Corvol P, et al. New 
monoclonal antibodies directed against human renin. Powerful tools for the 
investigation of the renin system. J Clin Invest. 1984;74(3):723-35. 
212. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen 
E, et al. Activity assays and immunoassays for plasma renin and prorenin: 
information provided and precautions necessary for accurate measurement. Clin 
Chem. 2009;55(5):867-77. 
213. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg 
NK, et al. Aliskiren accumulates in renin secretory granules and binds plasma 
prorenin. Hypertension. 2008;52(6):1076-83. 
214. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology. 
2007;22:310-9. 
215. Deinum J, Derkx FHM, Schalekamp MADH. Probing epitopes on human 
prorenin during its proteolytic and non-proteolytic activation. Biochim Biophys Acta. 
1998;1388(2):386-96. 
216. Derkx FHM, Schalekamp MPA, Schalekamp MADH. Two-step prorenin-renin 
conversion. Isolation of an intermediary form of activated prorenin. J Biol Chem. 
1987;262(6):2472-7. 
217. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 
1991;37(10 Pt 2):1811-9. 
 
160 
218. van Kesteren CAM, Saris JJ, Dekkers DHW, Lamers JMJ, Saxena PR, 
Schalekamp MADH, et al. Cultured neonatal rat cardiac myocytes and fibroblasts do 
not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte 
hypertrophy independent of angiotensin II. Cardiovasc Res. 1999;43(1):148-56. 
219. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, et 
al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly 
in murine cardiomyocytes. Circ Res. 2010;107(1):30-4. 
220. Lu X, Meima ME, Nelson JK, Sorrentino V, Loregger A, Scheij S, et al. 
Identification of the (pro)renin receptor as a novel regulator of low-density lipoprotein 
metabolism. Circ Res. 2016;118:222-9. 
221. Riediger F, Quack I, Qadri F, Hartleben B, Park J-K, Potthoff SA, et al. 
Prorenin receptor is essential for podocyte autophagy and survival J Am Soc 
Nephrol. 2011;22:2193-202. 
222. Trepiccione F, Gerber SD, Grahammer F, Lopez-Cayuqueo KI, Baudrie V, 
Paunescu TG, et al. Renal ATP6ap2/(pro)renin receptor is required for normal 
vacuolar H+-ATPase function but not for the renin-angiotensin system. J Am Soc 
Nephrol. 2016. 
223. Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders. 
5th ed. New York: McGraw-Hill, Medical Pub. Division; 2001. x, 992 p. p. 
224. Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. 
Clin J Am Soc Nephrol. 2014;9(9):1627-38. 
225. Garcia NH, Ramsey CR, Knox FG. Understanding the Role of Paracellular 
Transport in the Proximal Tubule. News Physiol Sci. 1998;13:38-43. 
226. Christensen EI, Birn H, Storm T, Weyer K, Nielsen R. Endocytic receptors in 
the renal proximal tubule. Physiology (Bethesda). 2012;27(4):223-36. 
227. Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule 
protein reabsorption: from experimental models to human disease. Kidney Int. 
2016;89(1):58-67. 
228. Dickson LE, Wagner MC, Sandoval RM, Molitoris BA. The proximal tubule and 
albuminuria: really! J Am Soc Nephrol. 2014;25(3):443-53. 
229. Bokenkamp A, Ludwig M. Disorders of the renal proximal tubule. Nephron 
Physiol. 2011;118(1):p1-6. 
230. Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, Garrelds IM, 
et al. On the Origin of Urinary Renin: A Translational Approach. Hypertension. 
2016;67(5):927-33. 
231. Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, 
et al. Novel conditionally immortalized human proximal tubule cell line expressing 
functional influx and efflux transporters. Cell Tissue Res. 2010;339(2):449-57. 
232. Caetano-Pinto P, Janssen MJ, Gijzen L, Verscheijden L, Wilmer MJ, 
Masereeuw R. Fluorescence-Based Transport Assays Revisited in a Human Renal 
Proximal Tubule Cell Line. Mol Pharm. 2016;13(3):933-44. 
233. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et 




234. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, et 
al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular 
smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28(6):1151-7. 
235. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, et 
al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity 
associated with deterioration of renal function in patients with chronic kidney disease. 
J Am Soc Nephrol. 2007;18(5):1558-65. 
236. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool 
JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, 
reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of 
renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens. 
2011;29(11):2147-55. 
237. Kobori H, Alper AB, Jr., Shenava R, Katsurada A, Saito T, Ohashi N, et al. 
Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin 
system status in hypertensive patients. Hypertension. 2009;53(2):344-50. 
238. van den Eijnden MM, Saris JJ, de Bruin RJ, de Wit E, Sluiter W, Reudelhuber 
TL, et al. Prorenin accumulation and activation in human endothelial cells: 
importance of mannose 6-phosphate receptors. Arterioscler Thromb Vasc Biol. 
2001;21(6):911-6. 
239. Saris JJ, Derkx FH, De Bruin RJ, Dekkers DH, Lamers JM, Saxena PR, et al. 
High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes 
proteolytic activation to renin. Am J Physiol Heart Circ Physiol. 2001;280(4):H1706-
15. 
240. Saris JJ, Derkx FH, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. 
Cardiomyocytes bind and activate native human prorenin : role of soluble mannose 
6-phosphate receptors. Hypertension. 2001;37(2 Pt 2):710-5. 
241. Saris JJ, van den Eijnden MM, Lamers JM, Saxena PR, Schalekamp MA, 
Danser AH. Prorenin-induced myocyte proliferation: no role for intracellular 
angiotensin II. Hypertension. 2002;39(2 Pt 2):573-7. 
242. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burckle CA, et 
al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of 
renin and prorenin in rat vascular smooth muscle cells overexpressing the human 
(pro)renin receptor. J Hypertens. 2007;25(12):2441-53. 
243. Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated endocytosis in 
renal proximal tubule. Pflugers Arch. 2009;458(6):1039-48. 
 
 
 
